1.6.34 start	0	1.0	2	Review thecontinued need for other blood glucose lowering therapies . 1.6.34 Start insulin therapy for adults with type 2 diabetes from a choice of a number of insulin types and regimens:.	Review thecontinued need for other blood glucose lowering therapies . 1.6.34 Start insulin therapy for adults with type 2 diabetes from a choice of a number of insulin types and regimens:.	
3–6 months	0	1.0	2	Medicines and Healthcare products Regulatory Agency (MHRA)guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'..	Medicines and Healthcare products Regulatory Agency (MHRA)guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'..	
abnormal haemoglobin	0	1.0	4	International Federation of Clinical Chemistry (IFCC) standardisation.1.6.3 If HbA1c monitoring is invalid because of disturbed erythrocyte turnover or abnormal haemoglobin type, estimate trends in blood glucose control using one.	Page 17of 44 of the following: quality-controlled plasma glucose profiles total glycated haemoglobin estimation (if abnormal haemoglobins) fructosamine estimation. 1.6.4 Investigate unexplained discrepancies between HbA1c and other glucose measurements.	International Federation of Clinical Chemistry (IFCC) standardisation.1.6.3 If HbA1c monitoring is invalid because of disturbed erythrocyte turnover or abnormal haemoglobin type, estimate trends in blood glucose control using one.	Page 17of 44 of the following: quality-controlled plasma glucose profiles total glycated haemoglobin estimation (if abnormal haemoglobins) fructosamine estimation. 1.6.4 Investigate unexplained discrepancies between HbA1c and other glucose measurements.	
acquisition cost).	0	1.0	2	Page 20of 44 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost)..	Page 20of 44 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost)..	
acute intercurrent	0	1.0	2	For more information, seethe NICE guideline on diabetes in pregnancy. 1.6.14 Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia. 1.6.15 Be aware that adults with type 2 diabetes who have acute intercurrent illness are at risk of worsening hyperglycaemia.	For more information, seethe NICE guideline on diabetes in pregnancy. 1.6.14 Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia. 1.6.15 Be aware that adults with type 2 diabetes who have acute intercurrent illness are at risk of worsening hyperglycaemia.	
agency (mhra)guidance	0	1.0	2	Medicines and Healthcare products Regulatory Agency (MHRA)guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'..	Medicines and Healthcare products Regulatory Agency (MHRA)guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'..	
agency mhra	0	1.0	2	Page 20of 44 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost)..	Page 20of 44 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost)..	
annual reinforcement	0	1.0	2	Page 12of 44 annual reinforcement and review.	Page 12of 44 annual reinforcement and review.	
bladder cancer	0	1.0	4	Pioglitazone is associated with an increased risk of heart failure,bladder cancer and bone fracture.	Page 22of 44 hepatic impairment diabetic ketoacidosis current, or a history of, bladder cancer uninvestigated macroscopic haematuria..	Pioglitazone is associated with an increased risk of heart failure,bladder cancer and bone fracture.	Page 22of 44 hepatic impairment diabetic ketoacidosis current, or a history of, bladder cancer uninvestigated macroscopic haematuria..	
bone fracture	0	1.0	2	Pioglitazone is associated with an increased risk of heart failure,bladder cancer and bone fracture.	Pioglitazone is associated with an increased risk of heart failure,bladder cancer and bone fracture.	
care advice	0	1.0	2	Page 24of 44 1.6.31 In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team ..	Page 24of 44 1.6.31 In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team ..	
chronic kidney	0	1.0	2	NICE guideline on chronic kidney disease in adults..	NICE guideline on chronic kidney disease in adults..	
class level	0	1.0	2	Recommendations in this section that cover dipeptidyl peptidase-4 (DPP-4) inhibitors,glucagon-like peptide-1 (GLP-1) mimetics and sulfonylureas refer to each of these groups of drugs at a class level. 1.6.17 For adults with type 2 diabetes, discuss the benefits and risks of drug treatment, and the options available.	Recommendations in this section that cover dipeptidyl peptidase-4 (DPP-4) inhibitors,glucagon-like peptide-1 (GLP-1) mimetics and sulfonylureas refer to each of these groups of drugs at a class level. 1.6.17 For adults with type 2 diabetes, discuss the benefits and risks of drug treatment, and the options available.	
clinical chemistry	0	1.0	2	International Federation of Clinical Chemistry (IFCC) standardisation.1.6.3 If HbA1c monitoring is invalid because of disturbed erythrocyte turnover or abnormal haemoglobin type, estimate trends in blood glucose control using one.	International Federation of Clinical Chemistry (IFCC) standardisation.1.6.3 If HbA1c monitoring is invalid because of disturbed erythrocyte turnover or abnormal haemoglobin type, estimate trends in blood glucose control using one.	
clinical circumstances	0	1.0	2	Page 20of 44 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost)..	Page 20of 44 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost)..	
consultant-led multidisciplinary	0	1.0	2	Page 24of 44 1.6.31 In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team ..	Page 24of 44 1.6.31 In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team ..	
control support	0	1.0	2	DVLA guidance (At a glance guide to the current medical standards of fitness to drive)management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional. 1.6.33 When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance.	DVLA guidance (At a glance guide to the current medical standards of fitness to drive)management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional. 1.6.33 When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance.	
details ofthe	0	1.0	2	The full guideline gives details ofthe methods and the evidence used to develop the guidance..	The full guideline gives details ofthe methods and the evidence used to develop the guidance..	
diabetes orclinical	0	1.0	2	Seek advice from a team with specialist expertise in diabetes orclinical biochemistry..	Seek advice from a team with specialist expertise in diabetes orclinical biochemistry..	
diabetic ketoacidosis	0	1.0	2	Page 22of 44 hepatic impairment diabetic ketoacidosis current, or a history of, bladder cancer uninvestigated macroscopic haematuria..	Page 22of 44 hepatic impairment diabetic ketoacidosis current, or a history of, bladder cancer uninvestigated macroscopic haematuria..	
disturbed erythrocyte	0	1.0	2	International Federation of Clinical Chemistry (IFCC) standardisation.1.6.3 If HbA1c monitoring is invalid because of disturbed erythrocyte turnover or abnormal haemoglobin type, estimate trends in blood glucose control using one.	International Federation of Clinical Chemistry (IFCC) standardisation.1.6.3 If HbA1c monitoring is invalid because of disturbed erythrocyte turnover or abnormal haemoglobin type, estimate trends in blood glucose control using one.	
dose titration	0	1.0	2	Insulin-based treatments1.6.32 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding.	Insulin-based treatments1.6.32 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding.	
dvla guidance	0	1.0	2	DVLA guidance (At a glance guide to the current medical standards of fitness to drive)management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional. 1.6.33 When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance.	DVLA guidance (At a glance guide to the current medical standards of fitness to drive)management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional. 1.6.33 When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance.	
educational theoryappropriate	0	1.0	2	It is delivered by trained educators who have an understanding of educational theoryappropriate to the age and needs of the person, and who are trained and competent to deliver the principles and content of the programme..	It is delivered by trained educators who have an understanding of educational theoryappropriate to the age and needs of the person, and who are trained and competent to deliver the principles and content of the programme..	
erythrocyte turnover	0	1.0	2	International Federation of Clinical Chemistry (IFCC) standardisation.1.6.3 If HbA1c monitoring is invalid because of disturbed erythrocyte turnover or abnormal haemoglobin type, estimate trends in blood glucose control using one.	International Federation of Clinical Chemistry (IFCC) standardisation.1.6.3 If HbA1c monitoring is invalid because of disturbed erythrocyte turnover or abnormal haemoglobin type, estimate trends in blood glucose control using one.	
estimate trends	0	1.0	2	International Federation of Clinical Chemistry (IFCC) standardisation.1.6.3 If HbA1c monitoring is invalid because of disturbed erythrocyte turnover or abnormal haemoglobin type, estimate trends in blood glucose control using one.	International Federation of Clinical Chemistry (IFCC) standardisation.1.6.3 If HbA1c monitoring is invalid because of disturbed erythrocyte turnover or abnormal haemoglobin type, estimate trends in blood glucose control using one.	
estimated glomerular	0	1.0	2	Page 21of 44 1.6.22 In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute 1.73m2:.	Page 21of 44 1.6.22 In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute 1.73m2:.	
evidence-based andresource-effective	0	1.0	2	It has a structured curriculum that is theory-driven, evidence-based andresource-effective, has supporting materials, and is written down..	It has a structured curriculum that is theory-driven, evidence-based andresource-effective, has supporting materials, and is written down..	
failure,bladder cancer	0	1.0	2	Pioglitazone is associated with an increased risk of heart failure,bladder cancer and bone fracture.	Pioglitazone is associated with an increased risk of heart failure,bladder cancer and bone fracture.	
filtration rate	0	1.0	2	Page 21of 44 1.6.22 In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute 1.73m2:.	Page 21of 44 1.6.22 In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute 1.73m2:.	
forsome adults	0	1.0	2	Treatment with sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate forsome adults with type 2 diabetes if metformin is contraindicated or not tolerated (see NICE's guidance on canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes)..	Treatment with sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate forsome adults with type 2 diabetes if metformin is contraindicated or not tolerated (see NICE's guidance on canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes)..	
full guideline	0	1.0	2	The full guideline gives details ofthe methods and the evidence used to develop the guidance..	The full guideline gives details ofthe methods and the evidence used to develop the guidance..	
glomerular filtration	0	1.0	2	Page 21of 44 1.6.22 In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute 1.73m2:.	Page 21of 44 1.6.22 In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute 1.73m2:.	
haemoglobin type	0	1.0	2	International Federation of Clinical Chemistry (IFCC) standardisation.1.6.3 If HbA1c monitoring is invalid because of disturbed erythrocyte turnover or abnormal haemoglobin type, estimate trends in blood glucose control using one.	International Federation of Clinical Chemistry (IFCC) standardisation.1.6.3 If HbA1c monitoring is invalid because of disturbed erythrocyte turnover or abnormal haemoglobin type, estimate trends in blood glucose control using one.	
hba1c measurement	0	1.0	2	HbA1c measurement and targets.	HbA1c measurement and targets.	
hba1c monitoring	0	1.0	2	International Federation of Clinical Chemistry (IFCC) standardisation.1.6.3 If HbA1c monitoring is invalid because of disturbed erythrocyte turnover or abnormal haemoglobin type, estimate trends in blood glucose control using one.	International Federation of Clinical Chemistry (IFCC) standardisation.1.6.3 If HbA1c monitoring is invalid because of disturbed erythrocyte turnover or abnormal haemoglobin type, estimate trends in blood glucose control using one.	
hba1c targets	0	1.0	2	Be aware that there are other possible reasons for a low HbA1clevel, for example, deteriorating renal function or sudden weight loss. 1.6.11 For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy..	Be aware that there are other possible reasons for a low HbA1clevel, for example, deteriorating renal function or sudden weight loss. 1.6.11 For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy..	
heart failure	0	1.0	4	Pioglitazone is associated with an increased risk of heart failure,bladder cancer and bone fracture.	Prescribe metformin with caution for those at risk of a sudden deterioration in kidneyfunction and those at risk of eGFR falling below 45 ml minute 1.73m2. 1.6.23 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea. 1.6.24 In adults with type 2 diabetes, do not offer or continue pioglitazone if they have any of the following: heart failure or history of heart failure.	Pioglitazone is associated with an increased risk of heart failure,bladder cancer and bone fracture.	Prescribe metformin with caution for those at risk of a sudden deterioration in kidneyfunction and those at risk of eGFR falling below 45 ml minute 1.73m2. 1.6.23 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea. 1.6.24 In adults with type 2 diabetes, do not offer or continue pioglitazone if they have any of the following: heart failure or history of heart failure.	
heart failure,bladder	0	1.0	2	Pioglitazone is associated with an increased risk of heart failure,bladder cancer and bone fracture.	Pioglitazone is associated with an increased risk of heart failure,bladder cancer and bone fracture.	
hepatic impairment	0	1.0	2	Page 22of 44 hepatic impairment diabetic ketoacidosis current, or a history of, bladder cancer uninvestigated macroscopic haematuria..	Page 22of 44 hepatic impairment diabetic ketoacidosis current, or a history of, bladder cancer uninvestigated macroscopic haematuria..	
hypoglycaemia management	0	1.0	2	DVLA guidance (At a glance guide to the current medical standards of fitness to drive)management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional. 1.6.33 When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance.	DVLA guidance (At a glance guide to the current medical standards of fitness to drive)management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional. 1.6.33 When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance.	
impairment diabetic	0	1.0	2	Page 22of 44 hepatic impairment diabetic ketoacidosis current, or a history of, bladder cancer uninvestigated macroscopic haematuria..	Page 22of 44 hepatic impairment diabetic ketoacidosis current, or a history of, bladder cancer uninvestigated macroscopic haematuria..	
independent assessors	0	1.0	2	It is quality assured, and reviewed by trained, competent, independent assessors whomeasure it against criteria that ensure consistency..	It is quality assured, and reviewed by trained, competent, independent assessors whomeasure it against criteria that ensure consistency..	
individual clinical	0	1.0	2	Page 20of 44 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost)..	Page 20of 44 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost)..	
individual hba1c	0	1.0	2	Targets1.6.5 Involve adults with type 2 diabetes in decisions about their individual HbA1c target.	Targets1.6.5 Involve adults with type 2 diabetes in decisions about their individual HbA1c target.	
individual preferences	0	1.0	2	Page 20of 44 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost)..	Page 20of 44 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost)..	
inhibitors,glucagon-like peptide-1	0	1.0	2	Recommendations in this section that cover dipeptidyl peptidase-4 (DPP-4) inhibitors,glucagon-like peptide-1 (GLP-1) mimetics and sulfonylureas refer to each of these groups of drugs at a class level. 1.6.17 For adults with type 2 diabetes, discuss the benefits and risks of drug treatment, and the options available.	Recommendations in this section that cover dipeptidyl peptidase-4 (DPP-4) inhibitors,glucagon-like peptide-1 (GLP-1) mimetics and sulfonylureas refer to each of these groups of drugs at a class level. 1.6.17 For adults with type 2 diabetes, discuss the benefits and risks of drug treatment, and the options available.	
initial drugtreatment	0	1.0	2	Initial drugtreatment.	Initial drugtreatment.	
insulin delivery	0	1.0	2	Insulin delivery1.6.38 For guidance on insulin delivery for adults with type 2 diabetes, see the insulin delivery section in the NICE guideline on type 1 diabetes. 1.7 Managing complications.	Insulin delivery1.6.38 For guidance on insulin delivery for adults with type 2 diabetes, see the insulin delivery section in the NICE guideline on type 1 diabetes. 1.7 Managing complications.	
insulin preparation.	0	1.0	2	HbA1c is 75 mmol mol 9.0percent or higher), administered either:separately or as a pre-mixed (biphasic) human insulin preparation..	HbA1c is 75 mmol mol 9.0percent or higher), administered either:separately or as a pre-mixed (biphasic) human insulin preparation..	
insulin types	0	1.0	2	Review thecontinued need for other blood glucose lowering therapies . 1.6.34 Start insulin therapy for adults with type 2 diabetes from a choice of a number of insulin types and regimens:.	Review thecontinued need for other blood glucose lowering therapies . 1.6.34 Start insulin therapy for adults with type 2 diabetes from a choice of a number of insulin types and regimens:.	
intercurrent illness	0	1.0	2	For more information, seethe NICE guideline on diabetes in pregnancy. 1.6.14 Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia. 1.6.15 Be aware that adults with type 2 diabetes who have acute intercurrent illness are at risk of worsening hyperglycaemia.	For more information, seethe NICE guideline on diabetes in pregnancy. 1.6.14 Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia. 1.6.15 Be aware that adults with type 2 diabetes who have acute intercurrent illness are at risk of worsening hyperglycaemia.	
international federation	0	1.0	2	International Federation of Clinical Chemistry (IFCC) standardisation.1.6.3 If HbA1c monitoring is invalid because of disturbed erythrocyte turnover or abnormal haemoglobin type, estimate trends in blood glucose control using one.	International Federation of Clinical Chemistry (IFCC) standardisation.1.6.3 If HbA1c monitoring is invalid because of disturbed erythrocyte turnover or abnormal haemoglobin type, estimate trends in blood glucose control using one.	
intravenous corticosteroids	0	1.0	2	For more information, seethe NICE guideline on diabetes in pregnancy. 1.6.14 Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia. 1.6.15 Be aware that adults with type 2 diabetes who have acute intercurrent illness are at risk of worsening hyperglycaemia.	For more information, seethe NICE guideline on diabetes in pregnancy. 1.6.14 Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia. 1.6.15 Be aware that adults with type 2 diabetes who have acute intercurrent illness are at risk of worsening hyperglycaemia.	
involve adults	0	1.0	2	Targets1.6.5 Involve adults with type 2 diabetes in decisions about their individual HbA1c target.	Targets1.6.5 Involve adults with type 2 diabetes in decisions about their individual HbA1c target.	
ketoacidosis current	0	1.0	2	Page 22of 44 hepatic impairment diabetic ketoacidosis current, or a history of, bladder cancer uninvestigated macroscopic haematuria..	Page 22of 44 hepatic impairment diabetic ketoacidosis current, or a history of, bladder cancer uninvestigated macroscopic haematuria..	
licensed indications	0	1.0	2	Page 20of 44 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost)..	Page 20of 44 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost)..	
low hba1clevel	0	1.0	2	Be aware that there are other possible reasons for a low HbA1clevel, for example, deteriorating renal function or sudden weight loss. 1.6.11 For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy..	Be aware that there are other possible reasons for a low HbA1clevel, for example, deteriorating renal function or sudden weight loss. 1.6.11 For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy..	
macroscopic haematuria.	0	1.0	2	Page 22of 44 hepatic impairment diabetic ketoacidosis current, or a history of, bladder cancer uninvestigated macroscopic haematuria..	Page 22of 44 hepatic impairment diabetic ketoacidosis current, or a history of, bladder cancer uninvestigated macroscopic haematuria..	
medications used.	0	1.0	2	Offer and reinforcepreventive lifestyle advice. 1.4.2 For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used..	Offer and reinforcepreventive lifestyle advice. 1.4.2 For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used..	
minute 1.73m2.	0	1.0	4	Stop metformin if the eGFR is below 30 ml minute 1.73m2..	Prescribe metformin with caution for those at risk of a sudden deterioration in kidneyfunction and those at risk of eGFR falling below 45 ml minute 1.73m2. 1.6.23 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea. 1.6.24 In adults with type 2 diabetes, do not offer or continue pioglitazone if they have any of the following: heart failure or history of heart failure.	Stop metformin if the eGFR is below 30 ml minute 1.73m2..	Prescribe metformin with caution for those at risk of a sudden deterioration in kidneyfunction and those at risk of eGFR falling below 45 ml minute 1.73m2. 1.6.23 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea. 1.6.24 In adults with type 2 diabetes, do not offer or continue pioglitazone if they have any of the following: heart failure or history of heart failure.	
mol 9.0percent	0	1.0	2	HbA1c is 75 mmol mol 9.0percent or higher), administered either:separately or as a pre-mixed (biphasic) human insulin preparation..	HbA1c is 75 mmol mol 9.0percent or higher), administered either:separately or as a pre-mixed (biphasic) human insulin preparation..	
multidisciplinary team	0	1.0	2	Page 24of 44 1.6.31 In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team ..	Page 24of 44 1.6.31 In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team ..	
neuropathy symptoms	0	1.0	2	Page 28of 44 1.7.10 In managing autonomic neuropathy symptoms, include specific interventions indicated by the manifestations (for example, for abnormal sweating or nocturnal diarrhoea)..	Page 28of 44 1.7.10 In managing autonomic neuropathy symptoms, include specific interventions indicated by the manifestations (for example, for abnormal sweating or nocturnal diarrhoea)..	
nocturnal diarrhoea).	0	1.0	2	Page 28of 44 1.7.10 In managing autonomic neuropathy symptoms, include specific interventions indicated by the manifestations (for example, for abnormal sweating or nocturnal diarrhoea)..	Page 28of 44 1.7.10 In managing autonomic neuropathy symptoms, include specific interventions indicated by the manifestations (for example, for abnormal sweating or nocturnal diarrhoea)..	
offer nph	0	1.0	2	Offer NPH insulin injected once or twice daily according to need..	Offer NPH insulin injected once or twice daily according to need..	
ofthe methods	0	1.0	2	The full guideline gives details ofthe methods and the evidence used to develop the guidance..	The full guideline gives details ofthe methods and the evidence used to develop the guidance..	
ongoing support	0	1.0	2	Page 24of 44 1.6.31 In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team ..	Page 24of 44 1.6.31 In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team ..	
orclinical biochemistry.	0	1.0	2	Seek advice from a team with specialist expertise in diabetes orclinical biochemistry..	Seek advice from a team with specialist expertise in diabetes orclinical biochemistry..	
page 11of	0	1.0	2	Page 11of 44 1 Recommendations.	Page 11of 44 1 Recommendations.	
page 12of	0	1.0	2	Page 12of 44 annual reinforcement and review.	Page 12of 44 annual reinforcement and review.	
page 19of	0	1.0	2	Page 19of 44 the person is pregnant, or is planning to become pregnant.	Page 19of 44 the person is pregnant, or is planning to become pregnant.	
page 20of	0	1.0	2	Page 20of 44 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost)..	Page 20of 44 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost)..	
page 21of	0	1.0	2	Page 21of 44 1.6.22 In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute 1.73m2:.	Page 21of 44 1.6.22 In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute 1.73m2:.	
page 22of	0	1.0	2	Page 22of 44 hepatic impairment diabetic ketoacidosis current, or a history of, bladder cancer uninvestigated macroscopic haematuria..	Page 22of 44 hepatic impairment diabetic ketoacidosis current, or a history of, bladder cancer uninvestigated macroscopic haematuria..	
page 23of	0	1.0	2	Page 23of 44.	Page 23of 44.	
page 24of	0	1.0	2	Page 24of 44 1.6.31 In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team ..	Page 24of 44 1.6.31 In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team ..	
page 25of	0	1.0	2	Page 25of 44.	Page 25of 44.	
page 28of	0	1.0	2	Page 28of 44 1.7.10 In managing autonomic neuropathy symptoms, include specific interventions indicated by the manifestations (for example, for abnormal sweating or nocturnal diarrhoea)..	Page 28of 44 1.7.10 In managing autonomic neuropathy symptoms, include specific interventions indicated by the manifestations (for example, for abnormal sweating or nocturnal diarrhoea)..	
painful diabetic	0	1.0	2	Painful diabetic neuropathy1.7.5 For guidance on managing painful diabetic peripheral neuropathy in adults with type 2 diabetes, see the NICE guideline on neuropathic pain in adults..	Painful diabetic neuropathy1.7.5 For guidance on managing painful diabetic peripheral neuropathy in adults with type 2 diabetes, see the NICE guideline on neuropathic pain in adults..	
pdf here.	0	1.0	2	Download the PDF here..	Download the PDF here..	
pressure control	0	1.0	2	Offer and reinforcepreventive lifestyle advice. 1.4.2 For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used..	Offer and reinforcepreventive lifestyle advice. 1.4.2 For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used..	
product characteristics	0	1.0	2	Known risk factors for these conditions, including increased age,should be carefully evaluated before treatment: see the manufacturers' summaries of product characteristics for details.	Known risk factors for these conditions, including increased age,should be carefully evaluated before treatment: see the manufacturers' summaries of product characteristics for details.	
reinforcepreventive lifestyle	0	1.0	2	Offer and reinforcepreventive lifestyle advice. 1.4.2 For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used..	Offer and reinforcepreventive lifestyle advice. 1.4.2 For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used..	
renal function	0	1.0	2	Be aware that there are other possible reasons for a low HbA1clevel, for example, deteriorating renal function or sudden weight loss. 1.6.11 For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy..	Be aware that there are other possible reasons for a low HbA1clevel, for example, deteriorating renal function or sudden weight loss. 1.6.11 For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy..	
rescue therapy	0	1.0	2	Rescue therapy at any phase of treatment1.6.18 If an adult with type 2 diabetes is symptomatically hyperglycaemic, consider insulin (see recommendations 1.6.32–1.6.34) or a sulfonylurea, and review treatment when blood glucose control has been achieved..	Rescue therapy at any phase of treatment1.6.18 If an adult with type 2 diabetes is symptomatically hyperglycaemic, consider insulin (see recommendations 1.6.32–1.6.34) or a sulfonylurea, and review treatment when blood glucose control has been achieved..	
review thecontinued	0	1.0	2	Review thecontinued need for other blood glucose lowering therapies . 1.6.34 Start insulin therapy for adults with type 2 diabetes from a choice of a number of insulin types and regimens:.	Review thecontinued need for other blood glucose lowering therapies . 1.6.34 Start insulin therapy for adults with type 2 diabetes from a choice of a number of insulin types and regimens:.	
risk factors	0	1.0	2	Known risk factors for these conditions, including increased age,should be carefully evaluated before treatment: see the manufacturers' summaries of product characteristics for details.	Known risk factors for these conditions, including increased age,should be carefully evaluated before treatment: see the manufacturers' summaries of product characteristics for details.	
seek advice	0	1.0	2	Seek advice from a team with specialist expertise in diabetes orclinical biochemistry..	Seek advice from a team with specialist expertise in diabetes orclinical biochemistry..	
seethe nice	0	1.0	2	For more information, seethe NICE guideline on diabetes in pregnancy. 1.6.14 Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia. 1.6.15 Be aware that adults with type 2 diabetes who have acute intercurrent illness are at risk of worsening hyperglycaemia.	For more information, seethe NICE guideline on diabetes in pregnancy. 1.6.14 Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia. 1.6.15 Be aware that adults with type 2 diabetes who have acute intercurrent illness are at risk of worsening hyperglycaemia.	
self-manage diabetes.	0	1.0	2	It has specific aims and learning objectives, and supports the person and their familymembers and carers in developing attitudes, beliefs, knowledge and skills to self-manage diabetes..	It has specific aims and learning objectives, and supports the person and their familymembers and carers in developing attitudes, beliefs, knowledge and skills to self-manage diabetes..	
short-acting insulin	0	1.0	6	Consider starting both NPH and short-acting insulin (particularly if the person's.	Consider pre-mixed (biphasic) preparations that include short-acting insulinanalogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals. 1.6.35 Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of.	Page 26of 44 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 1.6.36 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 1.6.37 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate..	Consider starting both NPH and short-acting insulin (particularly if the person's.	Consider pre-mixed (biphasic) preparations that include short-acting insulinanalogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals. 1.6.35 Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of.	Page 26of 44 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 1.6.36 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 1.6.37 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate..	
short-term self-monitoring	0	1.0	2	For more information, seethe NICE guideline on diabetes in pregnancy. 1.6.14 Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia. 1.6.15 Be aware that adults with type 2 diabetes who have acute intercurrent illness are at risk of worsening hyperglycaemia.	For more information, seethe NICE guideline on diabetes in pregnancy. 1.6.14 Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia. 1.6.15 Be aware that adults with type 2 diabetes who have acute intercurrent illness are at risk of worsening hyperglycaemia.	
single non-insulin	0	1.0	2	Treatment with a single non-insulin blood glucose lowering therapy(monotherapy).	Treatment with a single non-insulin blood glucose lowering therapy(monotherapy).	
specialist care	0	1.0	2	Page 24of 44 1.6.31 In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team ..	Page 24of 44 1.6.31 In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team ..	
specialist expertise	0	1.0	2	Seek advice from a team with specialist expertise in diabetes orclinical biochemistry..	Seek advice from a team with specialist expertise in diabetes orclinical biochemistry..	
specific aims	0	1.0	2	It has specific aims and learning objectives, and supports the person and their familymembers and carers in developing attitudes, beliefs, knowledge and skills to self-manage diabetes..	It has specific aims and learning objectives, and supports the person and their familymembers and carers in developing attitudes, beliefs, knowledge and skills to self-manage diabetes..	
specific interventions	0	1.0	2	Page 28of 44 1.7.10 In managing autonomic neuropathy symptoms, include specific interventions indicated by the manifestations (for example, for abnormal sweating or nocturnal diarrhoea)..	Page 28of 44 1.7.10 In managing autonomic neuropathy symptoms, include specific interventions indicated by the manifestations (for example, for abnormal sweating or nocturnal diarrhoea)..	
standard-release metformin	0	1.0	2	Initial drug treatment1.6.19 Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes. 1.6.20 Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes. 1.6.21 If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin..	Initial drug treatment1.6.19 Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes. 1.6.20 Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes. 1.6.21 If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin..	
start insulin	0	1.0	2	Review thecontinued need for other blood glucose lowering therapies . 1.6.34 Start insulin therapy for adults with type 2 diabetes from a choice of a number of insulin types and regimens:.	Review thecontinued need for other blood glucose lowering therapies . 1.6.34 Start insulin therapy for adults with type 2 diabetes from a choice of a number of insulin types and regimens:.	
starting insulin	0	1.0	6	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	Insulin-based treatments1.6.32 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding.	DVLA guidance (At a glance guide to the current medical standards of fitness to drive)management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional. 1.6.33 When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance.	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	Insulin-based treatments1.6.32 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding.	DVLA guidance (At a glance guide to the current medical standards of fitness to drive)management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional. 1.6.33 When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance.	
stop metformin	0	1.0	2	Stop metformin if the eGFR is below 30 ml minute 1.73m2..	Stop metformin if the eGFR is below 30 ml minute 1.73m2..	
structured assessment	0	1.0	2	Review treatment as necessary.1.6.16 If adults with type 2 diabetes are self-monitoring their blood glucose levels, carry out a structured assessment at least annually.	Review treatment as necessary.1.6.16 If adults with type 2 diabetes are self-monitoring their blood glucose levels, carry out a structured assessment at least annually.	
structured curriculum	0	1.0	2	It has a structured curriculum that is theory-driven, evidence-based andresource-effective, has supporting materials, and is written down..	It has a structured curriculum that is theory-driven, evidence-based andresource-effective, has supporting materials, and is written down..	
sudden weight	0	1.0	2	Be aware that there are other possible reasons for a low HbA1clevel, for example, deteriorating renal function or sudden weight loss. 1.6.11 For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy..	Be aware that there are other possible reasons for a low HbA1clevel, for example, deteriorating renal function or sudden weight loss. 1.6.11 For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy..	
supporting materials	0	1.0	2	It has a structured curriculum that is theory-driven, evidence-based andresource-effective, has supporting materials, and is written down..	It has a structured curriculum that is theory-driven, evidence-based andresource-effective, has supporting materials, and is written down..	
suspected hypoglycaemia	0	1.0	2	For more information, seethe NICE guideline on diabetes in pregnancy. 1.6.14 Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia. 1.6.15 Be aware that adults with type 2 diabetes who have acute intercurrent illness are at risk of worsening hyperglycaemia.	For more information, seethe NICE guideline on diabetes in pregnancy. 1.6.14 Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia. 1.6.15 Be aware that adults with type 2 diabetes who have acute intercurrent illness are at risk of worsening hyperglycaemia.	
targets1.6.5 involve	0	1.0	2	Targets1.6.5 Involve adults with type 2 diabetes in decisions about their individual HbA1c target.	Targets1.6.5 Involve adults with type 2 diabetes in decisions about their individual HbA1c target.	
terms-and-conditions notice-of-rights	0	1.0	36	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	
theadverse effects	0	1.0	2	When prescribing pioglitazone, exercise particular caution if the person is at high risk of theadverse effects of the drug.	When prescribing pioglitazone, exercise particular caution if the person is at high risk of theadverse effects of the drug.	
thecalcium-channel blocker	0	1.0	2	Add the other drug (that is, thecalcium-channel blocker or diuretic) if the target is not reached with dual therapy 2009, amended 2015.	Add the other drug (that is, thecalcium-channel blocker or diuretic) if the target is not reached with dual therapy 2009, amended 2015.	
trained educators	0	1.0	2	It is delivered by trained educators who have an understanding of educational theoryappropriate to the age and needs of the person, and who are trained and competent to deliver the principles and content of the programme..	It is delivered by trained educators who have an understanding of educational theoryappropriate to the age and needs of the person, and who are trained and competent to deliver the principles and content of the programme..	
www.nice.org.uk terms-and-conditions	0	1.0	36	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	Subject to Notice of rights (https: www.nice.org.uk terms-and-conditions notice-of-rights).	
autonomic neuropathy	0	0.933	4	Autonomic neuropathy1.7.6 Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015 1.7.7 Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015 1.7.8 When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension. 1.7.9 Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems..	Page 28of 44 1.7.10 In managing autonomic neuropathy symptoms, include specific interventions indicated by the manifestations (for example, for abnormal sweating or nocturnal diarrhoea)..	Autonomic neuropathy1.7.6 Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015 1.7.7 Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015 1.7.8 When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension. 1.7.9 Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems..	Page 28of 44 1.7.10 In managing autonomic neuropathy symptoms, include specific interventions indicated by the manifestations (for example, for abnormal sweating or nocturnal diarrhoea)..	
drug treatment(s)	0	0.933	4	Base the choice of drug treatment(s) on:the effectiveness of the drug treatment(s) in terms of metabolic response.	Page 20of 44 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost)..	Base the choice of drug treatment(s) on:the effectiveness of the drug treatment(s) in terms of metabolic response.	Page 20of 44 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost)..	
calcium-channel blocker	0	0.8662	4	Caribbean family origin should be an ACE inhibitor plus either a diuretic or ageneric calcium-channel blocker. 1.4.9 A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant. 1.4.10 For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor. 1.4.11 Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension. 1.4.12 If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic).	Add the other drug (that is, thecalcium-channel blocker or diuretic) if the target is not reached with dual therapy 2009, amended 2015.	Caribbean family origin should be an ACE inhibitor plus either a diuretic or ageneric calcium-channel blocker. 1.4.9 A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant. 1.4.10 For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor. 1.4.11 Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension. 1.4.12 If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic).	Add the other drug (that is, thecalcium-channel blocker or diuretic) if the target is not reached with dual therapy 2009, amended 2015.	
healthcare products	0	0.866	4	Medicines and Healthcare products Regulatory Agency (MHRA)guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'..	Page 20of 44 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost)..	Medicines and Healthcare products Regulatory Agency (MHRA)guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'..	Page 20of 44 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost)..	
products regulatory	0	0.866	4	Medicines and Healthcare products Regulatory Agency (MHRA)guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'..	Page 20of 44 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost)..	Medicines and Healthcare products Regulatory Agency (MHRA)guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'..	Page 20of 44 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost)..	
regulatory agency	0	0.866	4	Medicines and Healthcare products Regulatory Agency (MHRA)guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'..	Page 20of 44 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost)..	Medicines and Healthcare products Regulatory Agency (MHRA)guidance (2011) advises that 'prescribers should review the safety and efficacy of pioglitazone in individuals after 3–6 months of treatment to ensure that only patients who are deriving benefit continue to be treated'..	Page 20of 44 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost)..	
combination therapy	0	0.811	8	Treatment with combinations of medicines including sodium–glucose cotransporter 2 (SGLT-2)inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes..	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate forsome people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in triple therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes..	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate forsome people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes..	Treatment with combinations of medicines including sodium–glucose cotransporter 2 (SGLT-2)inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes..	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate forsome people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in triple therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes..	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate forsome people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes..	
care 1.1.1	0	0.8013	2	Treatment with either 3 non-insulin blood glucose lowering therapies incombination (triple therapy) or any treatment combination containing insulin 1.1 Individualised care 1.1.1 Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy..	Treatment with either 3 non-insulin blood glucose lowering therapies incombination (triple therapy) or any treatment combination containing insulin 1.1 Individualised care 1.1.1 Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy..	
individualised care	0	0.8013	2	Treatment with either 3 non-insulin blood glucose lowering therapies incombination (triple therapy) or any treatment combination containing insulin 1.1 Individualised care 1.1.1 Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy..	Treatment with either 3 non-insulin blood glucose lowering therapies incombination (triple therapy) or any treatment combination containing insulin 1.1 Individualised care 1.1.1 Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy..	
insulin 1.1	0	0.8013	2	Treatment with either 3 non-insulin blood glucose lowering therapies incombination (triple therapy) or any treatment combination containing insulin 1.1 Individualised care 1.1.1 Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy..	Treatment with either 3 non-insulin blood glucose lowering therapies incombination (triple therapy) or any treatment combination containing insulin 1.1 Individualised care 1.1.1 Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy..	
life expectancy.	0	0.8013	2	Treatment with either 3 non-insulin blood glucose lowering therapies incombination (triple therapy) or any treatment combination containing insulin 1.1 Individualised care 1.1.1 Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy..	Treatment with either 3 non-insulin blood glucose lowering therapies incombination (triple therapy) or any treatment combination containing insulin 1.1 Individualised care 1.1.1 Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy..	
long-term interventions	0	0.8013	2	Treatment with either 3 non-insulin blood glucose lowering therapies incombination (triple therapy) or any treatment combination containing insulin 1.1 Individualised care 1.1.1 Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy..	Treatment with either 3 non-insulin blood glucose lowering therapies incombination (triple therapy) or any treatment combination containing insulin 1.1 Individualised care 1.1.1 Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy..	
personal preferences	0	0.8013	2	Treatment with either 3 non-insulin blood glucose lowering therapies incombination (triple therapy) or any treatment combination containing insulin 1.1 Individualised care 1.1.1 Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy..	Treatment with either 3 non-insulin blood glucose lowering therapies incombination (triple therapy) or any treatment combination containing insulin 1.1 Individualised care 1.1.1 Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy..	
treatment combination	0	0.8013	2	Treatment with either 3 non-insulin blood glucose lowering therapies incombination (triple therapy) or any treatment combination containing insulin 1.1 Individualised care 1.1.1 Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy..	Treatment with either 3 non-insulin blood glucose lowering therapies incombination (triple therapy) or any treatment combination containing insulin 1.1 Individualised care 1.1.1 Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy..	
review treatment	0	0.7875	6	For more information, seethe NICE guideline on diabetes in pregnancy. 1.6.14 Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia. 1.6.15 Be aware that adults with type 2 diabetes who have acute intercurrent illness are at risk of worsening hyperglycaemia.	Review treatment as necessary.1.6.16 If adults with type 2 diabetes are self-monitoring their blood glucose levels, carry out a structured assessment at least annually.	Rescue therapy at any phase of treatment1.6.18 If an adult with type 2 diabetes is symptomatically hyperglycaemic, consider insulin (see recommendations 1.6.32–1.6.34) or a sulfonylurea, and review treatment when blood glucose control has been achieved..	For more information, seethe NICE guideline on diabetes in pregnancy. 1.6.14 Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia. 1.6.15 Be aware that adults with type 2 diabetes who have acute intercurrent illness are at risk of worsening hyperglycaemia.	Review treatment as necessary.1.6.16 If adults with type 2 diabetes are self-monitoring their blood glucose levels, carry out a structured assessment at least annually.	Rescue therapy at any phase of treatment1.6.18 If an adult with type 2 diabetes is symptomatically hyperglycaemic, consider insulin (see recommendations 1.6.32–1.6.34) or a sulfonylurea, and review treatment when blood glucose control has been achieved..	
therapies incombination	0	0.7799	4	Treatment with 2 non-insulin blood glucose lowering therapies incombination (dual therapy).	Treatment with either 3 non-insulin blood glucose lowering therapies incombination (triple therapy) or any treatment combination containing insulin 1.1 Individualised care 1.1.1 Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy..	Treatment with 2 non-insulin blood glucose lowering therapies incombination (dual therapy).	Treatment with either 3 non-insulin blood glucose lowering therapies incombination (triple therapy) or any treatment combination containing insulin 1.1 Individualised care 1.1.1 Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy..	
antiplatelet therapy	0	0.7699	2	Check forpossible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure. 1.5 Antiplatelet therapy 1.5.1 Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease. 1.5.2 For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction. 1.6 Blood glucose management.	Check forpossible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure. 1.5 Antiplatelet therapy 1.5.1 Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease. 1.5.2 For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction. 1.6 Blood glucose management.	
1.3.4 integrate	0	0.7649	2	Encouragehigh-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids. 1.3.4 Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight. 1.3.5 For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent.	Encouragehigh-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids. 1.3.4 Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight. 1.3.5 For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent.	
dairy products	0	0.7649	2	Encouragehigh-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids. 1.3.4 Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight. 1.3.5 For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent.	Encouragehigh-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids. 1.3.4 Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight. 1.3.5 For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent.	
diabetes management	0	0.7649	2	Encouragehigh-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids. 1.3.4 Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight. 1.3.5 For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent.	Encouragehigh-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids. 1.3.4 Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight. 1.3.5 For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent.	
fatty acids	0	0.7649	2	Encouragehigh-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids. 1.3.4 Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight. 1.3.5 For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent.	Encouragehigh-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids. 1.3.4 Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight. 1.3.5 For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent.	
integrate dietary	0	0.7649	2	Encouragehigh-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids. 1.3.4 Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight. 1.3.5 For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent.	Encouragehigh-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids. 1.3.4 Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight. 1.3.5 For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent.	
lifestyle modification	0	0.7649	2	Encouragehigh-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids. 1.3.4 Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight. 1.3.5 For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent.	Encouragehigh-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids. 1.3.4 Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight. 1.3.5 For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent.	
loss target	0	0.7649	2	Encouragehigh-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids. 1.3.4 Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight. 1.3.5 For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent.	Encouragehigh-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids. 1.3.4 Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight. 1.3.5 For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent.	
low-fat dairy	0	0.7649	2	Encouragehigh-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids. 1.3.4 Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight. 1.3.5 For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent.	Encouragehigh-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids. 1.3.4 Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight. 1.3.5 For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent.	
low-glycaemic-index sources	0	0.7649	2	Encouragehigh-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids. 1.3.4 Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight. 1.3.5 For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent.	Encouragehigh-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids. 1.3.4 Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight. 1.3.5 For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent.	
management plan	0	0.7649	2	Encouragehigh-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids. 1.3.4 Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight. 1.3.5 For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent.	Encouragehigh-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids. 1.3.4 Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight. 1.3.5 For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent.	
oily fish	0	0.7649	2	Encouragehigh-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids. 1.3.4 Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight. 1.3.5 For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent.	Encouragehigh-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids. 1.3.4 Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight. 1.3.5 For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent.	
recommendation 1.6.26	0	0.7649	2	HbA1c and a weight loss of at least 3percent of initial body weight in 6 months).1.6.30 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation 1.6.26) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations 1.6.32–1.6.34)..	HbA1c and a weight loss of at least 3percent of initial body weight in 6 months).1.6.30 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation 1.6.26) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations 1.6.32–1.6.34)..	
recommendations 1.6.32–1.6.34).	0	0.7649	4	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	HbA1c and a weight loss of at least 3percent of initial body weight in 6 months).1.6.30 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation 1.6.26) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations 1.6.32–1.6.34)..	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	HbA1c and a weight loss of at least 3percent of initial body weight in 6 months).1.6.30 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation 1.6.26) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations 1.6.32–1.6.34)..	
trans fatty	0	0.7649	2	Encouragehigh-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids. 1.3.4 Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight. 1.3.5 For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent.	Encouragehigh-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids. 1.3.4 Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight. 1.3.5 For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent.	
non-insulin blood	0	0.7354	6	Treatment with a single non-insulin blood glucose lowering therapy(monotherapy).	Treatment with 2 non-insulin blood glucose lowering therapies incombination (dual therapy).	Treatment with either 3 non-insulin blood glucose lowering therapies incombination (triple therapy) or any treatment combination containing insulin 1.1 Individualised care 1.1.1 Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy..	Treatment with a single non-insulin blood glucose lowering therapy(monotherapy).	Treatment with 2 non-insulin blood glucose lowering therapies incombination (dual therapy).	Treatment with either 3 non-insulin blood glucose lowering therapies incombination (triple therapy) or any treatment combination containing insulin 1.1 Individualised care 1.1.1 Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy..	
ace inhibitor	0	0.7313	4	Caribbean family origin should be an ACE inhibitor plus either a diuretic or ageneric calcium-channel blocker. 1.4.9 A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant. 1.4.10 For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor. 1.4.11 Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension. 1.4.12 If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic).	Page 16of 44 1.4.13 If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist). 1.4.14 Monitor the blood pressure of a person who has attained and consistently remained at his or her blood pressure target every 4–6 months.	Caribbean family origin should be an ACE inhibitor plus either a diuretic or ageneric calcium-channel blocker. 1.4.9 A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant. 1.4.10 For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor. 1.4.11 Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension. 1.4.12 If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic).	Page 16of 44 1.4.13 If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist). 1.4.14 Monitor the blood pressure of a person who has attained and consistently remained at his or her blood pressure target every 4–6 months.	
kidney disease	1	0.7287	4	Diabetic kidney disease1.7.12 For guidance on managing kidney disease in adults with type 2 diabetes, see the.	NICE guideline on chronic kidney disease in adults..	Diabetic kidney disease1.7.12 For guidance on managing kidney disease in adults with type 2 diabetes, see the.	NICE guideline on chronic kidney disease in adults..	
hba1c target	0	0.6837	6	Targets1.6.5 Involve adults with type 2 diabetes in decisions about their individual HbA1c target.	Encourage them to achieve the target and maintain it unless anyresulting adverse effects (including hypoglycaemia), or their efforts to achieve their target, impair their quality of life. 1.6.6 Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section 1.3).	Be aware that there are other possible reasons for a low HbA1clevel, for example, deteriorating renal function or sudden weight loss. 1.6.11 For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy..	Targets1.6.5 Involve adults with type 2 diabetes in decisions about their individual HbA1c target.	Encourage them to achieve the target and maintain it unless anyresulting adverse effects (including hypoglycaemia), or their efforts to achieve their target, impair their quality of life. 1.6.6 Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section 1.3).	Be aware that there are other possible reasons for a low HbA1clevel, for example, deteriorating renal function or sudden weight loss. 1.6.11 For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy..	
1.2 patient	0	0.6831	2	Reassess the person's needs and circumstances at each review and think aboutwhether to stop any medicines that are not effective. 1.1.2 Take into account any disabilities, including visual impairment, when planning and delivering care for adults with type 2 diabetes. 1.2 Patient education 1.2.1 Offer structured education to adults with type 2 diabetes and or their family members or carers (as appropriate) at and around the time of diagnosis, with.	Reassess the person's needs and circumstances at each review and think aboutwhether to stop any medicines that are not effective. 1.1.2 Take into account any disabilities, including visual impairment, when planning and delivering care for adults with type 2 diabetes. 1.2 Patient education 1.2.1 Offer structured education to adults with type 2 diabetes and or their family members or carers (as appropriate) at and around the time of diagnosis, with.	
1.2.1 offer	0	0.6831	2	Reassess the person's needs and circumstances at each review and think aboutwhether to stop any medicines that are not effective. 1.1.2 Take into account any disabilities, including visual impairment, when planning and delivering care for adults with type 2 diabetes. 1.2 Patient education 1.2.1 Offer structured education to adults with type 2 diabetes and or their family members or carers (as appropriate) at and around the time of diagnosis, with.	Reassess the person's needs and circumstances at each review and think aboutwhether to stop any medicines that are not effective. 1.1.2 Take into account any disabilities, including visual impairment, when planning and delivering care for adults with type 2 diabetes. 1.2 Patient education 1.2.1 Offer structured education to adults with type 2 diabetes and or their family members or carers (as appropriate) at and around the time of diagnosis, with.	
1.2.2 ensure	0	0.6831	2	Explain to people and their carers thatstructured education is an integral part of diabetes care. 1.2.2 Ensure that any structured education programme for adults with type 2 diabetes includes the following components:.	Explain to people and their carers thatstructured education is an integral part of diabetes care. 1.2.2 Ensure that any structured education programme for adults with type 2 diabetes includes the following components:.	
carers thatstructured	0	0.6831	2	Explain to people and their carers thatstructured education is an integral part of diabetes care. 1.2.2 Ensure that any structured education programme for adults with type 2 diabetes includes the following components:.	Explain to people and their carers thatstructured education is an integral part of diabetes care. 1.2.2 Ensure that any structured education programme for adults with type 2 diabetes includes the following components:.	
diabetic kidney	0	0.6831	2	Diabetic kidney disease1.7.12 For guidance on managing kidney disease in adults with type 2 diabetes, see the.	Diabetic kidney disease1.7.12 For guidance on managing kidney disease in adults with type 2 diabetes, see the.	
education 1.2.1	0	0.6831	2	Reassess the person's needs and circumstances at each review and think aboutwhether to stop any medicines that are not effective. 1.1.2 Take into account any disabilities, including visual impairment, when planning and delivering care for adults with type 2 diabetes. 1.2 Patient education 1.2.1 Offer structured education to adults with type 2 diabetes and or their family members or carers (as appropriate) at and around the time of diagnosis, with.	Reassess the person's needs and circumstances at each review and think aboutwhether to stop any medicines that are not effective. 1.1.2 Take into account any disabilities, including visual impairment, when planning and delivering care for adults with type 2 diabetes. 1.2 Patient education 1.2.1 Offer structured education to adults with type 2 diabetes and or their family members or carers (as appropriate) at and around the time of diagnosis, with.	
education programme	1	0.6831	6	Explain to people and their carers thatstructured education is an integral part of diabetes care. 1.2.2 Ensure that any structured education programme for adults with type 2 diabetes includes the following components:.	The outcomes are audited regularly.1.2.3 Ensure the patient-education programme provides the necessary resources to support the educators, and that educators are properly trained and given time to develop and maintain their skills. 1.2.4 Offer group education programmes as the preferred option.	Provide analternative of equal standard for a person unable or unwilling to participate in group education. 1.2.5 Ensure that the patient-education programmes available meet the cultural, linguistic, cognitive and literacy needs within the local area. 1.2.6 Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes..	Explain to people and their carers thatstructured education is an integral part of diabetes care. 1.2.2 Ensure that any structured education programme for adults with type 2 diabetes includes the following components:.	The outcomes are audited regularly.1.2.3 Ensure the patient-education programme provides the necessary resources to support the educators, and that educators are properly trained and given time to develop and maintain their skills. 1.2.4 Offer group education programmes as the preferred option.	Provide analternative of equal standard for a person unable or unwilling to participate in group education. 1.2.5 Ensure that the patient-education programmes available meet the cultural, linguistic, cognitive and literacy needs within the local area. 1.2.6 Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes..	
integral part	0	0.6831	2	Explain to people and their carers thatstructured education is an integral part of diabetes care. 1.2.2 Ensure that any structured education programme for adults with type 2 diabetes includes the following components:.	Explain to people and their carers thatstructured education is an integral part of diabetes care. 1.2.2 Ensure that any structured education programme for adults with type 2 diabetes includes the following components:.	
kidney disease1.7.12	0	0.6831	2	Diabetic kidney disease1.7.12 For guidance on managing kidney disease in adults with type 2 diabetes, see the.	Diabetic kidney disease1.7.12 For guidance on managing kidney disease in adults with type 2 diabetes, see the.	
offer structured	0	0.6831	2	Reassess the person's needs and circumstances at each review and think aboutwhether to stop any medicines that are not effective. 1.1.2 Take into account any disabilities, including visual impairment, when planning and delivering care for adults with type 2 diabetes. 1.2 Patient education 1.2.1 Offer structured education to adults with type 2 diabetes and or their family members or carers (as appropriate) at and around the time of diagnosis, with.	Reassess the person's needs and circumstances at each review and think aboutwhether to stop any medicines that are not effective. 1.1.2 Take into account any disabilities, including visual impairment, when planning and delivering care for adults with type 2 diabetes. 1.2 Patient education 1.2.1 Offer structured education to adults with type 2 diabetes and or their family members or carers (as appropriate) at and around the time of diagnosis, with.	
patient education	1	0.6831	2	Reassess the person's needs and circumstances at each review and think aboutwhether to stop any medicines that are not effective. 1.1.2 Take into account any disabilities, including visual impairment, when planning and delivering care for adults with type 2 diabetes. 1.2 Patient education 1.2.1 Offer structured education to adults with type 2 diabetes and or their family members or carers (as appropriate) at and around the time of diagnosis, with.	Reassess the person's needs and circumstances at each review and think aboutwhether to stop any medicines that are not effective. 1.1.2 Take into account any disabilities, including visual impairment, when planning and delivering care for adults with type 2 diabetes. 1.2 Patient education 1.2.1 Offer structured education to adults with type 2 diabetes and or their family members or carers (as appropriate) at and around the time of diagnosis, with.	
thatstructured education	0	0.6831	2	Explain to people and their carers thatstructured education is an integral part of diabetes care. 1.2.2 Ensure that any structured education programme for adults with type 2 diabetes includes the following components:.	Explain to people and their carers thatstructured education is an integral part of diabetes care. 1.2.2 Ensure that any structured education programme for adults with type 2 diabetes includes the following components:.	
visual impairment	0	0.6831	2	Reassess the person's needs and circumstances at each review and think aboutwhether to stop any medicines that are not effective. 1.1.2 Take into account any disabilities, including visual impairment, when planning and delivering care for adults with type 2 diabetes. 1.2 Patient education 1.2.1 Offer structured education to adults with type 2 diabetes and or their family members or carers (as appropriate) at and around the time of diagnosis, with.	Reassess the person's needs and circumstances at each review and think aboutwhether to stop any medicines that are not effective. 1.1.2 Take into account any disabilities, including visual impairment, when planning and delivering care for adults with type 2 diabetes. 1.2 Patient education 1.2.1 Offer structured education to adults with type 2 diabetes and or their family members or carers (as appropriate) at and around the time of diagnosis, with.	
mhra guidance	0	0.683	4	Page 20of 44 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost)..	Page 27of 44 take into account its safety profile, in particular its cardiac risk and potential interactions with other medicines. 1.7.3 For treating vomiting caused by gastroparesis in adults with type 2 diabetes: consider alternating use of erythomycin and metoclopramide consider domperidone only in exceptional circumstances (if domperidone is the only effective treatment) and in accordance with MHRA guidance. 1.7.4 If gastroparesis is suspected, consider referral to specialist services if: the differential diagnosis is in doubt or persistent or severe vomiting occurs..	Page 20of 44 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost)..	Page 27of 44 take into account its safety profile, in particular its cardiac risk and potential interactions with other medicines. 1.7.3 For treating vomiting caused by gastroparesis in adults with type 2 diabetes: consider alternating use of erythomycin and metoclopramide consider domperidone only in exceptional circumstances (if domperidone is the only effective treatment) and in accordance with MHRA guidance. 1.7.4 If gastroparesis is suspected, consider referral to specialist services if: the differential diagnosis is in doubt or persistent or severe vomiting occurs..	
diabetic foot	0	0.6667	2	Diabetic foot problems1.7.11 For guidance on preventing and managing foot problems in adults with type 2 diabetes, see the NICE guideline on diabetic foot problems..	Diabetic foot problems1.7.11 For guidance on preventing and managing foot problems in adults with type 2 diabetes, see the NICE guideline on diabetic foot problems..	
gastrointestinal side	0	0.6667	2	Initial drug treatment1.6.19 Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes. 1.6.20 Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes. 1.6.21 If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin..	Initial drug treatment1.6.19 Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes. 1.6.20 Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes. 1.6.21 If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin..	
significant hypoglycaemia	0	0.6667	2	Consider pre-mixed (biphasic) preparations that include short-acting insulinanalogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals. 1.6.35 Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of.	Consider pre-mixed (biphasic) preparations that include short-acting insulinanalogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals. 1.6.35 Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of.	
recent-onset type	0	0.6666	2	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	
body weight	0	0.6624	4	Encouragehigh-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids. 1.3.4 Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight. 1.3.5 For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent.	HbA1c and a weight loss of at least 3percent of initial body weight in 6 months).1.6.30 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation 1.6.26) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations 1.6.32–1.6.34)..	Encouragehigh-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids. 1.3.4 Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight. 1.3.5 For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent.	HbA1c and a weight loss of at least 3percent of initial body weight in 6 months).1.6.30 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation 1.6.26) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations 1.6.32–1.6.34)..	
initial body	0	0.6624	4	Encouragehigh-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids. 1.3.4 Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight. 1.3.5 For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent.	HbA1c and a weight loss of at least 3percent of initial body weight in 6 months).1.6.30 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation 1.6.26) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations 1.6.32–1.6.34)..	Encouragehigh-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids. 1.3.4 Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight. 1.3.5 For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent.	HbA1c and a weight loss of at least 3percent of initial body weight in 6 months).1.6.30 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation 1.6.26) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations 1.6.32–1.6.34)..	
ml minute	0	0.6563	6	Page 21of 44 1.6.22 In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute 1.73m2:.	Stop metformin if the eGFR is below 30 ml minute 1.73m2..	Prescribe metformin with caution for those at risk of a sudden deterioration in kidneyfunction and those at risk of eGFR falling below 45 ml minute 1.73m2. 1.6.23 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea. 1.6.24 In adults with type 2 diabetes, do not offer or continue pioglitazone if they have any of the following: heart failure or history of heart failure.	Page 21of 44 1.6.22 In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute 1.73m2:.	Stop metformin if the eGFR is below 30 ml minute 1.73m2..	Prescribe metformin with caution for those at risk of a sudden deterioration in kidneyfunction and those at risk of eGFR falling below 45 ml minute 1.73m2. 1.6.23 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea. 1.6.24 In adults with type 2 diabetes, do not offer or continue pioglitazone if they have any of the following: heart failure or history of heart failure.	
dipeptidyl peptidase-4	0	0.6495	4	Recommendations in this section that cover dipeptidyl peptidase-4 (DPP-4) inhibitors,glucagon-like peptide-1 (GLP-1) mimetics and sulfonylureas refer to each of these groups of drugs at a class level. 1.6.17 For adults with type 2 diabetes, discuss the benefits and risks of drug treatment, and the options available.	Prescribe metformin with caution for those at risk of a sudden deterioration in kidneyfunction and those at risk of eGFR falling below 45 ml minute 1.73m2. 1.6.23 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea. 1.6.24 In adults with type 2 diabetes, do not offer or continue pioglitazone if they have any of the following: heart failure or history of heart failure.	Recommendations in this section that cover dipeptidyl peptidase-4 (DPP-4) inhibitors,glucagon-like peptide-1 (GLP-1) mimetics and sulfonylureas refer to each of these groups of drugs at a class level. 1.6.17 For adults with type 2 diabetes, discuss the benefits and risks of drug treatment, and the options available.	Prescribe metformin with caution for those at risk of a sudden deterioration in kidneyfunction and those at risk of eGFR falling below 45 ml minute 1.73m2. 1.6.23 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea. 1.6.24 In adults with type 2 diabetes, do not offer or continue pioglitazone if they have any of the following: heart failure or history of heart failure.	
minute 1.73m2	0	0.6495	6	Page 21of 44 1.6.22 In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute 1.73m2:.	Stop metformin if the eGFR is below 30 ml minute 1.73m2..	Prescribe metformin with caution for those at risk of a sudden deterioration in kidneyfunction and those at risk of eGFR falling below 45 ml minute 1.73m2. 1.6.23 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea. 1.6.24 In adults with type 2 diabetes, do not offer or continue pioglitazone if they have any of the following: heart failure or history of heart failure.	Page 21of 44 1.6.22 In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute 1.73m2:.	Stop metformin if the eGFR is below 30 ml minute 1.73m2..	Prescribe metformin with caution for those at risk of a sudden deterioration in kidneyfunction and those at risk of eGFR falling below 45 ml minute 1.73m2. 1.6.23 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea. 1.6.24 In adults with type 2 diabetes, do not offer or continue pioglitazone if they have any of the following: heart failure or history of heart failure.	
plasma glucose	0	0.6495	4	Page 17of 44 of the following: quality-controlled plasma glucose profiles total glycated haemoglobin estimation (if abnormal haemoglobins) fructosamine estimation. 1.6.4 Investigate unexplained discrepancies between HbA1c and other glucose measurements.	DVLA guidance (At a glance guide to the current medical standards of fitness to drive)management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional. 1.6.33 When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance.	Page 17of 44 of the following: quality-controlled plasma glucose profiles total glycated haemoglobin estimation (if abnormal haemoglobins) fructosamine estimation. 1.6.4 Investigate unexplained discrepancies between HbA1c and other glucose measurements.	DVLA guidance (At a glance guide to the current medical standards of fitness to drive)management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional. 1.6.33 When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance.	
dietary advice	0	0.6431	4	Page 13of 44 1.3 Dietary advice and bariatric surgery 1.3.1 Provide individualised and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition. 1.3.2 Provide dietary advice in a form sensitive to the person's needs, culture and beliefs, being sensitive to their willingness to change and the effects on their quality of life. 1.3.3 Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes.	Encouragehigh-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids. 1.3.4 Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight. 1.3.5 For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent.	Page 13of 44 1.3 Dietary advice and bariatric surgery 1.3.1 Provide individualised and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition. 1.3.2 Provide dietary advice in a form sensitive to the person's needs, culture and beliefs, being sensitive to their willingness to change and the effects on their quality of life. 1.3.3 Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes.	Encouragehigh-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids. 1.3.4 Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight. 1.3.5 For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent.	
diabetes care	0	0.6427	4	Treatment with either 3 non-insulin blood glucose lowering therapies incombination (triple therapy) or any treatment combination containing insulin 1.1 Individualised care 1.1.1 Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy..	Explain to people and their carers thatstructured education is an integral part of diabetes care. 1.2.2 Ensure that any structured education programme for adults with type 2 diabetes includes the following components:.	Treatment with either 3 non-insulin blood glucose lowering therapies incombination (triple therapy) or any treatment combination containing insulin 1.1 Individualised care 1.1.1 Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy..	Explain to people and their carers thatstructured education is an integral part of diabetes care. 1.2.2 Ensure that any structured education programme for adults with type 2 diabetes includes the following components:.	
offer'and	0	0.6349	2	The wording used in the recommendations in this guideline (for example, words such as 'offer'and 'consider') denotes the certainty with which the recommendation is made (the strength of the recommendation).	The wording used in the recommendations in this guideline (for example, words such as 'offer'and 'consider') denotes the certainty with which the recommendation is made (the strength of the recommendation).	
assessment shouldinclude	0	0.6322	2	The assessment shouldinclude: the person's self-monitoring skills the quality and frequency of testing checking that the person knows how to interpret the blood glucose results and what action to take the impact on the person's quality of life the continued benefit to the person the equipment used..	The assessment shouldinclude: the person's self-monitoring skills the quality and frequency of testing checking that the person knows how to interpret the blood glucose results and what action to take the impact on the person's quality of life the continued benefit to the person the equipment used..	
continued benefit	0	0.6322	2	The assessment shouldinclude: the person's self-monitoring skills the quality and frequency of testing checking that the person knows how to interpret the blood glucose results and what action to take the impact on the person's quality of life the continued benefit to the person the equipment used..	The assessment shouldinclude: the person's self-monitoring skills the quality and frequency of testing checking that the person knows how to interpret the blood glucose results and what action to take the impact on the person's quality of life the continued benefit to the person the equipment used..	
equipment used.	0	0.6322	2	The assessment shouldinclude: the person's self-monitoring skills the quality and frequency of testing checking that the person knows how to interpret the blood glucose results and what action to take the impact on the person's quality of life the continued benefit to the person the equipment used..	The assessment shouldinclude: the person's self-monitoring skills the quality and frequency of testing checking that the person knows how to interpret the blood glucose results and what action to take the impact on the person's quality of life the continued benefit to the person the equipment used..	
glucose results	0	0.6322	2	The assessment shouldinclude: the person's self-monitoring skills the quality and frequency of testing checking that the person knows how to interpret the blood glucose results and what action to take the impact on the person's quality of life the continued benefit to the person the equipment used..	The assessment shouldinclude: the person's self-monitoring skills the quality and frequency of testing checking that the person knows how to interpret the blood glucose results and what action to take the impact on the person's quality of life the continued benefit to the person the equipment used..	
self-monitoring skills	0	0.6322	2	The assessment shouldinclude: the person's self-monitoring skills the quality and frequency of testing checking that the person knows how to interpret the blood glucose results and what action to take the impact on the person's quality of life the continued benefit to the person the equipment used..	The assessment shouldinclude: the person's self-monitoring skills the quality and frequency of testing checking that the person knows how to interpret the blood glucose results and what action to take the impact on the person's quality of life the continued benefit to the person the equipment used..	
sodium–glucose cotransporter	0	0.6302	4	Treatment with sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate forsome adults with type 2 diabetes if metformin is contraindicated or not tolerated (see NICE's guidance on canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes)..	Treatment with combinations of medicines including sodium–glucose cotransporter 2 (SGLT-2)inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes..	Treatment with sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate forsome adults with type 2 diabetes if metformin is contraindicated or not tolerated (see NICE's guidance on canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes)..	Treatment with combinations of medicines including sodium–glucose cotransporter 2 (SGLT-2)inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes..	
caribbean family	0	0.625	4	African or Caribbean family origin, or women for whom there is a possibility ofbecoming pregnant. 1.4.8 The first-line antihypertensive drug treatment for a person of African or.	Caribbean family origin should be an ACE inhibitor plus either a diuretic or ageneric calcium-channel blocker. 1.4.9 A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant. 1.4.10 For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor. 1.4.11 Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension. 1.4.12 If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic).	African or Caribbean family origin, or women for whom there is a possibility ofbecoming pregnant. 1.4.8 The first-line antihypertensive drug treatment for a person of African or.	Caribbean family origin should be an ACE inhibitor plus either a diuretic or ageneric calcium-channel blocker. 1.4.9 A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant. 1.4.10 For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor. 1.4.11 Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension. 1.4.12 If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic).	
family origin	0	0.625	4	African or Caribbean family origin, or women for whom there is a possibility ofbecoming pregnant. 1.4.8 The first-line antihypertensive drug treatment for a person of African or.	Caribbean family origin should be an ACE inhibitor plus either a diuretic or ageneric calcium-channel blocker. 1.4.9 A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant. 1.4.10 For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor. 1.4.11 Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension. 1.4.12 If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic).	African or Caribbean family origin, or women for whom there is a possibility ofbecoming pregnant. 1.4.8 The first-line antihypertensive drug treatment for a person of African or.	Caribbean family origin should be an ACE inhibitor plus either a diuretic or ageneric calcium-channel blocker. 1.4.9 A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant. 1.4.10 For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor. 1.4.11 Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension. 1.4.12 If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic).	
dpp-4 inhibitor	0	0.6123	4	First intensification of drug treatment1.6.25 In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea. 1.6.26 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea..	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	First intensification of drug treatment1.6.25 In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea. 1.6.26 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea..	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	
mmol mol	0	0.5997	8	For moreinformation about supporting adherence, see the NICE guideline on medicines adherence. 1.6.7 For adults with type 2 diabetes managed either by lifestyle and diet, or by lifestyle and diet combined with a single drug not associated with hypoglycaemia, support the person to aim for an HbA1c level of 48 mmol mol (6.5percent).	For adults on a drug associated with hypoglycaemia, support the personto aim for an HbA1c level of 53 mmol mol (7.0percent). 1.6.8 In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol (7.5percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol (7.0percent) and intensify drug treatment. 1.6.9 Consider relaxing the target HbA1c level (see recommendations 1.6.7 and 1.6.8).	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	HbA1c is 75 mmol mol 9.0percent or higher), administered either:separately or as a pre-mixed (biphasic) human insulin preparation..	For moreinformation about supporting adherence, see the NICE guideline on medicines adherence. 1.6.7 For adults with type 2 diabetes managed either by lifestyle and diet, or by lifestyle and diet combined with a single drug not associated with hypoglycaemia, support the person to aim for an HbA1c level of 48 mmol mol (6.5percent).	For adults on a drug associated with hypoglycaemia, support the personto aim for an HbA1c level of 53 mmol mol (7.0percent). 1.6.8 In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol (7.5percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol (7.0percent) and intensify drug treatment. 1.6.9 Consider relaxing the target HbA1c level (see recommendations 1.6.7 and 1.6.8).	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	HbA1c is 75 mmol mol 9.0percent or higher), administered either:separately or as a pre-mixed (biphasic) human insulin preparation..	
current medical	0	0.5996	4	Self-monitoring of blood glucose1.6.12 Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes. 1.6.13 Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or.	DVLA guidance (At a glance guide to the current medical standards of fitness to drive)management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional. 1.6.33 When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance.	Self-monitoring of blood glucose1.6.12 Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes. 1.6.13 Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or.	DVLA guidance (At a glance guide to the current medical standards of fitness to drive)management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional. 1.6.33 When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance.	
glance guide	0	0.5996	4	Self-monitoring of blood glucose1.6.12 Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes. 1.6.13 Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or.	DVLA guidance (At a glance guide to the current medical standards of fitness to drive)management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional. 1.6.33 When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance.	Self-monitoring of blood glucose1.6.12 Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes. 1.6.13 Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or.	DVLA guidance (At a glance guide to the current medical standards of fitness to drive)management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional. 1.6.33 When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance.	
medical standards	0	0.5996	4	Self-monitoring of blood glucose1.6.12 Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes. 1.6.13 Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or.	DVLA guidance (At a glance guide to the current medical standards of fitness to drive)management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional. 1.6.33 When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance.	Self-monitoring of blood glucose1.6.12 Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes. 1.6.13 Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or.	DVLA guidance (At a glance guide to the current medical standards of fitness to drive)management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional. 1.6.33 When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance.	
structured education	0	0.5915	4	Reassess the person's needs and circumstances at each review and think aboutwhether to stop any medicines that are not effective. 1.1.2 Take into account any disabilities, including visual impairment, when planning and delivering care for adults with type 2 diabetes. 1.2 Patient education 1.2.1 Offer structured education to adults with type 2 diabetes and or their family members or carers (as appropriate) at and around the time of diagnosis, with.	Explain to people and their carers thatstructured education is an integral part of diabetes care. 1.2.2 Ensure that any structured education programme for adults with type 2 diabetes includes the following components:.	Reassess the person's needs and circumstances at each review and think aboutwhether to stop any medicines that are not effective. 1.1.2 Take into account any disabilities, including visual impairment, when planning and delivering care for adults with type 2 diabetes. 1.2 Patient education 1.2.1 Offer structured education to adults with type 2 diabetes and or their family members or carers (as appropriate) at and around the time of diagnosis, with.	Explain to people and their carers thatstructured education is an integral part of diabetes care. 1.2.2 Ensure that any structured education programme for adults with type 2 diabetes includes the following components:.	
1.6.6 offer	0	0.5792	2	Encourage them to achieve the target and maintain it unless anyresulting adverse effects (including hypoglycaemia), or their efforts to achieve their target, impair their quality of life. 1.6.6 Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section 1.3).	Encourage them to achieve the target and maintain it unless anyresulting adverse effects (including hypoglycaemia), or their efforts to achieve their target, impair their quality of life. 1.6.6 Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section 1.3).	
adults nice	0	0.5792	2	Provide lifestyle advice (diet and exercise) at the same time.1.4.4 Provide lifestyle advice (see section 1.3 in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood.	Provide lifestyle advice (diet and exercise) at the same time.1.4.4 Provide lifestyle advice (see section 1.3 in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood.	
anyresulting adverse	0	0.5792	2	Encourage them to achieve the target and maintain it unless anyresulting adverse effects (including hypoglycaemia), or their efforts to achieve their target, impair their quality of life. 1.6.6 Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section 1.3).	Encourage them to achieve the target and maintain it unless anyresulting adverse effects (including hypoglycaemia), or their efforts to achieve their target, impair their quality of life. 1.6.6 Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section 1.3).	
guideline cg127	0	0.5792	2	Provide lifestyle advice (diet and exercise) at the same time.1.4.4 Provide lifestyle advice (see section 1.3 in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood.	Provide lifestyle advice (diet and exercise) at the same time.1.4.4 Provide lifestyle advice (see section 1.3 in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood.	
interventions section	0	0.5792	2	Provide lifestyle advice (diet and exercise) at the same time.1.4.4 Provide lifestyle advice (see section 1.3 in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood.	Provide lifestyle advice (diet and exercise) at the same time.1.4.4 Provide lifestyle advice (see section 1.3 in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood.	
lifestyle interventions	0	0.5792	2	Provide lifestyle advice (diet and exercise) at the same time.1.4.4 Provide lifestyle advice (see section 1.3 in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood.	Provide lifestyle advice (diet and exercise) at the same time.1.4.4 Provide lifestyle advice (see section 1.3 in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood.	
offer lifestyle	0	0.5792	2	Encourage them to achieve the target and maintain it unless anyresulting adverse effects (including hypoglycaemia), or their efforts to achieve their target, impair their quality of life. 1.6.6 Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section 1.3).	Encourage them to achieve the target and maintain it unless anyresulting adverse effects (including hypoglycaemia), or their efforts to achieve their target, impair their quality of life. 1.6.6 Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section 1.3).	
1.2.4 offer	0	0.5774	2	The outcomes are audited regularly.1.2.3 Ensure the patient-education programme provides the necessary resources to support the educators, and that educators are properly trained and given time to develop and maintain their skills. 1.2.4 Offer group education programmes as the preferred option.	The outcomes are audited regularly.1.2.3 Ensure the patient-education programme provides the necessary resources to support the educators, and that educators are properly trained and given time to develop and maintain their skills. 1.2.4 Offer group education programmes as the preferred option.	
1.2.5 ensure	0	0.5774	2	Provide analternative of equal standard for a person unable or unwilling to participate in group education. 1.2.5 Ensure that the patient-education programmes available meet the cultural, linguistic, cognitive and literacy needs within the local area. 1.2.6 Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes..	Provide analternative of equal standard for a person unable or unwilling to participate in group education. 1.2.5 Ensure that the patient-education programmes available meet the cultural, linguistic, cognitive and literacy needs within the local area. 1.2.6 Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes..	
1.2.6 ensure	0	0.5774	2	Provide analternative of equal standard for a person unable or unwilling to participate in group education. 1.2.5 Ensure that the patient-education programmes available meet the cultural, linguistic, cognitive and literacy needs within the local area. 1.2.6 Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes..	Provide analternative of equal standard for a person unable or unwilling to participate in group education. 1.2.5 Ensure that the patient-education programmes available meet the cultural, linguistic, cognitive and literacy needs within the local area. 1.2.6 Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes..	
1.3.7 advise	0	0.5774	2	Reducing the risk of hypoglycaemia should be a particular aim for aperson using insulin or an insulin secretagogue. 1.3.7 Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake. 1.3.8 Discourage the use of foods marketed specifically for people with diabetes..	Reducing the risk of hypoglycaemia should be a particular aim for aperson using insulin or an insulin secretagogue. 1.3.7 Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake. 1.3.8 Discourage the use of foods marketed specifically for people with diabetes..	
1.3.8 discourage	0	0.5774	2	Reducing the risk of hypoglycaemia should be a particular aim for aperson using insulin or an insulin secretagogue. 1.3.7 Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake. 1.3.8 Discourage the use of foods marketed specifically for people with diabetes..	Reducing the risk of hypoglycaemia should be a particular aim for aperson using insulin or an insulin secretagogue. 1.3.7 Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake. 1.3.8 Discourage the use of foods marketed specifically for people with diabetes..	
advise adults	0	0.5774	2	Reducing the risk of hypoglycaemia should be a particular aim for aperson using insulin or an insulin secretagogue. 1.3.7 Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake. 1.3.8 Discourage the use of foods marketed specifically for people with diabetes..	Reducing the risk of hypoglycaemia should be a particular aim for aperson using insulin or an insulin secretagogue. 1.3.7 Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake. 1.3.8 Discourage the use of foods marketed specifically for people with diabetes..	
alternative diagnoses	0	0.5774	2	Gastroparesis1.7.1 Think about a diagnosis of gastroparesis in adults with type 2 diabetes with erratic blood glucose control or unexplained gastric bloating or vomiting, taking into account possible alternative diagnoses 2009, amended 2015 1.7.2 For adults with type 2 diabetes who have vomiting caused by gastroparesis, explain that: there is not strong evidence that any available antiemetic therapy is effective some people have had benefit with domperidone , erythromycin or metoclopramide . the strongest evidence for effectiveness is for domperidone , but prescribers must.	Gastroparesis1.7.1 Think about a diagnosis of gastroparesis in adults with type 2 diabetes with erratic blood glucose control or unexplained gastric bloating or vomiting, taking into account possible alternative diagnoses 2009, amended 2015 1.7.2 For adults with type 2 diabetes who have vomiting caused by gastroparesis, explain that: there is not strong evidence that any available antiemetic therapy is effective some people have had benefit with domperidone , erythromycin or metoclopramide . the strongest evidence for effectiveness is for domperidone , but prescribers must.	
antiemetic therapy	0	0.5774	2	Gastroparesis1.7.1 Think about a diagnosis of gastroparesis in adults with type 2 diabetes with erratic blood glucose control or unexplained gastric bloating or vomiting, taking into account possible alternative diagnoses 2009, amended 2015 1.7.2 For adults with type 2 diabetes who have vomiting caused by gastroparesis, explain that: there is not strong evidence that any available antiemetic therapy is effective some people have had benefit with domperidone , erythromycin or metoclopramide . the strongest evidence for effectiveness is for domperidone , but prescribers must.	Gastroparesis1.7.1 Think about a diagnosis of gastroparesis in adults with type 2 diabetes with erratic blood glucose control or unexplained gastric bloating or vomiting, taking into account possible alternative diagnoses 2009, amended 2015 1.7.2 For adults with type 2 diabetes who have vomiting caused by gastroparesis, explain that: there is not strong evidence that any available antiemetic therapy is effective some people have had benefit with domperidone , erythromycin or metoclopramide . the strongest evidence for effectiveness is for domperidone , but prescribers must.	
cardiac risk	0	0.5774	2	Page 27of 44 take into account its safety profile, in particular its cardiac risk and potential interactions with other medicines. 1.7.3 For treating vomiting caused by gastroparesis in adults with type 2 diabetes: consider alternating use of erythomycin and metoclopramide consider domperidone only in exceptional circumstances (if domperidone is the only effective treatment) and in accordance with MHRA guidance. 1.7.4 If gastroparesis is suspected, consider referral to specialist services if: the differential diagnosis is in doubt or persistent or severe vomiting occurs..	Page 27of 44 take into account its safety profile, in particular its cardiac risk and potential interactions with other medicines. 1.7.3 For treating vomiting caused by gastroparesis in adults with type 2 diabetes: consider alternating use of erythomycin and metoclopramide consider domperidone only in exceptional circumstances (if domperidone is the only effective treatment) and in accordance with MHRA guidance. 1.7.4 If gastroparesis is suspected, consider referral to specialist services if: the differential diagnosis is in doubt or persistent or severe vomiting occurs..	
care pathway	0	0.5774	2	Provide analternative of equal standard for a person unable or unwilling to participate in group education. 1.2.5 Ensure that the patient-education programmes available meet the cultural, linguistic, cognitive and literacy needs within the local area. 1.2.6 Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes..	Provide analternative of equal standard for a person unable or unwilling to participate in group education. 1.2.5 Ensure that the patient-education programmes available meet the cultural, linguistic, cognitive and literacy needs within the local area. 1.2.6 Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes..	
cerebrovascular damage	0	0.5774	4	Make changes only if there is poor control or if current drug treatment is notappropriate because of microvascular complications or metabolic problems. 1.4.3 Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage..	Page 15of 44 pressure is confirmed as being consistently above 140 80 mmHg (or above 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.5 Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.6 Monitor blood pressure every 1–2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.7 First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor.	Make changes only if there is poor control or if current drug treatment is notappropriate because of microvascular complications or metabolic problems. 1.4.3 Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage..	Page 15of 44 pressure is confirmed as being consistently above 140 80 mmHg (or above 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.5 Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.6 Monitor blood pressure every 1–2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.7 First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor.	
diabetes healthcare	0	0.5774	2	Provide analternative of equal standard for a person unable or unwilling to participate in group education. 1.2.5 Ensure that the patient-education programmes available meet the cultural, linguistic, cognitive and literacy needs within the local area. 1.2.6 Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes..	Provide analternative of equal standard for a person unable or unwilling to participate in group education. 1.2.5 Ensure that the patient-education programmes available meet the cultural, linguistic, cognitive and literacy needs within the local area. 1.2.6 Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes..	
differential diagnosis	0	0.5774	2	Page 27of 44 take into account its safety profile, in particular its cardiac risk and potential interactions with other medicines. 1.7.3 For treating vomiting caused by gastroparesis in adults with type 2 diabetes: consider alternating use of erythomycin and metoclopramide consider domperidone only in exceptional circumstances (if domperidone is the only effective treatment) and in accordance with MHRA guidance. 1.7.4 If gastroparesis is suspected, consider referral to specialist services if: the differential diagnosis is in doubt or persistent or severe vomiting occurs..	Page 27of 44 take into account its safety profile, in particular its cardiac risk and potential interactions with other medicines. 1.7.3 For treating vomiting caused by gastroparesis in adults with type 2 diabetes: consider alternating use of erythomycin and metoclopramide consider domperidone only in exceptional circumstances (if domperidone is the only effective treatment) and in accordance with MHRA guidance. 1.7.4 If gastroparesis is suspected, consider referral to specialist services if: the differential diagnosis is in doubt or persistent or severe vomiting occurs..	
education programmes	1	0.5774	4	The outcomes are audited regularly.1.2.3 Ensure the patient-education programme provides the necessary resources to support the educators, and that educators are properly trained and given time to develop and maintain their skills. 1.2.4 Offer group education programmes as the preferred option.	Provide analternative of equal standard for a person unable or unwilling to participate in group education. 1.2.5 Ensure that the patient-education programmes available meet the cultural, linguistic, cognitive and literacy needs within the local area. 1.2.6 Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes..	The outcomes are audited regularly.1.2.3 Ensure the patient-education programme provides the necessary resources to support the educators, and that educators are properly trained and given time to develop and maintain their skills. 1.2.4 Offer group education programmes as the preferred option.	Provide analternative of equal standard for a person unable or unwilling to participate in group education. 1.2.5 Ensure that the patient-education programmes available meet the cultural, linguistic, cognitive and literacy needs within the local area. 1.2.6 Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes..	
effective treatment	0	0.5774	2	Page 27of 44 take into account its safety profile, in particular its cardiac risk and potential interactions with other medicines. 1.7.3 For treating vomiting caused by gastroparesis in adults with type 2 diabetes: consider alternating use of erythomycin and metoclopramide consider domperidone only in exceptional circumstances (if domperidone is the only effective treatment) and in accordance with MHRA guidance. 1.7.4 If gastroparesis is suspected, consider referral to specialist services if: the differential diagnosis is in doubt or persistent or severe vomiting occurs..	Page 27of 44 take into account its safety profile, in particular its cardiac risk and potential interactions with other medicines. 1.7.3 For treating vomiting caused by gastroparesis in adults with type 2 diabetes: consider alternating use of erythomycin and metoclopramide consider domperidone only in exceptional circumstances (if domperidone is the only effective treatment) and in accordance with MHRA guidance. 1.7.4 If gastroparesis is suspected, consider referral to specialist services if: the differential diagnosis is in doubt or persistent or severe vomiting occurs..	
energy intake	0	0.5774	2	Reducing the risk of hypoglycaemia should be a particular aim for aperson using insulin or an insulin secretagogue. 1.3.7 Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake. 1.3.8 Discourage the use of foods marketed specifically for people with diabetes..	Reducing the risk of hypoglycaemia should be a particular aim for aperson using insulin or an insulin secretagogue. 1.3.7 Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake. 1.3.8 Discourage the use of foods marketed specifically for people with diabetes..	
equal standard	0	0.5774	2	Provide analternative of equal standard for a person unable or unwilling to participate in group education. 1.2.5 Ensure that the patient-education programmes available meet the cultural, linguistic, cognitive and literacy needs within the local area. 1.2.6 Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes..	Provide analternative of equal standard for a person unable or unwilling to participate in group education. 1.2.5 Ensure that the patient-education programmes available meet the cultural, linguistic, cognitive and literacy needs within the local area. 1.2.6 Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes..	
erratic blood	0	0.5774	2	Gastroparesis1.7.1 Think about a diagnosis of gastroparesis in adults with type 2 diabetes with erratic blood glucose control or unexplained gastric bloating or vomiting, taking into account possible alternative diagnoses 2009, amended 2015 1.7.2 For adults with type 2 diabetes who have vomiting caused by gastroparesis, explain that: there is not strong evidence that any available antiemetic therapy is effective some people have had benefit with domperidone , erythromycin or metoclopramide . the strongest evidence for effectiveness is for domperidone , but prescribers must.	Gastroparesis1.7.1 Think about a diagnosis of gastroparesis in adults with type 2 diabetes with erratic blood glucose control or unexplained gastric bloating or vomiting, taking into account possible alternative diagnoses 2009, amended 2015 1.7.2 For adults with type 2 diabetes who have vomiting caused by gastroparesis, explain that: there is not strong evidence that any available antiemetic therapy is effective some people have had benefit with domperidone , erythromycin or metoclopramide . the strongest evidence for effectiveness is for domperidone , but prescribers must.	
exceptional circumstances	0	0.5774	2	Page 27of 44 take into account its safety profile, in particular its cardiac risk and potential interactions with other medicines. 1.7.3 For treating vomiting caused by gastroparesis in adults with type 2 diabetes: consider alternating use of erythomycin and metoclopramide consider domperidone only in exceptional circumstances (if domperidone is the only effective treatment) and in accordance with MHRA guidance. 1.7.4 If gastroparesis is suspected, consider referral to specialist services if: the differential diagnosis is in doubt or persistent or severe vomiting occurs..	Page 27of 44 take into account its safety profile, in particular its cardiac risk and potential interactions with other medicines. 1.7.3 For treating vomiting caused by gastroparesis in adults with type 2 diabetes: consider alternating use of erythomycin and metoclopramide consider domperidone only in exceptional circumstances (if domperidone is the only effective treatment) and in accordance with MHRA guidance. 1.7.4 If gastroparesis is suspected, consider referral to specialist services if: the differential diagnosis is in doubt or persistent or severe vomiting occurs..	
excess energy	0	0.5774	2	Reducing the risk of hypoglycaemia should be a particular aim for aperson using insulin or an insulin secretagogue. 1.3.7 Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake. 1.3.8 Discourage the use of foods marketed specifically for people with diabetes..	Reducing the risk of hypoglycaemia should be a particular aim for aperson using insulin or an insulin secretagogue. 1.3.7 Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake. 1.3.8 Discourage the use of foods marketed specifically for people with diabetes..	
forwhom repaglinide	0	0.5774	2	However, discuss with any person forwhom repaglinide is being considered, that there is no licensed non-metformin-based combination containing repaglinide that can be offered at first intensification..	However, discuss with any person forwhom repaglinide is being considered, that there is no licensed non-metformin-based combination containing repaglinide that can be offered at first intensification..	
healthcare team	0	0.5774	2	Provide analternative of equal standard for a person unable or unwilling to participate in group education. 1.2.5 Ensure that the patient-education programmes available meet the cultural, linguistic, cognitive and literacy needs within the local area. 1.2.6 Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes..	Provide analternative of equal standard for a person unable or unwilling to participate in group education. 1.2.5 Ensure that the patient-education programmes available meet the cultural, linguistic, cognitive and literacy needs within the local area. 1.2.6 Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes..	
insulin secretagogue	0	0.5774	2	Reducing the risk of hypoglycaemia should be a particular aim for aperson using insulin or an insulin secretagogue. 1.3.7 Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake. 1.3.8 Discourage the use of foods marketed specifically for people with diabetes..	Reducing the risk of hypoglycaemia should be a particular aim for aperson using insulin or an insulin secretagogue. 1.3.7 Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake. 1.3.8 Discourage the use of foods marketed specifically for people with diabetes..	
licensed non-metformin-based	0	0.5774	2	However, discuss with any person forwhom repaglinide is being considered, that there is no licensed non-metformin-based combination containing repaglinide that can be offered at first intensification..	However, discuss with any person forwhom repaglinide is being considered, that there is no licensed non-metformin-based combination containing repaglinide that can be offered at first intensification..	
limited substitution	0	0.5774	2	Reducing the risk of hypoglycaemia should be a particular aim for aperson using insulin or an insulin secretagogue. 1.3.7 Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake. 1.3.8 Discourage the use of foods marketed specifically for people with diabetes..	Reducing the risk of hypoglycaemia should be a particular aim for aperson using insulin or an insulin secretagogue. 1.3.7 Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake. 1.3.8 Discourage the use of foods marketed specifically for people with diabetes..	
local area	1	0.5774	2	Provide analternative of equal standard for a person unable or unwilling to participate in group education. 1.2.5 Ensure that the patient-education programmes available meet the cultural, linguistic, cognitive and literacy needs within the local area. 1.2.6 Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes..	Provide analternative of equal standard for a person unable or unwilling to participate in group education. 1.2.5 Ensure that the patient-education programmes available meet the cultural, linguistic, cognitive and literacy needs within the local area. 1.2.6 Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes..	
local programmes.	0	0.5774	2	Provide analternative of equal standard for a person unable or unwilling to participate in group education. 1.2.5 Ensure that the patient-education programmes available meet the cultural, linguistic, cognitive and literacy needs within the local area. 1.2.6 Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes..	Provide analternative of equal standard for a person unable or unwilling to participate in group education. 1.2.5 Ensure that the patient-education programmes available meet the cultural, linguistic, cognitive and literacy needs within the local area. 1.2.6 Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes..	
meal plan	0	0.5774	4	Reducing the risk of hypoglycaemia should be a particular aim for aperson using insulin or an insulin secretagogue. 1.3.7 Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake. 1.3.8 Discourage the use of foods marketed specifically for people with diabetes..	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	Reducing the risk of hypoglycaemia should be a particular aim for aperson using insulin or an insulin secretagogue. 1.3.7 Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake. 1.3.8 Discourage the use of foods marketed specifically for people with diabetes..	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	
medicines adherence	0	0.5774	2	For moreinformation about supporting adherence, see the NICE guideline on medicines adherence. 1.6.7 For adults with type 2 diabetes managed either by lifestyle and diet, or by lifestyle and diet combined with a single drug not associated with hypoglycaemia, support the person to aim for an HbA1c level of 48 mmol mol (6.5percent).	For moreinformation about supporting adherence, see the NICE guideline on medicines adherence. 1.6.7 For adults with type 2 diabetes managed either by lifestyle and diet, or by lifestyle and diet combined with a single drug not associated with hypoglycaemia, support the person to aim for an HbA1c level of 48 mmol mol (6.5percent).	
non-metformin-based combination	0	0.5774	2	However, discuss with any person forwhom repaglinide is being considered, that there is no licensed non-metformin-based combination containing repaglinide that can be offered at first intensification..	However, discuss with any person forwhom repaglinide is being considered, that there is no licensed non-metformin-based combination containing repaglinide that can be offered at first intensification..	
offer group	0	0.5774	2	The outcomes are audited regularly.1.2.3 Ensure the patient-education programme provides the necessary resources to support the educators, and that educators are properly trained and given time to develop and maintain their skills. 1.2.4 Offer group education programmes as the preferred option.	The outcomes are audited regularly.1.2.3 Ensure the patient-education programme provides the necessary resources to support the educators, and that educators are properly trained and given time to develop and maintain their skills. 1.2.4 Offer group education programmes as the preferred option.	
on:the effectiveness	0	0.5774	2	Base the choice of drug treatment(s) on:the effectiveness of the drug treatment(s) in terms of metabolic response.	Base the choice of drug treatment(s) on:the effectiveness of the drug treatment(s) in terms of metabolic response.	
page 27of	0	0.5774	2	Page 27of 44 take into account its safety profile, in particular its cardiac risk and potential interactions with other medicines. 1.7.3 For treating vomiting caused by gastroparesis in adults with type 2 diabetes: consider alternating use of erythomycin and metoclopramide consider domperidone only in exceptional circumstances (if domperidone is the only effective treatment) and in accordance with MHRA guidance. 1.7.4 If gastroparesis is suspected, consider referral to specialist services if: the differential diagnosis is in doubt or persistent or severe vomiting occurs..	Page 27of 44 take into account its safety profile, in particular its cardiac risk and potential interactions with other medicines. 1.7.3 For treating vomiting caused by gastroparesis in adults with type 2 diabetes: consider alternating use of erythomycin and metoclopramide consider domperidone only in exceptional circumstances (if domperidone is the only effective treatment) and in accordance with MHRA guidance. 1.7.4 If gastroparesis is suspected, consider referral to specialist services if: the differential diagnosis is in doubt or persistent or severe vomiting occurs..	
patient-education programme	0	0.5774	4	The outcomes are audited regularly.1.2.3 Ensure the patient-education programme provides the necessary resources to support the educators, and that educators are properly trained and given time to develop and maintain their skills. 1.2.4 Offer group education programmes as the preferred option.	Provide analternative of equal standard for a person unable or unwilling to participate in group education. 1.2.5 Ensure that the patient-education programmes available meet the cultural, linguistic, cognitive and literacy needs within the local area. 1.2.6 Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes..	The outcomes are audited regularly.1.2.3 Ensure the patient-education programme provides the necessary resources to support the educators, and that educators are properly trained and given time to develop and maintain their skills. 1.2.4 Offer group education programmes as the preferred option.	Provide analternative of equal standard for a person unable or unwilling to participate in group education. 1.2.5 Ensure that the patient-education programmes available meet the cultural, linguistic, cognitive and literacy needs within the local area. 1.2.6 Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes..	
person forwhom	0	0.5774	2	However, discuss with any person forwhom repaglinide is being considered, that there is no licensed non-metformin-based combination containing repaglinide that can be offered at first intensification..	However, discuss with any person forwhom repaglinide is being considered, that there is no licensed non-metformin-based combination containing repaglinide that can be offered at first intensification..	
person unable	0	0.5774	2	Provide analternative of equal standard for a person unable or unwilling to participate in group education. 1.2.5 Ensure that the patient-education programmes available meet the cultural, linguistic, cognitive and literacy needs within the local area. 1.2.6 Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes..	Provide analternative of equal standard for a person unable or unwilling to participate in group education. 1.2.5 Ensure that the patient-education programmes available meet the cultural, linguistic, cognitive and literacy needs within the local area. 1.2.6 Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes..	
potential interactions	0	0.5774	2	Page 27of 44 take into account its safety profile, in particular its cardiac risk and potential interactions with other medicines. 1.7.3 For treating vomiting caused by gastroparesis in adults with type 2 diabetes: consider alternating use of erythomycin and metoclopramide consider domperidone only in exceptional circumstances (if domperidone is the only effective treatment) and in accordance with MHRA guidance. 1.7.4 If gastroparesis is suspected, consider referral to specialist services if: the differential diagnosis is in doubt or persistent or severe vomiting occurs..	Page 27of 44 take into account its safety profile, in particular its cardiac risk and potential interactions with other medicines. 1.7.3 For treating vomiting caused by gastroparesis in adults with type 2 diabetes: consider alternating use of erythomycin and metoclopramide consider domperidone only in exceptional circumstances (if domperidone is the only effective treatment) and in accordance with MHRA guidance. 1.7.4 If gastroparesis is suspected, consider referral to specialist services if: the differential diagnosis is in doubt or persistent or severe vomiting occurs..	
preferred option	0	0.5774	2	The outcomes are audited regularly.1.2.3 Ensure the patient-education programme provides the necessary resources to support the educators, and that educators are properly trained and given time to develop and maintain their skills. 1.2.4 Offer group education programmes as the preferred option.	The outcomes are audited regularly.1.2.3 Ensure the patient-education programme provides the necessary resources to support the educators, and that educators are properly trained and given time to develop and maintain their skills. 1.2.4 Offer group education programmes as the preferred option.	
regularly.1.2.3 ensure	0	0.5774	2	The outcomes are audited regularly.1.2.3 Ensure the patient-education programme provides the necessary resources to support the educators, and that educators are properly trained and given time to develop and maintain their skills. 1.2.4 Offer group education programmes as the preferred option.	The outcomes are audited regularly.1.2.3 Ensure the patient-education programme provides the necessary resources to support the educators, and that educators are properly trained and given time to develop and maintain their skills. 1.2.4 Offer group education programmes as the preferred option.	
safety profile	0	0.5774	2	Page 27of 44 take into account its safety profile, in particular its cardiac risk and potential interactions with other medicines. 1.7.3 For treating vomiting caused by gastroparesis in adults with type 2 diabetes: consider alternating use of erythomycin and metoclopramide consider domperidone only in exceptional circumstances (if domperidone is the only effective treatment) and in accordance with MHRA guidance. 1.7.4 If gastroparesis is suspected, consider referral to specialist services if: the differential diagnosis is in doubt or persistent or severe vomiting occurs..	Page 27of 44 take into account its safety profile, in particular its cardiac risk and potential interactions with other medicines. 1.7.3 For treating vomiting caused by gastroparesis in adults with type 2 diabetes: consider alternating use of erythomycin and metoclopramide consider domperidone only in exceptional circumstances (if domperidone is the only effective treatment) and in accordance with MHRA guidance. 1.7.4 If gastroparesis is suspected, consider referral to specialist services if: the differential diagnosis is in doubt or persistent or severe vomiting occurs..	
specialist services	0	0.5774	2	Page 27of 44 take into account its safety profile, in particular its cardiac risk and potential interactions with other medicines. 1.7.3 For treating vomiting caused by gastroparesis in adults with type 2 diabetes: consider alternating use of erythomycin and metoclopramide consider domperidone only in exceptional circumstances (if domperidone is the only effective treatment) and in accordance with MHRA guidance. 1.7.4 If gastroparesis is suspected, consider referral to specialist services if: the differential diagnosis is in doubt or persistent or severe vomiting occurs..	Page 27of 44 take into account its safety profile, in particular its cardiac risk and potential interactions with other medicines. 1.7.3 For treating vomiting caused by gastroparesis in adults with type 2 diabetes: consider alternating use of erythomycin and metoclopramide consider domperidone only in exceptional circumstances (if domperidone is the only effective treatment) and in accordance with MHRA guidance. 1.7.4 If gastroparesis is suspected, consider referral to specialist services if: the differential diagnosis is in doubt or persistent or severe vomiting occurs..	
strong evidence	0	0.5774	2	Gastroparesis1.7.1 Think about a diagnosis of gastroparesis in adults with type 2 diabetes with erratic blood glucose control or unexplained gastric bloating or vomiting, taking into account possible alternative diagnoses 2009, amended 2015 1.7.2 For adults with type 2 diabetes who have vomiting caused by gastroparesis, explain that: there is not strong evidence that any available antiemetic therapy is effective some people have had benefit with domperidone , erythromycin or metoclopramide . the strongest evidence for effectiveness is for domperidone , but prescribers must.	Gastroparesis1.7.1 Think about a diagnosis of gastroparesis in adults with type 2 diabetes with erratic blood glucose control or unexplained gastric bloating or vomiting, taking into account possible alternative diagnoses 2009, amended 2015 1.7.2 For adults with type 2 diabetes who have vomiting caused by gastroparesis, explain that: there is not strong evidence that any available antiemetic therapy is effective some people have had benefit with domperidone , erythromycin or metoclopramide . the strongest evidence for effectiveness is for domperidone , but prescribers must.	
sucrose-containing foods	0	0.5774	2	Reducing the risk of hypoglycaemia should be a particular aim for aperson using insulin or an insulin secretagogue. 1.3.7 Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake. 1.3.8 Discourage the use of foods marketed specifically for people with diabetes..	Reducing the risk of hypoglycaemia should be a particular aim for aperson using insulin or an insulin secretagogue. 1.3.7 Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake. 1.3.8 Discourage the use of foods marketed specifically for people with diabetes..	
treatment(s) on:the	0	0.5774	2	Base the choice of drug treatment(s) on:the effectiveness of the drug treatment(s) in terms of metabolic response.	Base the choice of drug treatment(s) on:the effectiveness of the drug treatment(s) in terms of metabolic response.	
unexplained gastric	0	0.5774	2	Gastroparesis1.7.1 Think about a diagnosis of gastroparesis in adults with type 2 diabetes with erratic blood glucose control or unexplained gastric bloating or vomiting, taking into account possible alternative diagnoses 2009, amended 2015 1.7.2 For adults with type 2 diabetes who have vomiting caused by gastroparesis, explain that: there is not strong evidence that any available antiemetic therapy is effective some people have had benefit with domperidone , erythromycin or metoclopramide . the strongest evidence for effectiveness is for domperidone , but prescribers must.	Gastroparesis1.7.1 Think about a diagnosis of gastroparesis in adults with type 2 diabetes with erratic blood glucose control or unexplained gastric bloating or vomiting, taking into account possible alternative diagnoses 2009, amended 2015 1.7.2 For adults with type 2 diabetes who have vomiting caused by gastroparesis, explain that: there is not strong evidence that any available antiemetic therapy is effective some people have had benefit with domperidone , erythromycin or metoclopramide . the strongest evidence for effectiveness is for domperidone , but prescribers must.	
glp-1 mimetic	0	0.5773	4	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	Page 24of 44 1.6.31 In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team ..	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	Page 24of 44 1.6.31 In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team ..	
human insulin	0	0.5773	4	HbA1c is 75 mmol mol 9.0percent or higher), administered either:separately or as a pre-mixed (biphasic) human insulin preparation..	Consider pre-mixed (biphasic) preparations that include short-acting insulinanalogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals. 1.6.35 Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of.	HbA1c is 75 mmol mol 9.0percent or higher), administered either:separately or as a pre-mixed (biphasic) human insulin preparation..	Consider pre-mixed (biphasic) preparations that include short-acting insulinanalogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals. 1.6.35 Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of.	
recommendations 1.6.32–1.6.34	0	0.5773	6	Rescue therapy at any phase of treatment1.6.18 If an adult with type 2 diabetes is symptomatically hyperglycaemic, consider insulin (see recommendations 1.6.32–1.6.34) or a sulfonylurea, and review treatment when blood glucose control has been achieved..	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	HbA1c and a weight loss of at least 3percent of initial body weight in 6 months).1.6.30 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation 1.6.26) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations 1.6.32–1.6.34)..	Rescue therapy at any phase of treatment1.6.18 If an adult with type 2 diabetes is symptomatically hyperglycaemic, consider insulin (see recommendations 1.6.32–1.6.34) or a sulfonylurea, and review treatment when blood glucose control has been achieved..	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	HbA1c and a weight loss of at least 3percent of initial body weight in 6 months).1.6.30 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation 1.6.26) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations 1.6.32–1.6.34)..	
glucose levels	0	0.5679	8	Self-monitoring of blood glucose1.6.12 Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes. 1.6.13 Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or.	For more information, seethe NICE guideline on diabetes in pregnancy. 1.6.14 Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia. 1.6.15 Be aware that adults with type 2 diabetes who have acute intercurrent illness are at risk of worsening hyperglycaemia.	Review treatment as necessary.1.6.16 If adults with type 2 diabetes are self-monitoring their blood glucose levels, carry out a structured assessment at least annually.	Consider pre-mixed (biphasic) preparations that include short-acting insulinanalogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals. 1.6.35 Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of.	Self-monitoring of blood glucose1.6.12 Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes. 1.6.13 Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or.	For more information, seethe NICE guideline on diabetes in pregnancy. 1.6.14 Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia. 1.6.15 Be aware that adults with type 2 diabetes who have acute intercurrent illness are at risk of worsening hyperglycaemia.	Review treatment as necessary.1.6.16 If adults with type 2 diabetes are self-monitoring their blood glucose levels, carry out a structured assessment at least annually.	Consider pre-mixed (biphasic) preparations that include short-acting insulinanalogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals. 1.6.35 Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of.	
high risk	0	0.5674	4	When prescribing pioglitazone, exercise particular caution if the person is at high risk of theadverse effects of the drug.	Page 18of 44 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities. 1.6.10 If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it.	When prescribing pioglitazone, exercise particular caution if the person is at high risk of theadverse effects of the drug.	Page 18of 44 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities. 1.6.10 If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it.	
family members	0	0.5458	4	Reassess the person's needs and circumstances at each review and think aboutwhether to stop any medicines that are not effective. 1.1.2 Take into account any disabilities, including visual impairment, when planning and delivering care for adults with type 2 diabetes. 1.2 Patient education 1.2.1 Offer structured education to adults with type 2 diabetes and or their family members or carers (as appropriate) at and around the time of diagnosis, with.	Provide analternative of equal standard for a person unable or unwilling to participate in group education. 1.2.5 Ensure that the patient-education programmes available meet the cultural, linguistic, cognitive and literacy needs within the local area. 1.2.6 Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes..	Reassess the person's needs and circumstances at each review and think aboutwhether to stop any medicines that are not effective. 1.1.2 Take into account any disabilities, including visual impairment, when planning and delivering care for adults with type 2 diabetes. 1.2 Patient education 1.2.1 Offer structured education to adults with type 2 diabetes and or their family members or carers (as appropriate) at and around the time of diagnosis, with.	Provide analternative of equal standard for a person unable or unwilling to participate in group education. 1.2.5 Ensure that the patient-education programmes available meet the cultural, linguistic, cognitive and literacy needs within the local area. 1.2.6 Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes..	
blood pressure	0	0.5402	14	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	Offer and reinforcepreventive lifestyle advice. 1.4.2 For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used..	Make changes only if there is poor control or if current drug treatment is notappropriate because of microvascular complications or metabolic problems. 1.4.3 Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage..	Page 15of 44 pressure is confirmed as being consistently above 140 80 mmHg (or above 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.5 Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.6 Monitor blood pressure every 1–2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.7 First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor.	Caribbean family origin should be an ACE inhibitor plus either a diuretic or ageneric calcium-channel blocker. 1.4.9 A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant. 1.4.10 For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor. 1.4.11 Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension. 1.4.12 If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic).	Page 16of 44 1.4.13 If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist). 1.4.14 Monitor the blood pressure of a person who has attained and consistently remained at his or her blood pressure target every 4–6 months.	Check forpossible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure. 1.5 Antiplatelet therapy 1.5.1 Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease. 1.5.2 For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction. 1.6 Blood glucose management.	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	Offer and reinforcepreventive lifestyle advice. 1.4.2 For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used..	Make changes only if there is poor control or if current drug treatment is notappropriate because of microvascular complications or metabolic problems. 1.4.3 Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage..	Page 15of 44 pressure is confirmed as being consistently above 140 80 mmHg (or above 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.5 Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.6 Monitor blood pressure every 1–2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.7 First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor.	Caribbean family origin should be an ACE inhibitor plus either a diuretic or ageneric calcium-channel blocker. 1.4.9 A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant. 1.4.10 For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor. 1.4.11 Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension. 1.4.12 If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic).	Page 16of 44 1.4.13 If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist). 1.4.14 Monitor the blood pressure of a person who has attained and consistently remained at his or her blood pressure target every 4–6 months.	Check forpossible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure. 1.5 Antiplatelet therapy 1.5.1 Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease. 1.5.2 For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction. 1.6 Blood glucose management.	
1.4.14 monitor	0	0.5343	2	Page 16of 44 1.4.13 If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist). 1.4.14 Monitor the blood pressure of a person who has attained and consistently remained at his or her blood pressure target every 4–6 months.	Page 16of 44 1.4.13 If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist). 1.4.14 Monitor the blood pressure of a person who has attained and consistently remained at his or her blood pressure target every 4–6 months.	
4–6 months	0	0.5343	2	Page 16of 44 1.4.13 If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist). 1.4.14 Monitor the blood pressure of a person who has attained and consistently remained at his or her blood pressure target every 4–6 months.	Page 16of 44 1.4.13 If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist). 1.4.14 Monitor the blood pressure of a person who has attained and consistently remained at his or her blood pressure target every 4–6 months.	
page 16of	0	0.5343	2	Page 16of 44 1.4.13 If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist). 1.4.14 Monitor the blood pressure of a person who has attained and consistently remained at his or her blood pressure target every 4–6 months.	Page 16of 44 1.4.13 If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist). 1.4.14 Monitor the blood pressure of a person who has attained and consistently remained at his or her blood pressure target every 4–6 months.	
potassium-sparing diuretic	0	0.5343	2	Page 16of 44 1.4.13 If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist). 1.4.14 Monitor the blood pressure of a person who has attained and consistently remained at his or her blood pressure target every 4–6 months.	Page 16of 44 1.4.13 If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist). 1.4.14 Monitor the blood pressure of a person who has attained and consistently remained at his or her blood pressure target every 4–6 months.	
pressure target	0	0.5343	2	Page 16of 44 1.4.13 If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist). 1.4.14 Monitor the blood pressure of a person who has attained and consistently remained at his or her blood pressure target every 4–6 months.	Page 16of 44 1.4.13 If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist). 1.4.14 Monitor the blood pressure of a person who has attained and consistently remained at his or her blood pressure target every 4–6 months.	
weight loss	0	0.5323	10	Encouragehigh-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids. 1.3.4 Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight. 1.3.5 For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent.	Remember that lesser degrees of weight loss may still beof benefit, and that larger degrees of weight loss in the longer term will have advantageous metabolic impact. 1.3.6 Individualise recommendations for carbohydrate and alcohol intake, and meal patterns.	Be aware that there are other possible reasons for a low HbA1clevel, for example, deteriorating renal function or sudden weight loss. 1.6.11 For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy..	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	HbA1c and a weight loss of at least 3percent of initial body weight in 6 months).1.6.30 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation 1.6.26) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations 1.6.32–1.6.34)..	Encouragehigh-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids. 1.3.4 Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight. 1.3.5 For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent.	Remember that lesser degrees of weight loss may still beof benefit, and that larger degrees of weight loss in the longer term will have advantageous metabolic impact. 1.3.6 Individualise recommendations for carbohydrate and alcohol intake, and meal patterns.	Be aware that there are other possible reasons for a low HbA1clevel, for example, deteriorating renal function or sudden weight loss. 1.6.11 For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy..	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	HbA1c and a weight loss of at least 3percent of initial body weight in 6 months).1.6.30 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation 1.6.26) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations 1.6.32–1.6.34)..	
dual therapy	0	0.5261	10	Treatment with 2 non-insulin blood glucose lowering therapies incombination (dual therapy).	Add the other drug (that is, thecalcium-channel blocker or diuretic) if the target is not reached with dual therapy 2009, amended 2015.	First intensification of drug treatment1.6.25 In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea. 1.6.26 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea..	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	HbA1c and a weight loss of at least 3percent of initial body weight in 6 months).1.6.30 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation 1.6.26) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations 1.6.32–1.6.34)..	Treatment with 2 non-insulin blood glucose lowering therapies incombination (dual therapy).	Add the other drug (that is, thecalcium-channel blocker or diuretic) if the target is not reached with dual therapy 2009, amended 2015.	First intensification of drug treatment1.6.25 In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea. 1.6.26 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea..	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	HbA1c and a weight loss of at least 3percent of initial body weight in 6 months).1.6.30 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation 1.6.26) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations 1.6.32–1.6.34)..	
insulin therapy	0	0.5185	8	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	Insulin-based treatments1.6.32 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding.	DVLA guidance (At a glance guide to the current medical standards of fitness to drive)management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional. 1.6.33 When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance.	Review thecontinued need for other blood glucose lowering therapies . 1.6.34 Start insulin therapy for adults with type 2 diabetes from a choice of a number of insulin types and regimens:.	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	Insulin-based treatments1.6.32 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding.	DVLA guidance (At a glance guide to the current medical standards of fitness to drive)management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional. 1.6.33 When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance.	Review thecontinued need for other blood glucose lowering therapies . 1.6.34 Start insulin therapy for adults with type 2 diabetes from a choice of a number of insulin types and regimens:.	
hba1c level	0	0.504	8	Measurement1.6.1 In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable. 1.6.2 Use methods to measure HbA1c that have been calibrated according to.	For moreinformation about supporting adherence, see the NICE guideline on medicines adherence. 1.6.7 For adults with type 2 diabetes managed either by lifestyle and diet, or by lifestyle and diet combined with a single drug not associated with hypoglycaemia, support the person to aim for an HbA1c level of 48 mmol mol (6.5percent).	For adults on a drug associated with hypoglycaemia, support the personto aim for an HbA1c level of 53 mmol mol (7.0percent). 1.6.8 In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol (7.5percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol (7.0percent) and intensify drug treatment. 1.6.9 Consider relaxing the target HbA1c level (see recommendations 1.6.7 and 1.6.8).	Page 18of 44 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities. 1.6.10 If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it.	Measurement1.6.1 In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable. 1.6.2 Use methods to measure HbA1c that have been calibrated according to.	For moreinformation about supporting adherence, see the NICE guideline on medicines adherence. 1.6.7 For adults with type 2 diabetes managed either by lifestyle and diet, or by lifestyle and diet combined with a single drug not associated with hypoglycaemia, support the person to aim for an HbA1c level of 48 mmol mol (6.5percent).	For adults on a drug associated with hypoglycaemia, support the personto aim for an HbA1c level of 53 mmol mol (7.0percent). 1.6.8 In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol (7.5percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol (7.0percent) and intensify drug treatment. 1.6.9 Consider relaxing the target HbA1c level (see recommendations 1.6.7 and 1.6.8).	Page 18of 44 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities. 1.6.10 If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it.	
section 1.3	0	0.5015	4	Provide lifestyle advice (diet and exercise) at the same time.1.4.4 Provide lifestyle advice (see section 1.3 in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood.	Encourage them to achieve the target and maintain it unless anyresulting adverse effects (including hypoglycaemia), or their efforts to achieve their target, impair their quality of life. 1.6.6 Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section 1.3).	Provide lifestyle advice (diet and exercise) at the same time.1.4.4 Provide lifestyle advice (see section 1.3 in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood.	Encourage them to achieve the target and maintain it unless anyresulting adverse effects (including hypoglycaemia), or their efforts to achieve their target, impair their quality of life. 1.6.6 Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section 1.3).	
1.3.6 individualise	0	0.5	2	Remember that lesser degrees of weight loss may still beof benefit, and that larger degrees of weight loss in the longer term will have advantageous metabolic impact. 1.3.6 Individualise recommendations for carbohydrate and alcohol intake, and meal patterns.	Remember that lesser degrees of weight loss may still beof benefit, and that larger degrees of weight loss in the longer term will have advantageous metabolic impact. 1.3.6 Individualise recommendations for carbohydrate and alcohol intake, and meal patterns.	
3–6-monthly intervals	0	0.5	2	Measurement1.6.1 In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable. 1.6.2 Use methods to measure HbA1c that have been calibrated according to.	Measurement1.6.1 In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable. 1.6.2 Use methods to measure HbA1c that have been calibrated according to.	
6-monthly intervals	0	0.5	2	Measurement1.6.1 In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable. 1.6.2 Use methods to measure HbA1c that have been calibrated according to.	Measurement1.6.1 In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable. 1.6.2 Use methods to measure HbA1c that have been calibrated according to.	
abnormal haemoglobins	0	0.5	2	Page 17of 44 of the following: quality-controlled plasma glucose profiles total glycated haemoglobin estimation (if abnormal haemoglobins) fructosamine estimation. 1.6.4 Investigate unexplained discrepancies between HbA1c and other glucose measurements.	Page 17of 44 of the following: quality-controlled plasma glucose profiles total glycated haemoglobin estimation (if abnormal haemoglobins) fructosamine estimation. 1.6.4 Investigate unexplained discrepancies between HbA1c and other glucose measurements.	
active insulin	0	0.5	2	Insulin-based treatments1.6.32 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding.	Insulin-based treatments1.6.32 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding.	
advantageous metabolic	0	0.5	2	Remember that lesser degrees of weight loss may still beof benefit, and that larger degrees of weight loss in the longer term will have advantageous metabolic impact. 1.3.6 Individualise recommendations for carbohydrate and alcohol intake, and meal patterns.	Remember that lesser degrees of weight loss may still beof benefit, and that larger degrees of weight loss in the longer term will have advantageous metabolic impact. 1.3.6 Individualise recommendations for carbohydrate and alcohol intake, and meal patterns.	
alcohol intake	0	0.5	2	Remember that lesser degrees of weight loss may still beof benefit, and that larger degrees of weight loss in the longer term will have advantageous metabolic impact. 1.3.6 Individualise recommendations for carbohydrate and alcohol intake, and meal patterns.	Remember that lesser degrees of weight loss may still beof benefit, and that larger degrees of weight loss in the longer term will have advantageous metabolic impact. 1.3.6 Individualise recommendations for carbohydrate and alcohol intake, and meal patterns.	
cardiovascular disease	0	0.5	4	Check forpossible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure. 1.5 Antiplatelet therapy 1.5.1 Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease. 1.5.2 For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction. 1.6 Blood glucose management.	Erectile dysfunction1.7.13 Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review. 1.7.14 Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options. 1.7.15 Consider a phosphodiesterase-5 inhibitor to treat problematic ere	Check forpossible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure. 1.5 Antiplatelet therapy 1.5.1 Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease. 1.5.2 For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction. 1.6 Blood glucose management.	Erectile dysfunction1.7.13 Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review. 1.7.14 Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options. 1.7.15 Consider a phosphodiesterase-5 inhibitor to treat problematic ere	
delivery section	0	0.5	2	Insulin delivery1.6.38 For guidance on insulin delivery for adults with type 2 diabetes, see the insulin delivery section in the NICE guideline on type 1 diabetes. 1.7 Managing complications.	Insulin delivery1.6.38 For guidance on insulin delivery for adults with type 2 diabetes, see the insulin delivery section in the NICE guideline on type 1 diabetes. 1.7 Managing complications.	
diabetic neuropathy1.7.5	0	0.5	2	Painful diabetic neuropathy1.7.5 For guidance on managing painful diabetic peripheral neuropathy in adults with type 2 diabetes, see the NICE guideline on neuropathic pain in adults..	Painful diabetic neuropathy1.7.5 For guidance on managing painful diabetic peripheral neuropathy in adults with type 2 diabetes, see the NICE guideline on neuropathic pain in adults..	
diabetic peripheral	0	0.5	2	Painful diabetic neuropathy1.7.5 For guidance on managing painful diabetic peripheral neuropathy in adults with type 2 diabetes, see the NICE guideline on neuropathic pain in adults..	Painful diabetic neuropathy1.7.5 For guidance on managing painful diabetic peripheral neuropathy in adults with type 2 diabetes, see the NICE guideline on neuropathic pain in adults..	
dietary understanding	0	0.5	2	Insulin-based treatments1.6.32 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding.	Insulin-based treatments1.6.32 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding.	
fructosamine estimation	0	0.5	2	Page 17of 44 of the following: quality-controlled plasma glucose profiles total glycated haemoglobin estimation (if abnormal haemoglobins) fructosamine estimation. 1.6.4 Investigate unexplained discrepancies between HbA1c and other glucose measurements.	Page 17of 44 of the following: quality-controlled plasma glucose profiles total glycated haemoglobin estimation (if abnormal haemoglobins) fructosamine estimation. 1.6.4 Investigate unexplained discrepancies between HbA1c and other glucose measurements.	
glucose measurements	0	0.5	2	Page 17of 44 of the following: quality-controlled plasma glucose profiles total glycated haemoglobin estimation (if abnormal haemoglobins) fructosamine estimation. 1.6.4 Investigate unexplained discrepancies between HbA1c and other glucose measurements.	Page 17of 44 of the following: quality-controlled plasma glucose profiles total glycated haemoglobin estimation (if abnormal haemoglobins) fructosamine estimation. 1.6.4 Investigate unexplained discrepancies between HbA1c and other glucose measurements.	
glucose profiles	0	0.5	2	Page 17of 44 of the following: quality-controlled plasma glucose profiles total glycated haemoglobin estimation (if abnormal haemoglobins) fructosamine estimation. 1.6.4 Investigate unexplained discrepancies between HbA1c and other glucose measurements.	Page 17of 44 of the following: quality-controlled plasma glucose profiles total glycated haemoglobin estimation (if abnormal haemoglobins) fructosamine estimation. 1.6.4 Investigate unexplained discrepancies between HbA1c and other glucose measurements.	
glycated haemoglobin	0	0.5	2	Page 17of 44 of the following: quality-controlled plasma glucose profiles total glycated haemoglobin estimation (if abnormal haemoglobins) fructosamine estimation. 1.6.4 Investigate unexplained discrepancies between HbA1c and other glucose measurements.	Page 17of 44 of the following: quality-controlled plasma glucose profiles total glycated haemoglobin estimation (if abnormal haemoglobins) fructosamine estimation. 1.6.4 Investigate unexplained discrepancies between HbA1c and other glucose measurements.	
group education	0	0.5	4	The outcomes are audited regularly.1.2.3 Ensure the patient-education programme provides the necessary resources to support the educators, and that educators are properly trained and given time to develop and maintain their skills. 1.2.4 Offer group education programmes as the preferred option.	Provide analternative of equal standard for a person unable or unwilling to participate in group education. 1.2.5 Ensure that the patient-education programmes available meet the cultural, linguistic, cognitive and literacy needs within the local area. 1.2.6 Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes..	The outcomes are audited regularly.1.2.3 Ensure the patient-education programme provides the necessary resources to support the educators, and that educators are properly trained and given time to develop and maintain their skills. 1.2.4 Offer group education programmes as the preferred option.	Provide analternative of equal standard for a person unable or unwilling to participate in group education. 1.2.5 Ensure that the patient-education programmes available meet the cultural, linguistic, cognitive and literacy needs within the local area. 1.2.6 Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes..	
haemoglobin estimation	0	0.5	2	Page 17of 44 of the following: quality-controlled plasma glucose profiles total glycated haemoglobin estimation (if abnormal haemoglobins) fructosamine estimation. 1.6.4 Investigate unexplained discrepancies between HbA1c and other glucose measurements.	Page 17of 44 of the following: quality-controlled plasma glucose profiles total glycated haemoglobin estimation (if abnormal haemoglobins) fructosamine estimation. 1.6.4 Investigate unexplained discrepancies between HbA1c and other glucose measurements.	
individualise recommendations	0	0.5	2	Remember that lesser degrees of weight loss may still beof benefit, and that larger degrees of weight loss in the longer term will have advantageous metabolic impact. 1.3.6 Individualise recommendations for carbohydrate and alcohol intake, and meal patterns.	Remember that lesser degrees of weight loss may still beof benefit, and that larger degrees of weight loss in the longer term will have advantageous metabolic impact. 1.3.6 Individualise recommendations for carbohydrate and alcohol intake, and meal patterns.	
injection sites	0	0.5	2	Insulin-based treatments1.6.32 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding.	Insulin-based treatments1.6.32 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding.	
injection technique	0	0.5	2	Insulin-based treatments1.6.32 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding.	Insulin-based treatments1.6.32 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding.	
insulin delivery1.6.38	0	0.5	2	Insulin delivery1.6.38 For guidance on insulin delivery for adults with type 2 diabetes, see the insulin delivery section in the NICE guideline on type 1 diabetes. 1.7 Managing complications.	Insulin delivery1.6.38 For guidance on insulin delivery for adults with type 2 diabetes, see the insulin delivery section in the NICE guideline on type 1 diabetes. 1.7 Managing complications.	
insulin dose	0	0.5	2	Insulin-based treatments1.6.32 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding.	Insulin-based treatments1.6.32 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding.	
insulin-based treatments1.6.32	0	0.5	2	Insulin-based treatments1.6.32 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding.	Insulin-based treatments1.6.32 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding.	
investigate unexplained	0	0.5	2	Page 17of 44 of the following: quality-controlled plasma glucose profiles total glycated haemoglobin estimation (if abnormal haemoglobins) fructosamine estimation. 1.6.4 Investigate unexplained discrepancies between HbA1c and other glucose measurements.	Page 17of 44 of the following: quality-controlled plasma glucose profiles total glycated haemoglobin estimation (if abnormal haemoglobins) fructosamine estimation. 1.6.4 Investigate unexplained discrepancies between HbA1c and other glucose measurements.	
levels dietary	0	0.5	2	Insulin-based treatments1.6.32 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding.	Insulin-based treatments1.6.32 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding.	
meal patterns	0	0.5	2	Remember that lesser degrees of weight loss may still beof benefit, and that larger degrees of weight loss in the longer term will have advantageous metabolic impact. 1.3.6 Individualise recommendations for carbohydrate and alcohol intake, and meal patterns.	Remember that lesser degrees of weight loss may still beof benefit, and that larger degrees of weight loss in the longer term will have advantageous metabolic impact. 1.3.6 Individualise recommendations for carbohydrate and alcohol intake, and meal patterns.	
measure hba1c	0	0.5	2	Measurement1.6.1 In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable. 1.6.2 Use methods to measure HbA1c that have been calibrated according to.	Measurement1.6.1 In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable. 1.6.2 Use methods to measure HbA1c that have been calibrated according to.	
metabolic impact	0	0.5	2	Remember that lesser degrees of weight loss may still beof benefit, and that larger degrees of weight loss in the longer term will have advantageous metabolic impact. 1.3.6 Individualise recommendations for carbohydrate and alcohol intake, and meal patterns.	Remember that lesser degrees of weight loss may still beof benefit, and that larger degrees of weight loss in the longer term will have advantageous metabolic impact. 1.3.6 Individualise recommendations for carbohydrate and alcohol intake, and meal patterns.	
neuropathic pain	0	0.5	2	Painful diabetic neuropathy1.7.5 For guidance on managing painful diabetic peripheral neuropathy in adults with type 2 diabetes, see the NICE guideline on neuropathic pain in adults..	Painful diabetic neuropathy1.7.5 For guidance on managing painful diabetic peripheral neuropathy in adults with type 2 diabetes, see the NICE guideline on neuropathic pain in adults..	
page 17of	0	0.5	2	Page 17of 44 of the following: quality-controlled plasma glucose profiles total glycated haemoglobin estimation (if abnormal haemoglobins) fructosamine estimation. 1.6.4 Investigate unexplained discrepancies between HbA1c and other glucose measurements.	Page 17of 44 of the following: quality-controlled plasma glucose profiles total glycated haemoglobin estimation (if abnormal haemoglobins) fructosamine estimation. 1.6.4 Investigate unexplained discrepancies between HbA1c and other glucose measurements.	
peripheral neuropathy	0	0.5	2	Painful diabetic neuropathy1.7.5 For guidance on managing painful diabetic peripheral neuropathy in adults with type 2 diabetes, see the NICE guideline on neuropathic pain in adults..	Painful diabetic neuropathy1.7.5 For guidance on managing painful diabetic peripheral neuropathy in adults with type 2 diabetes, see the NICE guideline on neuropathic pain in adults..	
prescribe metformin	0	0.5	2	Prescribe metformin with caution for those at risk of a sudden deterioration in kidneyfunction and those at risk of eGFR falling below 45 ml minute 1.73m2. 1.6.23 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea. 1.6.24 In adults with type 2 diabetes, do not offer or continue pioglitazone if they have any of the following: heart failure or history of heart failure.	Prescribe metformin with caution for those at risk of a sudden deterioration in kidneyfunction and those at risk of eGFR falling below 45 ml minute 1.73m2. 1.6.23 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea. 1.6.24 In adults with type 2 diabetes, do not offer or continue pioglitazone if they have any of the following: heart failure or history of heart failure.	
quality-controlled plasma	0	0.5	2	Page 17of 44 of the following: quality-controlled plasma glucose profiles total glycated haemoglobin estimation (if abnormal haemoglobins) fructosamine estimation. 1.6.4 Investigate unexplained discrepancies between HbA1c and other glucose measurements.	Page 17of 44 of the following: quality-controlled plasma glucose profiles total glycated haemoglobin estimation (if abnormal haemoglobins) fructosamine estimation. 1.6.4 Investigate unexplained discrepancies between HbA1c and other glucose measurements.	
repeated injections	0	0.5	2	Insulin-based treatments1.6.32 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding.	Insulin-based treatments1.6.32 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding.	
self-monitoring dose	0	0.5	2	Insulin-based treatments1.6.32 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding.	Insulin-based treatments1.6.32 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding.	
structured programme	0	0.5	2	Insulin-based treatments1.6.32 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding.	Insulin-based treatments1.6.32 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding.	
sudden deterioration	0	0.5	2	Prescribe metformin with caution for those at risk of a sudden deterioration in kidneyfunction and those at risk of eGFR falling below 45 ml minute 1.73m2. 1.6.23 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea. 1.6.24 In adults with type 2 diabetes, do not offer or continue pioglitazone if they have any of the following: heart failure or history of heart failure.	Prescribe metformin with caution for those at risk of a sudden deterioration in kidneyfunction and those at risk of eGFR falling below 45 ml minute 1.73m2. 1.6.23 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea. 1.6.24 In adults with type 2 diabetes, do not offer or continue pioglitazone if they have any of the following: heart failure or history of heart failure.	
support self-monitoring	0	0.5	2	Insulin-based treatments1.6.32 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding.	Insulin-based treatments1.6.32 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding.	
telephone support	0	0.5	2	Insulin-based treatments1.6.32 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding.	Insulin-based treatments1.6.32 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding.	
therapy 6-monthly	0	0.5	2	Measurement1.6.1 In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable. 1.6.2 Use methods to measure HbA1c that have been calibrated according to.	Measurement1.6.1 In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable. 1.6.2 Use methods to measure HbA1c that have been calibrated according to.	
type 1	1	0.5	2	Insulin delivery1.6.38 For guidance on insulin delivery for adults with type 2 diabetes, see the insulin delivery section in the NICE guideline on type 1 diabetes. 1.7 Managing complications.	Insulin delivery1.6.38 For guidance on insulin delivery for adults with type 2 diabetes, see the insulin delivery section in the NICE guideline on type 1 diabetes. 1.7 Managing complications.	
unchanging therapy	0	0.5	2	Measurement1.6.1 In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable. 1.6.2 Use methods to measure HbA1c that have been calibrated according to.	Measurement1.6.1 In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable. 1.6.2 Use methods to measure HbA1c that have been calibrated according to.	
unexplained discrepancies	0	0.5	2	Page 17of 44 of the following: quality-controlled plasma glucose profiles total glycated haemoglobin estimation (if abnormal haemoglobins) fructosamine estimation. 1.6.4 Investigate unexplained discrepancies between HbA1c and other glucose measurements.	Page 17of 44 of the following: quality-controlled plasma glucose profiles total glycated haemoglobin estimation (if abnormal haemoglobins) fructosamine estimation. 1.6.4 Investigate unexplained discrepancies between HbA1c and other glucose measurements.	
initial drug	0	0.4954	8	Initial drugtreatment.	Initial drug treatment1.6.19 Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes. 1.6.20 Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes. 1.6.21 If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin..	Prescribe metformin with caution for those at risk of a sudden deterioration in kidneyfunction and those at risk of eGFR falling below 45 ml minute 1.73m2. 1.6.23 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea. 1.6.24 In adults with type 2 diabetes, do not offer or continue pioglitazone if they have any of the following: heart failure or history of heart failure.	First intensification of drug treatment1.6.25 In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea. 1.6.26 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea..	Initial drugtreatment.	Initial drug treatment1.6.19 Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes. 1.6.20 Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes. 1.6.21 If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin..	Prescribe metformin with caution for those at risk of a sudden deterioration in kidneyfunction and those at risk of eGFR falling below 45 ml minute 1.73m2. 1.6.23 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea. 1.6.24 In adults with type 2 diabetes, do not offer or continue pioglitazone if they have any of the following: heart failure or history of heart failure.	First intensification of drug treatment1.6.25 In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea. 1.6.26 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea..	
angiotensin ii-receptor	0	0.4813	4	Caribbean family origin should be an ACE inhibitor plus either a diuretic or ageneric calcium-channel blocker. 1.4.9 A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant. 1.4.10 For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor. 1.4.11 Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension. 1.4.12 If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic).	Page 16of 44 1.4.13 If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist). 1.4.14 Monitor the blood pressure of a person who has attained and consistently remained at his or her blood pressure target every 4–6 months.	Caribbean family origin should be an ACE inhibitor plus either a diuretic or ageneric calcium-channel blocker. 1.4.9 A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant. 1.4.10 For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor. 1.4.11 Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension. 1.4.12 If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic).	Page 16of 44 1.4.13 If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist). 1.4.14 Monitor the blood pressure of a person who has attained and consistently remained at his or her blood pressure target every 4–6 months.	
ii-receptor antagonist	0	0.4813	4	Caribbean family origin should be an ACE inhibitor plus either a diuretic or ageneric calcium-channel blocker. 1.4.9 A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant. 1.4.10 For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor. 1.4.11 Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension. 1.4.12 If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic).	Page 16of 44 1.4.13 If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist). 1.4.14 Monitor the blood pressure of a person who has attained and consistently remained at his or her blood pressure target every 4–6 months.	Caribbean family origin should be an ACE inhibitor plus either a diuretic or ageneric calcium-channel blocker. 1.4.9 A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant. 1.4.10 For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor. 1.4.11 Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension. 1.4.12 If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic).	Page 16of 44 1.4.13 If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist). 1.4.14 Monitor the blood pressure of a person who has attained and consistently remained at his or her blood pressure target every 4–6 months.	
insulin-based treatment	0	0.4756	6	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	HbA1c and a weight loss of at least 3percent of initial body weight in 6 months).1.6.30 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation 1.6.26) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations 1.6.32–1.6.34)..	Insulin-based treatments1.6.32 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding.	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	HbA1c and a weight loss of at least 3percent of initial body weight in 6 months).1.6.30 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation 1.6.26) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations 1.6.32–1.6.34)..	Insulin-based treatments1.6.32 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding.	
oral drugs	0	0.4756	4	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	HbA1c and a weight loss of at least 3percent of initial body weight in 6 months).1.6.30 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation 1.6.26) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations 1.6.32–1.6.34)..	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	HbA1c and a weight loss of at least 3percent of initial body weight in 6 months).1.6.30 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation 1.6.26) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations 1.6.32–1.6.34)..	
physical activity	0	0.4755	4	Encouragehigh-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids. 1.3.4 Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight. 1.3.5 For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent.	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	Encouragehigh-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids. 1.3.4 Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight. 1.3.5 For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent.	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	
nph insulin	1	0.4646	10	Offer NPH insulin injected once or twice daily according to need..	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if:the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs..	Consider pre-mixed (biphasic) preparations that include short-acting insulinanalogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals. 1.6.35 Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of.	HbA1c reached orwho cannot use the device needed to inject NPH insulin but who could administer their own insulin safely and accurately if a switch to one of the long-acting insulin analogues was made or.	Page 26of 44 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 1.6.36 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 1.6.37 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate..	Offer NPH insulin injected once or twice daily according to need..	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if:the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs..	Consider pre-mixed (biphasic) preparations that include short-acting insulinanalogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals. 1.6.35 Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of.	HbA1c reached orwho cannot use the device needed to inject NPH insulin but who could administer their own insulin safely and accurately if a switch to one of the long-acting insulin analogues was made or.	Page 26of 44 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 1.6.36 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 1.6.37 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate..	
personto aim	0	0.4554	2	For adults on a drug associated with hypoglycaemia, support the personto aim for an HbA1c level of 53 mmol mol (7.0percent). 1.6.8 In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol (7.5percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol (7.0percent) and intensify drug treatment. 1.6.9 Consider relaxing the target HbA1c level (see recommendations 1.6.7 and 1.6.8).	For adults on a drug associated with hypoglycaemia, support the personto aim for an HbA1c level of 53 mmol mol (7.0percent). 1.6.8 In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol (7.5percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol (7.0percent) and intensify drug treatment. 1.6.9 Consider relaxing the target HbA1c level (see recommendations 1.6.7 and 1.6.8).	
recommendations 1.6.7	0	0.4554	2	For adults on a drug associated with hypoglycaemia, support the personto aim for an HbA1c level of 53 mmol mol (7.0percent). 1.6.8 In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol (7.5percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol (7.0percent) and intensify drug treatment. 1.6.9 Consider relaxing the target HbA1c level (see recommendations 1.6.7 and 1.6.8).	For adults on a drug associated with hypoglycaemia, support the personto aim for an HbA1c level of 53 mmol mol (7.0percent). 1.6.8 In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol (7.5percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol (7.0percent) and intensify drug treatment. 1.6.9 Consider relaxing the target HbA1c level (see recommendations 1.6.7 and 1.6.8).	
side effects	0	0.4553	4	Initial drug treatment1.6.19 Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes. 1.6.20 Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes. 1.6.21 If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin..	Autonomic neuropathy1.7.6 Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015 1.7.7 Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015 1.7.8 When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension. 1.7.9 Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems..	Initial drug treatment1.6.19 Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes. 1.6.20 Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes. 1.6.21 If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin..	Autonomic neuropathy1.7.6 Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015 1.7.7 Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015 1.7.8 When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension. 1.7.9 Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems..	
triple therapy	0	0.4497	8	Treatment with either 3 non-insulin blood glucose lowering therapies incombination (triple therapy) or any treatment combination containing insulin 1.1 Individualised care 1.1.1 Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy..	Page 16of 44 1.4.13 If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist). 1.4.14 Monitor the blood pressure of a person who has attained and consistently remained at his or her blood pressure target every 4–6 months.	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate forsome people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in triple therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes..	Treatment with either 3 non-insulin blood glucose lowering therapies incombination (triple therapy) or any treatment combination containing insulin 1.1 Individualised care 1.1.1 Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy..	Page 16of 44 1.4.13 If the person's blood pressure is not reduced to the individually agreed target with triple therapy, add an alpha-blocker, a beta-blocker or a potassium-sparing diuretic (the last with caution if the person is already taking an ACE inhibitor or an angiotensin II-receptor antagonist). 1.4.14 Monitor the blood pressure of a person who has attained and consistently remained at his or her blood pressure target every 4–6 months.	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate forsome people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in triple therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes..	
lifestyle advice	0	0.4496	10	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	Offer and reinforcepreventive lifestyle advice. 1.4.2 For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used..	Provide lifestyle advice (diet and exercise) at the same time.1.4.4 Provide lifestyle advice (see section 1.3 in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood.	Page 15of 44 pressure is confirmed as being consistently above 140 80 mmHg (or above 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.5 Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.6 Monitor blood pressure every 1–2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.7 First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor.	Encourage them to achieve the target and maintain it unless anyresulting adverse effects (including hypoglycaemia), or their efforts to achieve their target, impair their quality of life. 1.6.6 Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section 1.3).	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	Offer and reinforcepreventive lifestyle advice. 1.4.2 For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used..	Provide lifestyle advice (diet and exercise) at the same time.1.4.4 Provide lifestyle advice (see section 1.3 in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood.	Page 15of 44 pressure is confirmed as being consistently above 140 80 mmHg (or above 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.5 Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.6 Monitor blood pressure every 1–2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.7 First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor.	Encourage them to achieve the target and maintain it unless anyresulting adverse effects (including hypoglycaemia), or their efforts to achieve their target, impair their quality of life. 1.6.6 Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section 1.3).	
single drug	0	0.4472	4	For moreinformation about supporting adherence, see the NICE guideline on medicines adherence. 1.6.7 For adults with type 2 diabetes managed either by lifestyle and diet, or by lifestyle and diet combined with a single drug not associated with hypoglycaemia, support the person to aim for an HbA1c level of 48 mmol mol (6.5percent).	For adults on a drug associated with hypoglycaemia, support the personto aim for an HbA1c level of 53 mmol mol (7.0percent). 1.6.8 In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol (7.5percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol (7.0percent) and intensify drug treatment. 1.6.9 Consider relaxing the target HbA1c level (see recommendations 1.6.7 and 1.6.8).	For moreinformation about supporting adherence, see the NICE guideline on medicines adherence. 1.6.7 For adults with type 2 diabetes managed either by lifestyle and diet, or by lifestyle and diet combined with a single drug not associated with hypoglycaemia, support the person to aim for an HbA1c level of 48 mmol mol (6.5percent).	For adults on a drug associated with hypoglycaemia, support the personto aim for an HbA1c level of 53 mmol mol (7.0percent). 1.6.8 In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol (7.5percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol (7.0percent) and intensify drug treatment. 1.6.9 Consider relaxing the target HbA1c level (see recommendations 1.6.7 and 1.6.8).	
bariatric surgery	0	0.4446	4	Page 13of 44 1.3 Dietary advice and bariatric surgery 1.3.1 Provide individualised and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition. 1.3.2 Provide dietary advice in a form sensitive to the person's needs, culture and beliefs, being sensitive to their willingness to change and the effects on their quality of life. 1.3.3 Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes.	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	Page 13of 44 1.3 Dietary advice and bariatric surgery 1.3.1 Provide individualised and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition. 1.3.2 Provide dietary advice in a form sensitive to the person's needs, culture and beliefs, being sensitive to their willingness to change and the effects on their quality of life. 1.3.3 Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes.	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	
glucose control	0	0.4421	12	International Federation of Clinical Chemistry (IFCC) standardisation.1.6.3 If HbA1c monitoring is invalid because of disturbed erythrocyte turnover or abnormal haemoglobin type, estimate trends in blood glucose control using one.	Page 18of 44 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities. 1.6.10 If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it.	Rescue therapy at any phase of treatment1.6.18 If an adult with type 2 diabetes is symptomatically hyperglycaemic, consider insulin (see recommendations 1.6.32–1.6.34) or a sulfonylurea, and review treatment when blood glucose control has been achieved..	DVLA guidance (At a glance guide to the current medical standards of fitness to drive)management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional. 1.6.33 When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance.	Page 26of 44 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 1.6.36 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 1.6.37 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate..	Gastroparesis1.7.1 Think about a diagnosis of gastroparesis in adults with type 2 diabetes with erratic blood glucose control or unexplained gastric bloating or vomiting, taking into account possible alternative diagnoses 2009, amended 2015 1.7.2 For adults with type 2 diabetes who have vomiting caused by gastroparesis, explain that: there is not strong evidence that any available antiemetic therapy is effective some people have had benefit with domperidone , erythromycin or metoclopramide . the strongest evidence for effectiveness is for domperidone , but prescribers must.	International Federation of Clinical Chemistry (IFCC) standardisation.1.6.3 If HbA1c monitoring is invalid because of disturbed erythrocyte turnover or abnormal haemoglobin type, estimate trends in blood glucose control using one.	Page 18of 44 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities. 1.6.10 If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it.	Rescue therapy at any phase of treatment1.6.18 If an adult with type 2 diabetes is symptomatically hyperglycaemic, consider insulin (see recommendations 1.6.32–1.6.34) or a sulfonylurea, and review treatment when blood glucose control has been achieved..	DVLA guidance (At a glance guide to the current medical standards of fitness to drive)management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional. 1.6.33 When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance.	Page 26of 44 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 1.6.36 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 1.6.37 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate..	Gastroparesis1.7.1 Think about a diagnosis of gastroparesis in adults with type 2 diabetes with erratic blood glucose control or unexplained gastric bloating or vomiting, taking into account possible alternative diagnoses 2009, amended 2015 1.7.2 For adults with type 2 diabetes who have vomiting caused by gastroparesis, explain that: there is not strong evidence that any available antiemetic therapy is effective some people have had benefit with domperidone , erythromycin or metoclopramide . the strongest evidence for effectiveness is for domperidone , but prescribers must.	
first-line antihypertensive	0	0.4295	6	Page 15of 44 pressure is confirmed as being consistently above 140 80 mmHg (or above 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.5 Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.6 Monitor blood pressure every 1–2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.7 First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor.	African or Caribbean family origin, or women for whom there is a possibility ofbecoming pregnant. 1.4.8 The first-line antihypertensive drug treatment for a person of African or.	Caribbean family origin should be an ACE inhibitor plus either a diuretic or ageneric calcium-channel blocker. 1.4.9 A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant. 1.4.10 For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor. 1.4.11 Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension. 1.4.12 If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic).	Page 15of 44 pressure is confirmed as being consistently above 140 80 mmHg (or above 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.5 Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.6 Monitor blood pressure every 1–2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.7 First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor.	African or Caribbean family origin, or women for whom there is a possibility ofbecoming pregnant. 1.4.8 The first-line antihypertensive drug treatment for a person of African or.	Caribbean family origin should be an ACE inhibitor plus either a diuretic or ageneric calcium-channel blocker. 1.4.9 A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant. 1.4.10 For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor. 1.4.11 Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension. 1.4.12 If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic).	
adverse effects	0	0.4174	6	When prescribing pioglitazone, exercise particular caution if the person is at high risk of theadverse effects of the drug.	Check forpossible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure. 1.5 Antiplatelet therapy 1.5.1 Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease. 1.5.2 For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction. 1.6 Blood glucose management.	Encourage them to achieve the target and maintain it unless anyresulting adverse effects (including hypoglycaemia), or their efforts to achieve their target, impair their quality of life. 1.6.6 Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section 1.3).	When prescribing pioglitazone, exercise particular caution if the person is at high risk of theadverse effects of the drug.	Check forpossible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure. 1.5 Antiplatelet therapy 1.5.1 Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease. 1.5.2 For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction. 1.6 Blood glucose management.	Encourage them to achieve the target and maintain it unless anyresulting adverse effects (including hypoglycaemia), or their efforts to achieve their target, impair their quality of life. 1.6.6 Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section 1.3).	
hba1c levels	0	0.4137	4	Measurement1.6.1 In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable. 1.6.2 Use methods to measure HbA1c that have been calibrated according to.	For adults on a drug associated with hypoglycaemia, support the personto aim for an HbA1c level of 53 mmol mol (7.0percent). 1.6.8 In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol (7.5percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol (7.0percent) and intensify drug treatment. 1.6.9 Consider relaxing the target HbA1c level (see recommendations 1.6.7 and 1.6.8).	Measurement1.6.1 In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable. 1.6.2 Use methods to measure HbA1c that have been calibrated according to.	For adults on a drug associated with hypoglycaemia, support the personto aim for an HbA1c level of 53 mmol mol (7.0percent). 1.6.8 In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol (7.5percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol (7.0percent) and intensify drug treatment. 1.6.9 Consider relaxing the target HbA1c level (see recommendations 1.6.7 and 1.6.8).	
metabolic response	0	0.3944	4	Base the choice of drug treatment(s) on:the effectiveness of the drug treatment(s) in terms of metabolic response.	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	Base the choice of drug treatment(s) on:the effectiveness of the drug treatment(s) in terms of metabolic response.	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	
forsome people	0	0.3943	4	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate forsome people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in triple therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes..	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate forsome people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes..	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate forsome people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in triple therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes..	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate forsome people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes..	
sglt-2 inhibitors	0	0.3943	4	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate forsome people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in triple therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes..	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate forsome people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes..	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate forsome people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in triple therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes..	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate forsome people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes..	
antihypertensive drug	0	0.392	12	Offer and reinforcepreventive lifestyle advice. 1.4.2 For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used..	Page 15of 44 pressure is confirmed as being consistently above 140 80 mmHg (or above 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.5 Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.6 Monitor blood pressure every 1–2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.7 First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor.	African or Caribbean family origin, or women for whom there is a possibility ofbecoming pregnant. 1.4.8 The first-line antihypertensive drug treatment for a person of African or.	Caribbean family origin should be an ACE inhibitor plus either a diuretic or ageneric calcium-channel blocker. 1.4.9 A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant. 1.4.10 For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor. 1.4.11 Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension. 1.4.12 If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic).	Check forpossible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure. 1.5 Antiplatelet therapy 1.5.1 Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease. 1.5.2 For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction. 1.6 Blood glucose management.	Autonomic neuropathy1.7.6 Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015 1.7.7 Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015 1.7.8 When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension. 1.7.9 Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems..	Offer and reinforcepreventive lifestyle advice. 1.4.2 For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used..	Page 15of 44 pressure is confirmed as being consistently above 140 80 mmHg (or above 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.5 Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.6 Monitor blood pressure every 1–2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.7 First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor.	African or Caribbean family origin, or women for whom there is a possibility ofbecoming pregnant. 1.4.8 The first-line antihypertensive drug treatment for a person of African or.	Caribbean family origin should be an ACE inhibitor plus either a diuretic or ageneric calcium-channel blocker. 1.4.9 A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant. 1.4.10 For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor. 1.4.11 Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension. 1.4.12 If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic).	Check forpossible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure. 1.5 Antiplatelet therapy 1.5.1 Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease. 1.5.2 For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction. 1.6 Blood glucose management.	Autonomic neuropathy1.7.6 Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015 1.7.7 Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015 1.7.8 When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension. 1.7.9 Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems..	
insulin analogues	0	0.3919	4	HbA1c reached orwho cannot use the device needed to inject NPH insulin but who could administer their own insulin safely and accurately if a switch to one of the long-acting insulin analogues was made or.	Page 26of 44 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 1.6.36 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 1.6.37 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate..	HbA1c reached orwho cannot use the device needed to inject NPH insulin but who could administer their own insulin safely and accurately if a switch to one of the long-acting insulin analogues was made or.	Page 26of 44 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 1.6.36 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 1.6.37 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate..	
1.5 antiplatelet	0	0.385	2	Check forpossible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure. 1.5 Antiplatelet therapy 1.5.1 Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease. 1.5.2 For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction. 1.6 Blood glucose management.	Check forpossible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure. 1.5 Antiplatelet therapy 1.5.1 Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease. 1.5.2 For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction. 1.6 Blood glucose management.	
1.6 blood	0	0.385	2	Check forpossible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure. 1.5 Antiplatelet therapy 1.5.1 Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease. 1.5.2 For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction. 1.6 Blood glucose management.	Check forpossible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure. 1.5 Antiplatelet therapy 1.5.1 Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease. 1.5.2 For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction. 1.6 Blood glucose management.	
blood glucose1.6.12	0	0.385	2	Self-monitoring of blood glucose1.6.12 Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes. 1.6.13 Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or.	Self-monitoring of blood glucose1.6.12 Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes. 1.6.13 Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or.	
check forpossible	0	0.385	2	Check forpossible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure. 1.5 Antiplatelet therapy 1.5.1 Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease. 1.5.2 For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction. 1.6 Blood glucose management.	Check forpossible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure. 1.5 Antiplatelet therapy 1.5.1 Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease. 1.5.2 For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction. 1.6 Blood glucose management.	
forpossible adverse	0	0.385	2	Check forpossible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure. 1.5 Antiplatelet therapy 1.5.1 Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease. 1.5.2 For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction. 1.6 Blood glucose management.	Check forpossible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure. 1.5 Antiplatelet therapy 1.5.1 Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease. 1.5.2 For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction. 1.6 Blood glucose management.	
glucose management	0	0.385	2	Check forpossible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure. 1.5 Antiplatelet therapy 1.5.1 Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease. 1.5.2 For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction. 1.6 Blood glucose management.	Check forpossible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure. 1.5 Antiplatelet therapy 1.5.1 Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease. 1.5.2 For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction. 1.6 Blood glucose management.	
licensing agency	0	0.385	2	Self-monitoring of blood glucose1.6.12 Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes. 1.6.13 Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or.	Self-monitoring of blood glucose1.6.12 Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes. 1.6.13 Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or.	
low blood	0	0.385	2	Check forpossible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure. 1.5 Antiplatelet therapy 1.5.1 Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease. 1.5.2 For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction. 1.6 Blood glucose management.	Check forpossible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure. 1.5 Antiplatelet therapy 1.5.1 Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease. 1.5.2 For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction. 1.6 Blood glucose management.	
myocardial infarction	1	0.385	2	Check forpossible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure. 1.5 Antiplatelet therapy 1.5.1 Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease. 1.5.2 For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction. 1.6 Blood glucose management.	Check forpossible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure. 1.5 Antiplatelet therapy 1.5.1 Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease. 1.5.2 For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction. 1.6 Blood glucose management.	
oral medication	0	0.385	2	Self-monitoring of blood glucose1.6.12 Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes. 1.6.13 Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or.	Self-monitoring of blood glucose1.6.12 Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes. 1.6.13 Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or.	
secondary prevention	0	0.385	2	Check forpossible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure. 1.5 Antiplatelet therapy 1.5.1 Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease. 1.5.2 For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction. 1.6 Blood glucose management.	Check forpossible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure. 1.5 Antiplatelet therapy 1.5.1 Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease. 1.5.2 For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction. 1.6 Blood glucose management.	
therapy 1.5.1	0	0.385	2	Check forpossible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure. 1.5 Antiplatelet therapy 1.5.1 Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease. 1.5.2 For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction. 1.6 Blood glucose management.	Check forpossible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure. 1.5 Antiplatelet therapy 1.5.1 Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease. 1.5.2 For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction. 1.6 Blood glucose management.	
vehicle licensing	0	0.385	2	Self-monitoring of blood glucose1.6.12 Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes. 1.6.13 Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or.	Self-monitoring of blood glucose1.6.12 Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes. 1.6.13 Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or.	
1.4.3 repeat	0	0.3849	2	Make changes only if there is poor control or if current drug treatment is notappropriate because of microvascular complications or metabolic problems. 1.4.3 Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage..	Make changes only if there is poor control or if current drug treatment is notappropriate because of microvascular complications or metabolic problems. 1.4.3 Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage..	
autonomic neuropathy1.7.6	0	0.3849	2	Autonomic neuropathy1.7.6 Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015 1.7.7 Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015 1.7.8 When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension. 1.7.9 Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems..	Autonomic neuropathy1.7.6 Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015 1.7.7 Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015 1.7.8 When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension. 1.7.9 Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems..	
bladder-emptying problems.	0	0.3849	2	Autonomic neuropathy1.7.6 Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015 1.7.7 Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015 1.7.8 When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension. 1.7.9 Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems..	Autonomic neuropathy1.7.6 Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015 1.7.7 Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015 1.7.8 When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension. 1.7.9 Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems..	
cerebrovascular damage.	0	0.3849	2	Make changes only if there is poor control or if current drug treatment is notappropriate because of microvascular complications or metabolic problems. 1.4.3 Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage..	Make changes only if there is poor control or if current drug treatment is notappropriate because of microvascular complications or metabolic problems. 1.4.3 Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage..	
contributory sympathetic	0	0.3849	2	Autonomic neuropathy1.7.6 Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015 1.7.7 Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015 1.7.8 When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension. 1.7.9 Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems..	Autonomic neuropathy1.7.6 Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015 1.7.7 Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015 1.7.8 When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension. 1.7.9 Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems..	
current drug	0	0.3849	2	Make changes only if there is poor control or if current drug treatment is notappropriate because of microvascular complications or metabolic problems. 1.4.3 Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage..	Make changes only if there is poor control or if current drug treatment is notappropriate because of microvascular complications or metabolic problems. 1.4.3 Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage..	
drug treatments	0	0.3849	2	Autonomic neuropathy1.7.6 Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015 1.7.7 Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015 1.7.8 When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension. 1.7.9 Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems..	Autonomic neuropathy1.7.6 Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015 1.7.7 Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015 1.7.8 When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension. 1.7.9 Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems..	
metabolic problems	0	0.3849	2	Make changes only if there is poor control or if current drug treatment is notappropriate because of microvascular complications or metabolic problems. 1.4.3 Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage..	Make changes only if there is poor control or if current drug treatment is notappropriate because of microvascular complications or metabolic problems. 1.4.3 Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage..	
microvascular complications	0	0.3849	2	Make changes only if there is poor control or if current drug treatment is notappropriate because of microvascular complications or metabolic problems. 1.4.3 Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage..	Make changes only if there is poor control or if current drug treatment is notappropriate because of microvascular complications or metabolic problems. 1.4.3 Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage..	
nervous system	0	0.3849	2	Autonomic neuropathy1.7.6 Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015 1.7.7 Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015 1.7.8 When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension. 1.7.9 Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems..	Autonomic neuropathy1.7.6 Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015 1.7.7 Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015 1.7.8 When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension. 1.7.9 Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems..	
orthostatic hypotension	0	0.3849	2	Autonomic neuropathy1.7.6 Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015 1.7.7 Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015 1.7.8 When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension. 1.7.9 Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems..	Autonomic neuropathy1.7.6 Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015 1.7.7 Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015 1.7.8 When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension. 1.7.9 Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems..	
poor control	0	0.3849	2	Make changes only if there is poor control or if current drug treatment is notappropriate because of microvascular complications or metabolic problems. 1.4.3 Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage..	Make changes only if there is poor control or if current drug treatment is notappropriate because of microvascular complications or metabolic problems. 1.4.3 Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage..	
pressure measurements	0	0.3849	2	Make changes only if there is poor control or if current drug treatment is notappropriate because of microvascular complications or metabolic problems. 1.4.3 Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage..	Make changes only if there is poor control or if current drug treatment is notappropriate because of microvascular complications or metabolic problems. 1.4.3 Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage..	
repeat blood	0	0.3849	2	Make changes only if there is poor control or if current drug treatment is notappropriate because of microvascular complications or metabolic problems. 1.4.3 Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage..	Make changes only if there is poor control or if current drug treatment is notappropriate because of microvascular complications or metabolic problems. 1.4.3 Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage..	
sympathetic nervous	0	0.3849	2	Autonomic neuropathy1.7.6 Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015 1.7.7 Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015 1.7.8 When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension. 1.7.9 Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems..	Autonomic neuropathy1.7.6 Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015 1.7.7 Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015 1.7.8 When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension. 1.7.9 Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems..	
system damage	0	0.3849	2	Autonomic neuropathy1.7.6 Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015 1.7.7 Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015 1.7.8 When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension. 1.7.9 Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems..	Autonomic neuropathy1.7.6 Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015 1.7.7 Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015 1.7.8 When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension. 1.7.9 Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems..	
tricyclic drugs	0	0.3849	2	Autonomic neuropathy1.7.6 Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015 1.7.7 Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015 1.7.8 When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension. 1.7.9 Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems..	Autonomic neuropathy1.7.6 Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015 1.7.7 Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015 1.7.8 When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension. 1.7.9 Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems..	
unexplained bladder-emptying	0	0.3849	2	Autonomic neuropathy1.7.6 Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015 1.7.7 Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015 1.7.8 When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension. 1.7.9 Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems..	Autonomic neuropathy1.7.6 Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015 1.7.7 Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015 1.7.8 When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension. 1.7.9 Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems..	
unexplained diarrhoea	0	0.3849	2	Autonomic neuropathy1.7.6 Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015 1.7.7 Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015 1.7.8 When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension. 1.7.9 Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems..	Autonomic neuropathy1.7.6 Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015 1.7.7 Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015 1.7.8 When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension. 1.7.9 Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems..	
drug treatment	0	0.3735	38	Firstintensification of drug treatment.	Secondintensification of drug treatment.	Offer and reinforcepreventive lifestyle advice. 1.4.2 For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used..	Make changes only if there is poor control or if current drug treatment is notappropriate because of microvascular complications or metabolic problems. 1.4.3 Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage..	Page 15of 44 pressure is confirmed as being consistently above 140 80 mmHg (or above 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.5 Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.6 Monitor blood pressure every 1–2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.7 First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor.	African or Caribbean family origin, or women for whom there is a possibility ofbecoming pregnant. 1.4.8 The first-line antihypertensive drug treatment for a person of African or.	Caribbean family origin should be an ACE inhibitor plus either a diuretic or ageneric calcium-channel blocker. 1.4.9 A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant. 1.4.10 For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor. 1.4.11 Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension. 1.4.12 If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic).	Check forpossible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure. 1.5 Antiplatelet therapy 1.5.1 Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease. 1.5.2 For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction. 1.6 Blood glucose management.	Encourage them to achieve the target and maintain it unless anyresulting adverse effects (including hypoglycaemia), or their efforts to achieve their target, impair their quality of life. 1.6.6 Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section 1.3).	For adults on a drug associated with hypoglycaemia, support the personto aim for an HbA1c level of 53 mmol mol (7.0percent). 1.6.8 In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol (7.5percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol (7.0percent) and intensify drug treatment. 1.6.9 Consider relaxing the target HbA1c level (see recommendations 1.6.7 and 1.6.8).	Drug treatment.	Recommendations in this section that cover dipeptidyl peptidase-4 (DPP-4) inhibitors,glucagon-like peptide-1 (GLP-1) mimetics and sulfonylureas refer to each of these groups of drugs at a class level. 1.6.17 For adults with type 2 diabetes, discuss the benefits and risks of drug treatment, and the options available.	Base the choice of drug treatment(s) on:the effectiveness of the drug treatment(s) in terms of metabolic response.	Page 20of 44 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost)..	Initial drug treatment1.6.19 Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes. 1.6.20 Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes. 1.6.21 If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin..	Prescribe metformin with caution for those at risk of a sudden deterioration in kidneyfunction and those at risk of eGFR falling below 45 ml minute 1.73m2. 1.6.23 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea. 1.6.24 In adults with type 2 diabetes, do not offer or continue pioglitazone if they have any of the following: heart failure or history of heart failure.	First intensification of drug treatment1.6.25 In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea. 1.6.26 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea..	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	Autonomic neuropathy1.7.6 Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015 1.7.7 Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015 1.7.8 When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension. 1.7.9 Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems..	Firstintensification of drug treatment.	Secondintensification of drug treatment.	Offer and reinforcepreventive lifestyle advice. 1.4.2 For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used..	Make changes only if there is poor control or if current drug treatment is notappropriate because of microvascular complications or metabolic problems. 1.4.3 Repeat blood pressure measurements within: 1 month if blood pressure is higher than 150 90 mmHg 2 months if blood pressure is higher than 140 80 mmHg 2 months if blood pressure is higher than 130 80 mmHg and there is kidney, eye or cerebrovascular damage..	Page 15of 44 pressure is confirmed as being consistently above 140 80 mmHg (or above 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.5 Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.6 Monitor blood pressure every 1–2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.7 First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor.	African or Caribbean family origin, or women for whom there is a possibility ofbecoming pregnant. 1.4.8 The first-line antihypertensive drug treatment for a person of African or.	Caribbean family origin should be an ACE inhibitor plus either a diuretic or ageneric calcium-channel blocker. 1.4.9 A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant. 1.4.10 For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor. 1.4.11 Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension. 1.4.12 If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic).	Check forpossible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure. 1.5 Antiplatelet therapy 1.5.1 Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease. 1.5.2 For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction. 1.6 Blood glucose management.	Encourage them to achieve the target and maintain it unless anyresulting adverse effects (including hypoglycaemia), or their efforts to achieve their target, impair their quality of life. 1.6.6 Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section 1.3).	For adults on a drug associated with hypoglycaemia, support the personto aim for an HbA1c level of 53 mmol mol (7.0percent). 1.6.8 In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol (7.5percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol (7.0percent) and intensify drug treatment. 1.6.9 Consider relaxing the target HbA1c level (see recommendations 1.6.7 and 1.6.8).	Drug treatment.	Recommendations in this section that cover dipeptidyl peptidase-4 (DPP-4) inhibitors,glucagon-like peptide-1 (GLP-1) mimetics and sulfonylureas refer to each of these groups of drugs at a class level. 1.6.17 For adults with type 2 diabetes, discuss the benefits and risks of drug treatment, and the options available.	Base the choice of drug treatment(s) on:the effectiveness of the drug treatment(s) in terms of metabolic response.	Page 20of 44 safety (see Medicines and Healthcare products Regulatory Agency MHRA guidance) and tolerability of the drug treatment(s) the person's individual clinical circumstances, for example, comorbidities, risks from polypharmacy the person's individual preferences and needs the licensed indications or combinations available cost (if 2 drugs in the same class are appropriate, choose the option with the lowest acquisition cost)..	Initial drug treatment1.6.19 Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes. 1.6.20 Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes. 1.6.21 If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin..	Prescribe metformin with caution for those at risk of a sudden deterioration in kidneyfunction and those at risk of eGFR falling below 45 ml minute 1.73m2. 1.6.23 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea. 1.6.24 In adults with type 2 diabetes, do not offer or continue pioglitazone if they have any of the following: heart failure or history of heart failure.	First intensification of drug treatment1.6.25 In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea. 1.6.26 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea..	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	Autonomic neuropathy1.7.6 Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015 1.7.7 Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015 1.7.8 When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension. 1.7.9 Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems..	
nice guideline	0	0.3723	20	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	Provide lifestyle advice (diet and exercise) at the same time.1.4.4 Provide lifestyle advice (see section 1.3 in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood.	Check forpossible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure. 1.5 Antiplatelet therapy 1.5.1 Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease. 1.5.2 For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction. 1.6 Blood glucose management.	For moreinformation about supporting adherence, see the NICE guideline on medicines adherence. 1.6.7 For adults with type 2 diabetes managed either by lifestyle and diet, or by lifestyle and diet combined with a single drug not associated with hypoglycaemia, support the person to aim for an HbA1c level of 48 mmol mol (6.5percent).	Be aware that there are other possible reasons for a low HbA1clevel, for example, deteriorating renal function or sudden weight loss. 1.6.11 For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy..	For more information, seethe NICE guideline on diabetes in pregnancy. 1.6.14 Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia. 1.6.15 Be aware that adults with type 2 diabetes who have acute intercurrent illness are at risk of worsening hyperglycaemia.	Insulin delivery1.6.38 For guidance on insulin delivery for adults with type 2 diabetes, see the insulin delivery section in the NICE guideline on type 1 diabetes. 1.7 Managing complications.	Painful diabetic neuropathy1.7.5 For guidance on managing painful diabetic peripheral neuropathy in adults with type 2 diabetes, see the NICE guideline on neuropathic pain in adults..	Diabetic foot problems1.7.11 For guidance on preventing and managing foot problems in adults with type 2 diabetes, see the NICE guideline on diabetic foot problems..	NICE guideline on chronic kidney disease in adults..	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	Provide lifestyle advice (diet and exercise) at the same time.1.4.4 Provide lifestyle advice (see section 1.3 in this guideline and the lifestyle interventions section in hypertension in adults NICE guideline CG127) if blood.	Check forpossible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure. 1.5 Antiplatelet therapy 1.5.1 Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease. 1.5.2 For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction. 1.6 Blood glucose management.	For moreinformation about supporting adherence, see the NICE guideline on medicines adherence. 1.6.7 For adults with type 2 diabetes managed either by lifestyle and diet, or by lifestyle and diet combined with a single drug not associated with hypoglycaemia, support the person to aim for an HbA1c level of 48 mmol mol (6.5percent).	Be aware that there are other possible reasons for a low HbA1clevel, for example, deteriorating renal function or sudden weight loss. 1.6.11 For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy..	For more information, seethe NICE guideline on diabetes in pregnancy. 1.6.14 Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia. 1.6.15 Be aware that adults with type 2 diabetes who have acute intercurrent illness are at risk of worsening hyperglycaemia.	Insulin delivery1.6.38 For guidance on insulin delivery for adults with type 2 diabetes, see the insulin delivery section in the NICE guideline on type 1 diabetes. 1.7 Managing complications.	Painful diabetic neuropathy1.7.5 For guidance on managing painful diabetic peripheral neuropathy in adults with type 2 diabetes, see the NICE guideline on neuropathic pain in adults..	Diabetic foot problems1.7.11 For guidance on preventing and managing foot problems in adults with type 2 diabetes, see the NICE guideline on diabetic foot problems..	NICE guideline on chronic kidney disease in adults..	
1.3 dietary	0	0.3603	2	Page 13of 44 1.3 Dietary advice and bariatric surgery 1.3.1 Provide individualised and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition. 1.3.2 Provide dietary advice in a form sensitive to the person's needs, culture and beliefs, being sensitive to their willingness to change and the effects on their quality of life. 1.3.3 Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes.	Page 13of 44 1.3 Dietary advice and bariatric surgery 1.3.1 Provide individualised and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition. 1.3.2 Provide dietary advice in a form sensitive to the person's needs, culture and beliefs, being sensitive to their willingness to change and the effects on their quality of life. 1.3.3 Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes.	
1.3.3 emphasise	0	0.3603	2	Page 13of 44 1.3 Dietary advice and bariatric surgery 1.3.1 Provide individualised and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition. 1.3.2 Provide dietary advice in a form sensitive to the person's needs, culture and beliefs, being sensitive to their willingness to change and the effects on their quality of life. 1.3.3 Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes.	Page 13of 44 1.3 Dietary advice and bariatric surgery 1.3.1 Provide individualised and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition. 1.3.2 Provide dietary advice in a form sensitive to the person's needs, culture and beliefs, being sensitive to their willingness to change and the effects on their quality of life. 1.3.3 Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes.	
balanced eating	0	0.3603	2	Page 13of 44 1.3 Dietary advice and bariatric surgery 1.3.1 Provide individualised and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition. 1.3.2 Provide dietary advice in a form sensitive to the person's needs, culture and beliefs, being sensitive to their willingness to change and the effects on their quality of life. 1.3.3 Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes.	Page 13of 44 1.3 Dietary advice and bariatric surgery 1.3.1 Provide individualised and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition. 1.3.2 Provide dietary advice in a form sensitive to the person's needs, culture and beliefs, being sensitive to their willingness to change and the effects on their quality of life. 1.3.3 Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes.	
drug treatment1.6.25	0	0.3603	2	First intensification of drug treatment1.6.25 In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea. 1.6.26 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea..	First intensification of drug treatment1.6.25 In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea. 1.6.26 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea..	
emphasise advice	0	0.3603	2	Page 13of 44 1.3 Dietary advice and bariatric surgery 1.3.1 Provide individualised and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition. 1.3.2 Provide dietary advice in a form sensitive to the person's needs, culture and beliefs, being sensitive to their willingness to change and the effects on their quality of life. 1.3.3 Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes.	Page 13of 44 1.3 Dietary advice and bariatric surgery 1.3.1 Provide individualised and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition. 1.3.2 Provide dietary advice in a form sensitive to the person's needs, culture and beliefs, being sensitive to their willingness to change and the effects on their quality of life. 1.3.3 Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes.	
form sensitive	0	0.3603	2	Page 13of 44 1.3 Dietary advice and bariatric surgery 1.3.1 Provide individualised and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition. 1.3.2 Provide dietary advice in a form sensitive to the person's needs, culture and beliefs, being sensitive to their willingness to change and the effects on their quality of life. 1.3.3 Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes.	Page 13of 44 1.3 Dietary advice and bariatric surgery 1.3.1 Provide individualised and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition. 1.3.2 Provide dietary advice in a form sensitive to the person's needs, culture and beliefs, being sensitive to their willingness to change and the effects on their quality of life. 1.3.3 Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes.	
general population	1	0.3603	2	Page 13of 44 1.3 Dietary advice and bariatric surgery 1.3.1 Provide individualised and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition. 1.3.2 Provide dietary advice in a form sensitive to the person's needs, culture and beliefs, being sensitive to their willingness to change and the effects on their quality of life. 1.3.3 Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes.	Page 13of 44 1.3 Dietary advice and bariatric surgery 1.3.1 Provide individualised and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition. 1.3.2 Provide dietary advice in a form sensitive to the person's needs, culture and beliefs, being sensitive to their willingness to change and the effects on their quality of life. 1.3.3 Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes.	
healthy balanced	0	0.3603	2	Page 13of 44 1.3 Dietary advice and bariatric surgery 1.3.1 Provide individualised and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition. 1.3.2 Provide dietary advice in a form sensitive to the person's needs, culture and beliefs, being sensitive to their willingness to change and the effects on their quality of life. 1.3.3 Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes.	Page 13of 44 1.3 Dietary advice and bariatric surgery 1.3.1 Provide individualised and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition. 1.3.2 Provide dietary advice in a form sensitive to the person's needs, culture and beliefs, being sensitive to their willingness to change and the effects on their quality of life. 1.3.3 Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes.	
nutritional advice	0	0.3603	2	Page 13of 44 1.3 Dietary advice and bariatric surgery 1.3.1 Provide individualised and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition. 1.3.2 Provide dietary advice in a form sensitive to the person's needs, culture and beliefs, being sensitive to their willingness to change and the effects on their quality of life. 1.3.3 Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes.	Page 13of 44 1.3 Dietary advice and bariatric surgery 1.3.1 Provide individualised and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition. 1.3.2 Provide dietary advice in a form sensitive to the person's needs, culture and beliefs, being sensitive to their willingness to change and the effects on their quality of life. 1.3.3 Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes.	
ongoing nutritional	0	0.3603	2	Page 13of 44 1.3 Dietary advice and bariatric surgery 1.3.1 Provide individualised and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition. 1.3.2 Provide dietary advice in a form sensitive to the person's needs, culture and beliefs, being sensitive to their willingness to change and the effects on their quality of life. 1.3.3 Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes.	Page 13of 44 1.3 Dietary advice and bariatric surgery 1.3.1 Provide individualised and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition. 1.3.2 Provide dietary advice in a form sensitive to the person's needs, culture and beliefs, being sensitive to their willingness to change and the effects on their quality of life. 1.3.3 Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes.	
page 13of	0	0.3603	2	Page 13of 44 1.3 Dietary advice and bariatric surgery 1.3.1 Provide individualised and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition. 1.3.2 Provide dietary advice in a form sensitive to the person's needs, culture and beliefs, being sensitive to their willingness to change and the effects on their quality of life. 1.3.3 Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes.	Page 13of 44 1.3 Dietary advice and bariatric surgery 1.3.1 Provide individualised and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition. 1.3.2 Provide dietary advice in a form sensitive to the person's needs, culture and beliefs, being sensitive to their willingness to change and the effects on their quality of life. 1.3.3 Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes.	
specific expertise	0	0.3603	2	Page 13of 44 1.3 Dietary advice and bariatric surgery 1.3.1 Provide individualised and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition. 1.3.2 Provide dietary advice in a form sensitive to the person's needs, culture and beliefs, being sensitive to their willingness to change and the effects on their quality of life. 1.3.3 Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes.	Page 13of 44 1.3 Dietary advice and bariatric surgery 1.3.1 Provide individualised and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition. 1.3.2 Provide dietary advice in a form sensitive to the person's needs, culture and beliefs, being sensitive to their willingness to change and the effects on their quality of life. 1.3.3 Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes.	
surgery 1.3.1	0	0.3603	2	Page 13of 44 1.3 Dietary advice and bariatric surgery 1.3.1 Provide individualised and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition. 1.3.2 Provide dietary advice in a form sensitive to the person's needs, culture and beliefs, being sensitive to their willingness to change and the effects on their quality of life. 1.3.3 Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes.	Page 13of 44 1.3 Dietary advice and bariatric surgery 1.3.1 Provide individualised and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition. 1.3.2 Provide dietary advice in a form sensitive to the person's needs, culture and beliefs, being sensitive to their willingness to change and the effects on their quality of life. 1.3.3 Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes.	
nice guidance	0	0.3587	6	Treatment with combinations of medicines including sodium–glucose cotransporter 2 (SGLT-2)inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes..	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate forsome people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in triple therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes..	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate forsome people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes..	Treatment with combinations of medicines including sodium–glucose cotransporter 2 (SGLT-2)inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes..	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate forsome people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in triple therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes..	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate forsome people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes..	
insulin detemir	0	0.3421	6	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if:the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs..	Consider pre-mixed (biphasic) preparations that include short-acting insulinanalogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals. 1.6.35 Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of.	Page 26of 44 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 1.6.36 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 1.6.37 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate..	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if:the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs..	Consider pre-mixed (biphasic) preparations that include short-acting insulinanalogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals. 1.6.35 Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of.	Page 26of 44 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 1.6.36 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 1.6.37 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate..	
insulin glargine	0	0.3421	6	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if:the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs..	Consider pre-mixed (biphasic) preparations that include short-acting insulinanalogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals. 1.6.35 Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of.	Page 26of 44 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 1.6.36 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 1.6.37 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate..	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if:the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs..	Consider pre-mixed (biphasic) preparations that include short-acting insulinanalogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals. 1.6.35 Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of.	Page 26of 44 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 1.6.36 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 1.6.37 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate..	
target hba1c	0	0.3415	4	For adults on a drug associated with hypoglycaemia, support the personto aim for an HbA1c level of 53 mmol mol (7.0percent). 1.6.8 In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol (7.5percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol (7.0percent) and intensify drug treatment. 1.6.9 Consider relaxing the target HbA1c level (see recommendations 1.6.7 and 1.6.8).	Consider pre-mixed (biphasic) preparations that include short-acting insulinanalogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals. 1.6.35 Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of.	For adults on a drug associated with hypoglycaemia, support the personto aim for an HbA1c level of 53 mmol mol (7.0percent). 1.6.8 In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol (7.5percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol (7.0percent) and intensify drug treatment. 1.6.9 Consider relaxing the target HbA1c level (see recommendations 1.6.7 and 1.6.8).	Consider pre-mixed (biphasic) preparations that include short-acting insulinanalogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals. 1.6.35 Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of.	
monitor adults	0	0.3394	2	Page 26of 44 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 1.6.36 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 1.6.37 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate..	Page 26of 44 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 1.6.36 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 1.6.37 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate..	
healthcare professional	0	0.3377	8	Page 13of 44 1.3 Dietary advice and bariatric surgery 1.3.1 Provide individualised and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition. 1.3.2 Provide dietary advice in a form sensitive to the person's needs, culture and beliefs, being sensitive to their willingness to change and the effects on their quality of life. 1.3.3 Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes.	DVLA guidance (At a glance guide to the current medical standards of fitness to drive)management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional. 1.6.33 When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance.	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if:the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs..	Page 26of 44 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 1.6.36 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 1.6.37 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate..	Page 13of 44 1.3 Dietary advice and bariatric surgery 1.3.1 Provide individualised and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition. 1.3.2 Provide dietary advice in a form sensitive to the person's needs, culture and beliefs, being sensitive to their willingness to change and the effects on their quality of life. 1.3.3 Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes.	DVLA guidance (At a glance guide to the current medical standards of fitness to drive)management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional. 1.6.33 When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance.	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if:the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs..	Page 26of 44 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 1.6.36 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 1.6.37 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate..	
beneficial metabolic	0	0.3334	2	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	
drug treatment1.6.27	0	0.3334	2	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	
ethnic groups	0	0.3334	2	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	
glucagon-like peptide-1	1	0.3334	4	Recommendations in this section that cover dipeptidyl peptidase-4 (DPP-4) inhibitors,glucagon-like peptide-1 (GLP-1) mimetics and sulfonylureas refer to each of these groups of drugs at a class level. 1.6.17 For adults with type 2 diabetes, discuss the benefits and risks of drug treatment, and the options available.	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	Recommendations in this section that cover dipeptidyl peptidase-4 (DPP-4) inhibitors,glucagon-like peptide-1 (GLP-1) mimetics and sulfonylureas refer to each of these groups of drugs at a class level. 1.6.17 For adults with type 2 diabetes, discuss the benefits and risks of drug treatment, and the options available.	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	
insulin preparations	0	0.3334	2	Consider pre-mixed (biphasic) preparations that include short-acting insulinanalogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals. 1.6.35 Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of.	Consider pre-mixed (biphasic) preparations that include short-acting insulinanalogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals. 1.6.35 Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of.	
kg m2	0	0.3334	2	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	
kg m2and	0	0.3334	2	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	
medical problems	0	0.3334	2	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	
mimetic therapy	0	0.3334	2	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	
minority ethnic	0	0.3334	2	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	
mol 1.0percent	0	0.3334	2	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	
obesity-related comorbidities	0	0.3334	2	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	
occupational implications	0	0.3334	2	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	
oral drug	0	0.3334	4	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	HbA1c and a weight loss of at least 3percent of initial body weight in 6 months).1.6.30 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation 1.6.26) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations 1.6.32–1.6.34)..	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	HbA1c and a weight loss of at least 3percent of initial body weight in 6 months).1.6.30 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation 1.6.26) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations 1.6.32–1.6.34)..	
recommendation 1.6.25	0	0.3334	2	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	
recommendation 1.6.27	0	0.3334	2	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	
short-acting human	0	0.3334	2	Consider pre-mixed (biphasic) preparations that include short-acting insulinanalogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals. 1.6.35 Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of.	Consider pre-mixed (biphasic) preparations that include short-acting insulinanalogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals. 1.6.35 Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of.	
short-acting insulinanalogues	0	0.3334	2	Consider pre-mixed (biphasic) preparations that include short-acting insulinanalogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals. 1.6.35 Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of.	Consider pre-mixed (biphasic) preparations that include short-acting insulinanalogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals. 1.6.35 Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of.	
significant obesity-related	0	0.3334	2	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	
significant occupational	0	0.3334	2	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	
specific psychological	0	0.3334	2	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	
1.4 blood	0	0.3333	2	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	
1.4.1 measure	0	0.3333	2	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	
carbohydrate content	0	0.3333	2	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	
drug treatment1.6.19	0	0.3333	2	Initial drug treatment1.6.19 Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes. 1.6.20 Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes. 1.6.21 If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin..	Initial drug treatment1.6.19 Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes. 1.6.20 Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes. 1.6.21 If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin..	
excess weight	0	0.3333	2	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	
foot problems	0	0.3333	2	Diabetic foot problems1.7.11 For guidance on preventing and managing foot problems in adults with type 2 diabetes, see the NICE guideline on diabetic foot problems..	Diabetic foot problems1.7.11 For guidance on preventing and managing foot problems in adults with type 2 diabetes, see the NICE guideline on diabetic foot problems..	
foot problems.	0	0.3333	2	Diabetic foot problems1.7.11 For guidance on preventing and managing foot problems in adults with type 2 diabetes, see the NICE guideline on diabetic foot problems..	Diabetic foot problems1.7.11 For guidance on preventing and managing foot problems in adults with type 2 diabetes, see the NICE guideline on diabetic foot problems..	
foot problems1.7.11	0	0.3333	2	Diabetic foot problems1.7.11 For guidance on preventing and managing foot problems in adults with type 2 diabetes, see the NICE guideline on diabetic foot problems..	Diabetic foot problems1.7.11 For guidance on preventing and managing foot problems in adults with type 2 diabetes, see the NICE guideline on diabetic foot problems..	
harm reduction	0	0.3333	2	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	
health services	1	0.3333	2	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	
management 1.4.1	0	0.3333	2	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	
meal planning	0	0.3333	2	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	
measure blood	0	0.3333	2	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	
mental health	1	0.3333	2	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	
modified-release metformin.	0	0.3333	2	Initial drug treatment1.6.19 Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes. 1.6.20 Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes. 1.6.21 If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin..	Initial drug treatment1.6.19 Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes. 1.6.20 Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes. 1.6.21 If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin..	
offer standard-release	0	0.3333	2	Initial drug treatment1.6.19 Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes. 1.6.20 Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes. 1.6.21 If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin..	Initial drug treatment1.6.19 Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes. 1.6.20 Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes. 1.6.21 If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin..	
page 14of	0	0.3333	2	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	
planning system	0	0.3333	2	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	
pressure management	0	0.3333	2	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	
renal disease	0	0.3333	2	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	
smoking services	0	0.3333	2	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	
treatment1.6.19 offer	0	0.3333	2	Initial drug treatment1.6.19 Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes. 1.6.20 Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes. 1.6.21 If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin..	Initial drug treatment1.6.19 Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes. 1.6.20 Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes. 1.6.21 If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin..	
weight gain	0	0.3333	2	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	
weight management	0	0.3333	2	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	
blood glucose	0	0.3327	34	Treatment with a single non-insulin blood glucose lowering therapy(monotherapy).	Treatment with 2 non-insulin blood glucose lowering therapies incombination (dual therapy).	Treatment with either 3 non-insulin blood glucose lowering therapies incombination (triple therapy) or any treatment combination containing insulin 1.1 Individualised care 1.1.1 Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy..	Check forpossible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure. 1.5 Antiplatelet therapy 1.5.1 Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease. 1.5.2 For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction. 1.6 Blood glucose management.	Measurement1.6.1 In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable. 1.6.2 Use methods to measure HbA1c that have been calibrated according to.	International Federation of Clinical Chemistry (IFCC) standardisation.1.6.3 If HbA1c monitoring is invalid because of disturbed erythrocyte turnover or abnormal haemoglobin type, estimate trends in blood glucose control using one.	Page 18of 44 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities. 1.6.10 If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it.	Self-monitoring of blood glucose1.6.12 Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes. 1.6.13 Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or.	For more information, seethe NICE guideline on diabetes in pregnancy. 1.6.14 Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia. 1.6.15 Be aware that adults with type 2 diabetes who have acute intercurrent illness are at risk of worsening hyperglycaemia.	Review treatment as necessary.1.6.16 If adults with type 2 diabetes are self-monitoring their blood glucose levels, carry out a structured assessment at least annually.	The assessment shouldinclude: the person's self-monitoring skills the quality and frequency of testing checking that the person knows how to interpret the blood glucose results and what action to take the impact on the person's quality of life the continued benefit to the person the equipment used..	Rescue therapy at any phase of treatment1.6.18 If an adult with type 2 diabetes is symptomatically hyperglycaemic, consider insulin (see recommendations 1.6.32–1.6.34) or a sulfonylurea, and review treatment when blood glucose control has been achieved..	Algorithm for blood glucose lowering therapy in adults with type 2 diabetes.	Review thecontinued need for other blood glucose lowering therapies . 1.6.34 Start insulin therapy for adults with type 2 diabetes from a choice of a number of insulin types and regimens:.	Consider pre-mixed (biphasic) preparations that include short-acting insulinanalogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals. 1.6.35 Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of.	Page 26of 44 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 1.6.36 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 1.6.37 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate..	Gastroparesis1.7.1 Think about a diagnosis of gastroparesis in adults with type 2 diabetes with erratic blood glucose control or unexplained gastric bloating or vomiting, taking into account possible alternative diagnoses 2009, amended 2015 1.7.2 For adults with type 2 diabetes who have vomiting caused by gastroparesis, explain that: there is not strong evidence that any available antiemetic therapy is effective some people have had benefit with domperidone , erythromycin or metoclopramide . the strongest evidence for effectiveness is for domperidone , but prescribers must.	Treatment with a single non-insulin blood glucose lowering therapy(monotherapy).	Treatment with 2 non-insulin blood glucose lowering therapies incombination (dual therapy).	Treatment with either 3 non-insulin blood glucose lowering therapies incombination (triple therapy) or any treatment combination containing insulin 1.1 Individualised care 1.1.1 Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy..	Check forpossible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure. 1.5 Antiplatelet therapy 1.5.1 Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease. 1.5.2 For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction. 1.6 Blood glucose management.	Measurement1.6.1 In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable. 1.6.2 Use methods to measure HbA1c that have been calibrated according to.	International Federation of Clinical Chemistry (IFCC) standardisation.1.6.3 If HbA1c monitoring is invalid because of disturbed erythrocyte turnover or abnormal haemoglobin type, estimate trends in blood glucose control using one.	Page 18of 44 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities. 1.6.10 If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it.	Self-monitoring of blood glucose1.6.12 Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes. 1.6.13 Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or.	For more information, seethe NICE guideline on diabetes in pregnancy. 1.6.14 Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia. 1.6.15 Be aware that adults with type 2 diabetes who have acute intercurrent illness are at risk of worsening hyperglycaemia.	Review treatment as necessary.1.6.16 If adults with type 2 diabetes are self-monitoring their blood glucose levels, carry out a structured assessment at least annually.	The assessment shouldinclude: the person's self-monitoring skills the quality and frequency of testing checking that the person knows how to interpret the blood glucose results and what action to take the impact on the person's quality of life the continued benefit to the person the equipment used..	Rescue therapy at any phase of treatment1.6.18 If an adult with type 2 diabetes is symptomatically hyperglycaemic, consider insulin (see recommendations 1.6.32–1.6.34) or a sulfonylurea, and review treatment when blood glucose control has been achieved..	Algorithm for blood glucose lowering therapy in adults with type 2 diabetes.	Review thecontinued need for other blood glucose lowering therapies . 1.6.34 Start insulin therapy for adults with type 2 diabetes from a choice of a number of insulin types and regimens:.	Consider pre-mixed (biphasic) preparations that include short-acting insulinanalogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals. 1.6.35 Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of.	Page 26of 44 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 1.6.36 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 1.6.37 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate..	Gastroparesis1.7.1 Think about a diagnosis of gastroparesis in adults with type 2 diabetes with erratic blood glucose control or unexplained gastric bloating or vomiting, taking into account possible alternative diagnoses 2009, amended 2015 1.7.2 For adults with type 2 diabetes who have vomiting caused by gastroparesis, explain that: there is not strong evidence that any available antiemetic therapy is effective some people have had benefit with domperidone , erythromycin or metoclopramide . the strongest evidence for effectiveness is for domperidone , but prescribers must.	
glargine if:the	0	0.3152	2	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if:the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs..	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if:the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs..	
glucose-lowering drugs.	0	0.3152	2	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if:the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs..	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if:the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs..	
if:the person	0	0.3152	2	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if:the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs..	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if:the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs..	
oral glucose-lowering	0	0.3152	2	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if:the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs..	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if:the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs..	
recurrent symptomatic	0	0.3152	2	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if:the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs..	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if:the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs..	
symptomatic hypoglycaemic	0	0.3152	2	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if:the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs..	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if:the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs..	
twice-daily nph	0	0.3152	2	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if:the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs..	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if:the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs..	
nice guidelines	0	0.311	4	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	Check forpossible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure. 1.5 Antiplatelet therapy 1.5.1 Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease. 1.5.2 For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction. 1.6 Blood glucose management.	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	Check forpossible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure. 1.5 Antiplatelet therapy 1.5.1 Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease. 1.5.2 For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction. 1.6 Blood glucose management.	
case-by-case basis	0	0.3104	2	Page 18of 44 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities. 1.6.10 If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it.	Page 18of 44 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities. 1.6.10 If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it.	
intensive management	0	0.3104	2	Page 18of 44 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities. 1.6.10 If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it.	Page 18of 44 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities. 1.6.10 If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it.	
life expectancy	0	0.3104	4	Treatment with either 3 non-insulin blood glucose lowering therapies incombination (triple therapy) or any treatment combination containing insulin 1.1 Individualised care 1.1.1 Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy..	Page 18of 44 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities. 1.6.10 If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it.	Treatment with either 3 non-insulin blood glucose lowering therapies incombination (triple therapy) or any treatment combination containing insulin 1.1 Individualised care 1.1.1 Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy..	Page 18of 44 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities. 1.6.10 If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it.	
page 18of	0	0.3104	2	Page 18of 44 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities. 1.6.10 If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it.	Page 18of 44 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities. 1.6.10 If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it.	
risk-reduction benefits	0	0.3104	2	Page 18of 44 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities. 1.6.10 If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it.	Page 18of 44 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities. 1.6.10 If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it.	
significant comorbidities	0	0.3104	2	Page 18of 44 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities. 1.6.10 If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it.	Page 18of 44 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities. 1.6.10 If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it.	
tight blood	0	0.3104	2	Page 18of 44 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities. 1.6.10 If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it.	Page 18of 44 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities. 1.6.10 If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it.	
hypoglycaemic episodes	0	0.3031	4	Self-monitoring of blood glucose1.6.12 Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes. 1.6.13 Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or.	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if:the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs..	Self-monitoring of blood glucose1.6.12 Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes. 1.6.13 Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or.	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if:the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs..	
ageneric calcium-channel	0	0.2887	2	Caribbean family origin should be an ACE inhibitor plus either a diuretic or ageneric calcium-channel blocker. 1.4.9 A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant. 1.4.10 For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor. 1.4.11 Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension. 1.4.12 If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic).	Caribbean family origin should be an ACE inhibitor plus either a diuretic or ageneric calcium-channel blocker. 1.4.9 A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant. 1.4.10 For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor. 1.4.11 Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension. 1.4.12 If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic).	
first-line therapy	0	0.2887	2	Caribbean family origin should be an ACE inhibitor plus either a diuretic or ageneric calcium-channel blocker. 1.4.9 A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant. 1.4.10 For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor. 1.4.11 Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension. 1.4.12 If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic).	Caribbean family origin should be an ACE inhibitor plus either a diuretic or ageneric calcium-channel blocker. 1.4.9 A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant. 1.4.10 For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor. 1.4.11 Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension. 1.4.12 If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic).	
informed discussion	0	0.2887	2	Caribbean family origin should be an ACE inhibitor plus either a diuretic or ageneric calcium-channel blocker. 1.4.9 A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant. 1.4.10 For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor. 1.4.11 Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension. 1.4.12 If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic).	Caribbean family origin should be an ACE inhibitor plus either a diuretic or ageneric calcium-channel blocker. 1.4.9 A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant. 1.4.10 For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor. 1.4.11 Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension. 1.4.12 If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic).	
renal deterioration	0	0.2887	2	Caribbean family origin should be an ACE inhibitor plus either a diuretic or ageneric calcium-channel blocker. 1.4.9 A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant. 1.4.10 For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor. 1.4.11 Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension. 1.4.12 If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic).	Caribbean family origin should be an ACE inhibitor plus either a diuretic or ageneric calcium-channel blocker. 1.4.9 A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant. 1.4.10 For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor. 1.4.11 Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension. 1.4.12 If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic).	
thiazide-related diuretic	0	0.2887	2	Caribbean family origin should be an ACE inhibitor plus either a diuretic or ageneric calcium-channel blocker. 1.4.9 A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant. 1.4.10 For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor. 1.4.11 Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension. 1.4.12 If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic).	Caribbean family origin should be an ACE inhibitor plus either a diuretic or ageneric calcium-channel blocker. 1.4.9 A calcium-channel blocker should be the first-line antihypertensive drug treatment for a woman for whom, after an informed discussion, it is agreed there is a possibility of her becoming pregnant. 1.4.10 For a person with continuing intolerance to an ACE inhibitor (other than renal deterioration or hyperkalaemia), substitute an angiotensin II-receptor antagonist for the ACE inhibitor. 1.4.11 Do not combine an ACE inhibitor with an angiotensin II-receptor antagonist to treat hypertension. 1.4.12 If the person's blood pressure is not reduced to the individually agreed target with first-line therapy, add a calcium-channel blocker or a diuretic (usually a thiazide or thiazide-related diuretic).	
type 2	1	0.2503	132	Be aware that, if metformin is contraindicated or not tolerated, repaglinide is both clinicallyeffective and cost effective in adults with type 2 diabetes.	Type 2 diabetes in adults: management (NG28) NICE 2019.	Treatment with either 3 non-insulin blood glucose lowering therapies incombination (triple therapy) or any treatment combination containing insulin 1.1 Individualised care 1.1.1 Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy..	Reassess the person's needs and circumstances at each review and think aboutwhether to stop any medicines that are not effective. 1.1.2 Take into account any disabilities, including visual impairment, when planning and delivering care for adults with type 2 diabetes. 1.2 Patient education 1.2.1 Offer structured education to adults with type 2 diabetes and or their family members or carers (as appropriate) at and around the time of diagnosis, with.	Type 2 diabetes in adults: management (NG28) NICE 2019.	Explain to people and their carers thatstructured education is an integral part of diabetes care. 1.2.2 Ensure that any structured education programme for adults with type 2 diabetes includes the following components:.	Provide analternative of equal standard for a person unable or unwilling to participate in group education. 1.2.5 Ensure that the patient-education programmes available meet the cultural, linguistic, cognitive and literacy needs within the local area. 1.2.6 Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes..	Type 2 diabetes in adults: management (NG28) NICE 2019.	Page 13of 44 1.3 Dietary advice and bariatric surgery 1.3.1 Provide individualised and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition. 1.3.2 Provide dietary advice in a form sensitive to the person's needs, culture and beliefs, being sensitive to their willingness to change and the effects on their quality of life. 1.3.3 Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes.	Encouragehigh-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids. 1.3.4 Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight. 1.3.5 For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent.	Reducing the risk of hypoglycaemia should be a particular aim for aperson using insulin or an insulin secretagogue. 1.3.7 Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake. 1.3.8 Discourage the use of foods marketed specifically for people with diabetes..	Type 2 diabetes in adults: management (NG28) NICE 2019.	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	Offer and reinforcepreventive lifestyle advice. 1.4.2 For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used..	Type 2 diabetes in adults: management (NG28) NICE 2019.	Type 2 diabetes in adults: management (NG28) NICE 2019.	Check forpossible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure. 1.5 Antiplatelet therapy 1.5.1 Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease. 1.5.2 For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction. 1.6 Blood glucose management.	Measurement1.6.1 In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable. 1.6.2 Use methods to measure HbA1c that have been calibrated according to.	Type 2 diabetes in adults: management (NG28) NICE 2019.	Targets1.6.5 Involve adults with type 2 diabetes in decisions about their individual HbA1c target.	Encourage them to achieve the target and maintain it unless anyresulting adverse effects (including hypoglycaemia), or their efforts to achieve their target, impair their quality of life. 1.6.6 Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section 1.3).	For moreinformation about supporting adherence, see the NICE guideline on medicines adherence. 1.6.7 For adults with type 2 diabetes managed either by lifestyle and diet, or by lifestyle and diet combined with a single drug not associated with hypoglycaemia, support the person to aim for an HbA1c level of 48 mmol mol (6.5percent).	For adults on a drug associated with hypoglycaemia, support the personto aim for an HbA1c level of 53 mmol mol (7.0percent). 1.6.8 In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol (7.5percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol (7.0percent) and intensify drug treatment. 1.6.9 Consider relaxing the target HbA1c level (see recommendations 1.6.7 and 1.6.8).	Type 2 diabetes in adults: management (NG28) NICE 2019.	Page 18of 44 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities. 1.6.10 If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it.	Be aware that there are other possible reasons for a low HbA1clevel, for example, deteriorating renal function or sudden weight loss. 1.6.11 For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy..	Self-monitoring of blood glucose1.6.12 Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes. 1.6.13 Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or.	Type 2 diabetes in adults: management (NG28) NICE 2019.	For more information, seethe NICE guideline on diabetes in pregnancy. 1.6.14 Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia. 1.6.15 Be aware that adults with type 2 diabetes who have acute intercurrent illness are at risk of worsening hyperglycaemia.	Review treatment as necessary.1.6.16 If adults with type 2 diabetes are self-monitoring their blood glucose levels, carry out a structured assessment at least annually.	Recommendations in this section that cover dipeptidyl peptidase-4 (DPP-4) inhibitors,glucagon-like peptide-1 (GLP-1) mimetics and sulfonylureas refer to each of these groups of drugs at a class level. 1.6.17 For adults with type 2 diabetes, discuss the benefits and risks of drug treatment, and the options available.	Type 2 diabetes in adults: management (NG28) NICE 2019.	Rescue therapy at any phase of treatment1.6.18 If an adult with type 2 diabetes is symptomatically hyperglycaemic, consider insulin (see recommendations 1.6.32–1.6.34) or a sulfonylurea, and review treatment when blood glucose control has been achieved..	Initial drug treatment1.6.19 Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes. 1.6.20 Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes. 1.6.21 If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin..	Algorithm for blood glucose lowering therapy in adults with type 2 diabetes.	Type 2 diabetes in adults: management (NG28) NICE 2019.	Page 21of 44 1.6.22 In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute 1.73m2:.	Prescribe metformin with caution for those at risk of a sudden deterioration in kidneyfunction and those at risk of eGFR falling below 45 ml minute 1.73m2. 1.6.23 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea. 1.6.24 In adults with type 2 diabetes, do not offer or continue pioglitazone if they have any of the following: heart failure or history of heart failure.	Type 2 diabetes in adults: management (NG28) NICE 2019.	Treatment with sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate forsome adults with type 2 diabetes if metformin is contraindicated or not tolerated (see NICE's guidance on canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes)..	First intensification of drug treatment1.6.25 In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea. 1.6.26 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea..	Treatment with combinations of medicines including sodium–glucose cotransporter 2 (SGLT-2)inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes..	Type 2 diabetes in adults: management (NG28) NICE 2019.	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	HbA1c and a weight loss of at least 3percent of initial body weight in 6 months).1.6.30 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation 1.6.26) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations 1.6.32–1.6.34)..	Type 2 diabetes in adults: management (NG28) NICE 2019.	Page 24of 44 1.6.31 In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team ..	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate forsome people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in triple therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes..	Insulin-based treatments1.6.32 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding.	DVLA guidance (At a glance guide to the current medical standards of fitness to drive)management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional. 1.6.33 When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance.	Review thecontinued need for other blood glucose lowering therapies . 1.6.34 Start insulin therapy for adults with type 2 diabetes from a choice of a number of insulin types and regimens:.	Type 2 diabetes in adults: management (NG28) NICE 2019.	Consider pre-mixed (biphasic) preparations that include short-acting insulinanalogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals. 1.6.35 Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of.	Type 2 diabetes in adults: management (NG28) NICE 2019.	Page 26of 44 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 1.6.36 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 1.6.37 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate..	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate forsome people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes..	Insulin delivery1.6.38 For guidance on insulin delivery for adults with type 2 diabetes, see the insulin delivery section in the NICE guideline on type 1 diabetes. 1.7 Managing complications.	Gastroparesis1.7.1 Think about a diagnosis of gastroparesis in adults with type 2 diabetes with erratic blood glucose control or unexplained gastric bloating or vomiting, taking into account possible alternative diagnoses 2009, amended 2015 1.7.2 For adults with type 2 diabetes who have vomiting caused by gastroparesis, explain that: there is not strong evidence that any available antiemetic therapy is effective some people have had benefit with domperidone , erythromycin or metoclopramide . the strongest evidence for effectiveness is for domperidone , but prescribers must.	Type 2 diabetes in adults: management (NG28) NICE 2019.	Page 27of 44 take into account its safety profile, in particular its cardiac risk and potential interactions with other medicines. 1.7.3 For treating vomiting caused by gastroparesis in adults with type 2 diabetes: consider alternating use of erythomycin and metoclopramide consider domperidone only in exceptional circumstances (if domperidone is the only effective treatment) and in accordance with MHRA guidance. 1.7.4 If gastroparesis is suspected, consider referral to specialist services if: the differential diagnosis is in doubt or persistent or severe vomiting occurs..	Painful diabetic neuropathy1.7.5 For guidance on managing painful diabetic peripheral neuropathy in adults with type 2 diabetes, see the NICE guideline on neuropathic pain in adults..	Autonomic neuropathy1.7.6 Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015 1.7.7 Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015 1.7.8 When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension. 1.7.9 Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems..	Type 2 diabetes in adults: management (NG28) NICE 2019.	Diabetic foot problems1.7.11 For guidance on preventing and managing foot problems in adults with type 2 diabetes, see the NICE guideline on diabetic foot problems..	Diabetic kidney disease1.7.12 For guidance on managing kidney disease in adults with type 2 diabetes, see the.	Erectile dysfunction1.7.13 Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review. 1.7.14 Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options. 1.7.15 Consider a phosphodiesterase-5 inhibitor to treat problematic ere	Be aware that, if metformin is contraindicated or not tolerated, repaglinide is both clinicallyeffective and cost effective in adults with type 2 diabetes.	Type 2 diabetes in adults: management (NG28) NICE 2019.	Treatment with either 3 non-insulin blood glucose lowering therapies incombination (triple therapy) or any treatment combination containing insulin 1.1 Individualised care 1.1.1 Adopt an individualised approach to diabetes care that is tailored to the needs and circumstances of adults with type 2 diabetes, taking into account their personal preferences, comorbidities, risks from polypharmacy, and their ability to benefit from long-term interventions because of reduced life expectancy..	Reassess the person's needs and circumstances at each review and think aboutwhether to stop any medicines that are not effective. 1.1.2 Take into account any disabilities, including visual impairment, when planning and delivering care for adults with type 2 diabetes. 1.2 Patient education 1.2.1 Offer structured education to adults with type 2 diabetes and or their family members or carers (as appropriate) at and around the time of diagnosis, with.	Type 2 diabetes in adults: management (NG28) NICE 2019.	Explain to people and their carers thatstructured education is an integral part of diabetes care. 1.2.2 Ensure that any structured education programme for adults with type 2 diabetes includes the following components:.	Provide analternative of equal standard for a person unable or unwilling to participate in group education. 1.2.5 Ensure that the patient-education programmes available meet the cultural, linguistic, cognitive and literacy needs within the local area. 1.2.6 Ensure that all members of the diabetes healthcare team are familiar with the patient-education programmes available locally, that these programmes are integrated with the rest of the care pathway, and that adults with type 2 diabetes and their family members or carers (as appropriate) have the opportunity to contribute to the design and provision of local programmes..	Type 2 diabetes in adults: management (NG28) NICE 2019.	Page 13of 44 1.3 Dietary advice and bariatric surgery 1.3.1 Provide individualised and ongoing nutritional advice from a healthcare professional with specific expertise and competencies in nutrition. 1.3.2 Provide dietary advice in a form sensitive to the person's needs, culture and beliefs, being sensitive to their willingness to change and the effects on their quality of life. 1.3.3 Emphasise advice on healthy balanced eating that is applicable to the general population when providing advice to adults with type 2 diabetes.	Encouragehigh-fibre, low-glycaemic-index sources of carbohydrate in the diet, such as fruit, vegetables, wholegrains and pulses; include low-fat dairy products and oily fish; and control the intake of foods containing saturated and trans fatty acids. 1.3.4 Integrate dietary advice with a personalised diabetes management plan, including other aspects of lifestyle modification, such as increasing physical activity and losing weight. 1.3.5 For adults with type 2 diabetes who are overweight, set an initial body weight loss target of 5–10percent.	Reducing the risk of hypoglycaemia should be a particular aim for aperson using insulin or an insulin secretagogue. 1.3.7 Advise adults with type 2 diabetes that limited substitution of sucrose-containing foods for other carbohydrate in the meal plan is allowable, but that they should take care to avoid excess energy intake. 1.3.8 Discourage the use of foods marketed specifically for people with diabetes..	Type 2 diabetes in adults: management (NG28) NICE 2019.	Page 14of 44 1.3.9 When adults with type 2 diabetes are admitted to hospital as inpatients or to any other care setting, implement a meal planning system that provides consistency in the carbohydrate content of meals and snacks. 1.3.10 For recommendations on lifestyle advice, see the NICE guidelines on: preventing excess weight gain, weight management, obesity, physical activity, smoking: brief interventions and referrals, stop smoking services, smoking: harm reduction, and smoking: acute, maternity and mental health services. 1.3.11 For recommendations on bariatric surgery for people with recent-onset type 2 diabetes, see the section on bariatric surgery for people with recent-onset type 2 diabetes in the NICE guideline on obesity. 1.4 Blood pressure management 1.4.1 Measure blood pressure at least annually in an adult with type 2 diabetes without previously diagnosed hypertension or renal disease.	Offer and reinforcepreventive lifestyle advice. 1.4.2 For an adult with type 2 diabetes on antihypertensive drug treatment when diabetes is diagnosed, review blood pressure control and medications used..	Type 2 diabetes in adults: management (NG28) NICE 2019.	Type 2 diabetes in adults: management (NG28) NICE 2019.	Check forpossible adverse effects of antihypertensive drug treatment – including the risks from unnecessarily low blood pressure. 1.5 Antiplatelet therapy 1.5.1 Do not offer antiplatelet therapy (aspirin or clopidogrel) for adults with type 2 diabetes without cardiovascular disease. 1.5.2 For guidance on the primary and secondary prevention of cardiovascular disease in adults with type 2 diabetes, see the NICE guidelines on cardiovascular disease and myocardial infarction. 1.6 Blood glucose management.	Measurement1.6.1 In adults with type 2 diabetes, measure HbA1c levels at: 3–6-monthly intervals (tailored to individual needs), until the HbA1c is stable on unchanging therapy 6-monthly intervals once the HbA1c level and blood glucose lowering therapy are stable. 1.6.2 Use methods to measure HbA1c that have been calibrated according to.	Type 2 diabetes in adults: management (NG28) NICE 2019.	Targets1.6.5 Involve adults with type 2 diabetes in decisions about their individual HbA1c target.	Encourage them to achieve the target and maintain it unless anyresulting adverse effects (including hypoglycaemia), or their efforts to achieve their target, impair their quality of life. 1.6.6 Offer lifestyle advice and drug treatment to support adults with type 2 diabetes to achieve and maintain their HbA1c target (see section 1.3).	For moreinformation about supporting adherence, see the NICE guideline on medicines adherence. 1.6.7 For adults with type 2 diabetes managed either by lifestyle and diet, or by lifestyle and diet combined with a single drug not associated with hypoglycaemia, support the person to aim for an HbA1c level of 48 mmol mol (6.5percent).	For adults on a drug associated with hypoglycaemia, support the personto aim for an HbA1c level of 53 mmol mol (7.0percent). 1.6.8 In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol mol (7.5percent) or higher: reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol mol (7.0percent) and intensify drug treatment. 1.6.9 Consider relaxing the target HbA1c level (see recommendations 1.6.7 and 1.6.8).	Type 2 diabetes in adults: management (NG28) NICE 2019.	Page 18of 44 on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: who are unlikely to achieve longer-term risk-reduction benefits, for example, people with a reduced life expectancy for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job for whom intensive management would not be appropriate, for example, people with significant comorbidities. 1.6.10 If adults with type 2 diabetes achieve an HbA1c level that is lower than their target and they are not experiencing hypoglycaemia, encourage them to maintain it.	Be aware that there are other possible reasons for a low HbA1clevel, for example, deteriorating renal function or sudden weight loss. 1.6.11 For guidance on HbA1c targets for women with type 2 diabetes who are pregnant or planning to become pregnant, see the NICE guideline on diabetes in pregnancy..	Self-monitoring of blood glucose1.6.12 Take the Driver and Vehicle Licensing Agency (DVLA) At a glance guide to the current medical standards of fitness to drive into account when offering self-monitoring of blood glucose levels for adults with type 2 diabetes. 1.6.13 Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless: the person is on insulin or there is evidence of hypoglycaemic episodes or the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or.	Type 2 diabetes in adults: management (NG28) NICE 2019.	For more information, seethe NICE guideline on diabetes in pregnancy. 1.6.14 Consider short-term self-monitoring of blood glucose levels in adults with type 2 diabetes (and review treatment as necessary): when starting treatment with oral or intravenous corticosteroids or to confirm suspected hypoglycaemia. 1.6.15 Be aware that adults with type 2 diabetes who have acute intercurrent illness are at risk of worsening hyperglycaemia.	Review treatment as necessary.1.6.16 If adults with type 2 diabetes are self-monitoring their blood glucose levels, carry out a structured assessment at least annually.	Recommendations in this section that cover dipeptidyl peptidase-4 (DPP-4) inhibitors,glucagon-like peptide-1 (GLP-1) mimetics and sulfonylureas refer to each of these groups of drugs at a class level. 1.6.17 For adults with type 2 diabetes, discuss the benefits and risks of drug treatment, and the options available.	Type 2 diabetes in adults: management (NG28) NICE 2019.	Rescue therapy at any phase of treatment1.6.18 If an adult with type 2 diabetes is symptomatically hyperglycaemic, consider insulin (see recommendations 1.6.32–1.6.34) or a sulfonylurea, and review treatment when blood glucose control has been achieved..	Initial drug treatment1.6.19 Offer standard-release metformin as the initial drug treatment for adults with type 2 diabetes. 1.6.20 Gradually increase the dose of standard-release metformin over several weeks to minimise the risk of gastrointestinal side effects in adults with type 2 diabetes. 1.6.21 If an adult with type 2 diabetes experiences gastrointestinal side effects with standard-release metformin, consider a trial of modified-release metformin..	Algorithm for blood glucose lowering therapy in adults with type 2 diabetes.	Type 2 diabetes in adults: management (NG28) NICE 2019.	Page 21of 44 1.6.22 In adults with type 2 diabetes, review the dose of metformin if the estimated glomerular filtration rate (eGFR) is below 45 ml minute 1.73m2:.	Prescribe metformin with caution for those at risk of a sudden deterioration in kidneyfunction and those at risk of eGFR falling below 45 ml minute 1.73m2. 1.6.23 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, consider initial drug treatment with: a dipeptidyl peptidase-4 (DPP-4) inhibitor or pioglitazone or a sulfonylurea. 1.6.24 In adults with type 2 diabetes, do not offer or continue pioglitazone if they have any of the following: heart failure or history of heart failure.	Type 2 diabetes in adults: management (NG28) NICE 2019.	Treatment with sodium–glucose cotransporter 2 (SGLT-2) inhibitors , may be appropriate forsome adults with type 2 diabetes if metformin is contraindicated or not tolerated (see NICE's guidance on canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes)..	First intensification of drug treatment1.6.25 In adults with type 2 diabetes, if initial drug treatment with metformin has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: metformin and a DPP-4 inhibitor or metformin and pioglitazone or metformin and a sulfonylurea. 1.6.26 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated and initial drug treatment has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider dual therapy with: a DPP-4 inhibitor and pioglitazone or a DPP-4 inhibitor and a sulfonylurea or pioglitazone and a sulfonylurea..	Treatment with combinations of medicines including sodium–glucose cotransporter 2 (SGLT-2)inhibitors , may be appropriate for some people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes..	Type 2 diabetes in adults: management (NG28) NICE 2019.	Second intensification of drug treatment1.6.27 In adults with type 2 diabetes, if dual therapy with metformin and another oral drug (see recommendation 1.6.25) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider either: triple therapy with: metformin, a DPP-4 inhibitor and a sulfonylurea or metformin, pioglitazone and a sulfonylurea or starting insulin-based treatment (see recommendations 1.6.32–1.6.34). 1.6.28 If triple therapy with metformin and 2 other oral drugs (see recommendation 1.6.27) is not effective, not tolerated or contraindicated, consider combination therapy with metformin, a sulfonylurea and a glucagon-like peptide-1 (GLP-1) mimetic for adults with type 2 diabetes who: have a BMI of 35 kg m2 or higher (adjust accordingly for people from black, Asian and other minority ethnic groups) and specific psychological or other medical problems associated with obesity or have a BMI lower than 35 kg m2and: for whom insulin therapy would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities. 1.6.29 Only continue GLP-1 mimetic therapy if the person with type 2 diabetes has had a beneficial metabolic response (a reduction of at least 11 mmol mol 1.0percent in.	HbA1c and a weight loss of at least 3percent of initial body weight in 6 months).1.6.30 In adults with type 2 diabetes, if metformin is contraindicated or not tolerated, and if dual therapy with 2 oral drugs (see recommendation 1.6.26) has not continued to control HbA1c to below the person's individually agreed threshold for intensification, consider insulin-based treatment (see recommendations 1.6.32–1.6.34)..	Type 2 diabetes in adults: management (NG28) NICE 2019.	Page 24of 44 1.6.31 In adults with type 2 diabetes, only offer a GLP-1 mimetic in combination with insulin with specialist care advice and ongoing support from a consultant-led multidisciplinary team ..	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate forsome people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in triple therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes..	Insulin-based treatments1.6.32 When starting insulin therapy in adults with type 2 diabetes, use a structured programme employing active insulin dose titration that encompasses: injection technique, including rotating injection sites and avoiding repeated injections at the same point within sites continuing telephone support self-monitoring dose titration to target levels dietary understanding.	DVLA guidance (At a glance guide to the current medical standards of fitness to drive)management of hypoglycaemia management of acute changes in plasma glucose control support from an appropriately trained and experienced healthcare professional. 1.6.33 When starting insulin therapy in adults with type 2 diabetes, continue to offer metformin for people without contraindications or intolerance.	Review thecontinued need for other blood glucose lowering therapies . 1.6.34 Start insulin therapy for adults with type 2 diabetes from a choice of a number of insulin types and regimens:.	Type 2 diabetes in adults: management (NG28) NICE 2019.	Consider pre-mixed (biphasic) preparations that include short-acting insulinanalogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals. 1.6.35 Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of.	Type 2 diabetes in adults: management (NG28) NICE 2019.	Page 26of 44 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 1.6.36 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 1.6.37 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate..	Treatment with combinations of medicines including SGLT-2 inhibitors , may be appropriate forsome people with type 2 diabetes; see the NICE guidance on canagliflozin in combination therapy for treating type 2 diabetes, dapagliflozin in combination therapy for treating type 2 diabetes and empagliflozin in combination therapy for treating type 2 diabetes..	Insulin delivery1.6.38 For guidance on insulin delivery for adults with type 2 diabetes, see the insulin delivery section in the NICE guideline on type 1 diabetes. 1.7 Managing complications.	Gastroparesis1.7.1 Think about a diagnosis of gastroparesis in adults with type 2 diabetes with erratic blood glucose control or unexplained gastric bloating or vomiting, taking into account possible alternative diagnoses 2009, amended 2015 1.7.2 For adults with type 2 diabetes who have vomiting caused by gastroparesis, explain that: there is not strong evidence that any available antiemetic therapy is effective some people have had benefit with domperidone , erythromycin or metoclopramide . the strongest evidence for effectiveness is for domperidone , but prescribers must.	Type 2 diabetes in adults: management (NG28) NICE 2019.	Page 27of 44 take into account its safety profile, in particular its cardiac risk and potential interactions with other medicines. 1.7.3 For treating vomiting caused by gastroparesis in adults with type 2 diabetes: consider alternating use of erythomycin and metoclopramide consider domperidone only in exceptional circumstances (if domperidone is the only effective treatment) and in accordance with MHRA guidance. 1.7.4 If gastroparesis is suspected, consider referral to specialist services if: the differential diagnosis is in doubt or persistent or severe vomiting occurs..	Painful diabetic neuropathy1.7.5 For guidance on managing painful diabetic peripheral neuropathy in adults with type 2 diabetes, see the NICE guideline on neuropathic pain in adults..	Autonomic neuropathy1.7.6 Think about the possibility of contributory sympathetic nervous system damage for adults with type 2 diabetes who lose the warning signs of hypoglycaemia. 2009, amended 2015 1.7.7 Think about the possibility of autonomic neuropathy affecting the gut in adults with type 2 diabetes who have unexplained diarrhoea that happens particularly at night 2009, amended 2015 1.7.8 When using tricyclic drugs and antihypertensive drug treatments in adults with type 2 diabetes who have autonomic neuropathy, be aware of the increased likelihood of side effects such as orthostatic hypotension. 1.7.9 Investigate the possibility of autonomic neuropathy affecting the bladder in adults with type 2 diabetes who have unexplained bladder-emptying problems..	Type 2 diabetes in adults: management (NG28) NICE 2019.	Diabetic foot problems1.7.11 For guidance on preventing and managing foot problems in adults with type 2 diabetes, see the NICE guideline on diabetic foot problems..	Diabetic kidney disease1.7.12 For guidance on managing kidney disease in adults with type 2 diabetes, see the.	Erectile dysfunction1.7.13 Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review. 1.7.14 Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options. 1.7.15 Consider a phosphodiesterase-5 inhibitor to treat problematic ere	
insulin injections	0	0.2099	4	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if:the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs..	Page 26of 44 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 1.6.36 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 1.6.37 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate..	Consider, as an alternative to NPH insulin, using insulin detemir or insulin glargine if:the person needs assistance from a carer or healthcare professional to inject insulin, and use of insulin detemir or insulin glargine would reduce the frequency of injections from twice to once daily or the person's lifestyle is restricted by recurrent symptomatic hypoglycaemic episodes or the person would otherwise need twice-daily NPH insulin injections in combination with oral glucose-lowering drugs..	Page 26of 44 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 1.6.36 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 1.6.37 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate..	
1.4.6 monitor	0	0.1925	2	Page 15of 44 pressure is confirmed as being consistently above 140 80 mmHg (or above 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.5 Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.6 Monitor blood pressure every 1–2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.7 First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor.	Page 15of 44 pressure is confirmed as being consistently above 140 80 mmHg (or above 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.5 Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.6 Monitor blood pressure every 1–2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.7 First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor.	
1.4.7 first-line	0	0.1925	2	Page 15of 44 pressure is confirmed as being consistently above 140 80 mmHg (or above 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.5 Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.6 Monitor blood pressure every 1–2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.7 First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor.	Page 15of 44 pressure is confirmed as being consistently above 140 80 mmHg (or above 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.5 Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.6 Monitor blood pressure every 1–2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.7 First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor.	
1–2 months	0	0.1925	2	Page 15of 44 pressure is confirmed as being consistently above 140 80 mmHg (or above 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.5 Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.6 Monitor blood pressure every 1–2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.7 First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor.	Page 15of 44 pressure is confirmed as being consistently above 140 80 mmHg (or above 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.5 Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.6 Monitor blood pressure every 1–2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.7 First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor.	
angiotensin-converting enzyme	0	0.1925	2	Page 15of 44 pressure is confirmed as being consistently above 140 80 mmHg (or above 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.5 Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.6 Monitor blood pressure every 1–2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.7 First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor.	Page 15of 44 pressure is confirmed as being consistently above 140 80 mmHg (or above 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.5 Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.6 Monitor blood pressure every 1–2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.7 First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor.	
generic angiotensin-converting	0	0.1925	2	Page 15of 44 pressure is confirmed as being consistently above 140 80 mmHg (or above 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.5 Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.6 Monitor blood pressure every 1–2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.7 First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor.	Page 15of 44 pressure is confirmed as being consistently above 140 80 mmHg (or above 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.5 Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.6 Monitor blood pressure every 1–2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.7 First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor.	
monitor blood	0	0.1925	2	Page 15of 44 pressure is confirmed as being consistently above 140 80 mmHg (or above 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.5 Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.6 Monitor blood pressure every 1–2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.7 First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor.	Page 15of 44 pressure is confirmed as being consistently above 140 80 mmHg (or above 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.5 Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.6 Monitor blood pressure every 1–2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.7 First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor.	
page 15of	0	0.1925	2	Page 15of 44 pressure is confirmed as being consistently above 140 80 mmHg (or above 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.5 Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.6 Monitor blood pressure every 1–2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.7 First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor.	Page 15of 44 pressure is confirmed as being consistently above 140 80 mmHg (or above 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.5 Add medications if lifestyle advice does not reduce blood pressure to below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.6 Monitor blood pressure every 1–2 months, and intensify therapy if the person is already on antihypertensive drug treatment, until the blood pressure is consistently below 140 80 mmHg (below 130 80 mmHg if there is kidney, eye or cerebrovascular damage). 1.4.7 First-line antihypertensive drug treatment should be a once-daily, generic angiotensin-converting enzyme (ACE) inhibitor.	
1.6.36 monitor	0	0.1697	2	Page 26of 44 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 1.6.36 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 1.6.37 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate..	Page 26of 44 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 1.6.36 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 1.6.37 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate..	
1.6.37 monitor	0	0.1697	2	Page 26of 44 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 1.6.36 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 1.6.37 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate..	Page 26of 44 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 1.6.36 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 1.6.37 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate..	
basal bolus	0	0.1697	2	Page 26of 44 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 1.6.36 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 1.6.37 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate..	Page 26of 44 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 1.6.36 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 1.6.37 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate..	
basal insulin	0	0.1697	2	Page 26of 44 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 1.6.36 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 1.6.37 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate..	Page 26of 44 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 1.6.36 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 1.6.37 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate..	
biphasic insulin	0	0.1697	2	Page 26of 44 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 1.6.36 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 1.6.37 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate..	Page 26of 44 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 1.6.36 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 1.6.37 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate..	
bolus regimen	0	0.1697	2	Page 26of 44 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 1.6.36 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 1.6.37 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate..	Page 26of 44 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 1.6.36 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 1.6.37 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate..	
daily injections	0	0.1697	2	Page 26of 44 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 1.6.36 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 1.6.37 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate..	Page 26of 44 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 1.6.36 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 1.6.37 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate..	
insulin preparation	0	0.1697	6	HbA1c is 75 mmol mol 9.0percent or higher), administered either:separately or as a pre-mixed (biphasic) human insulin preparation..	Consider pre-mixed (biphasic) preparations that include short-acting insulinanalogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals. 1.6.35 Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of.	Page 26of 44 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 1.6.36 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 1.6.37 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate..	HbA1c is 75 mmol mol 9.0percent or higher), administered either:separately or as a pre-mixed (biphasic) human insulin preparation..	Consider pre-mixed (biphasic) preparations that include short-acting insulinanalogues, rather than pre-mixed (biphasic) preparations that include short-acting human insulin preparations, if: a person prefers injecting insulin immediately before a meal or hypoglycaemia is a problem or blood glucose levels rise markedly after meals. 1.6.35 Consider switching to insulin detemir or insulin glargine from NPH insulin in adults with type 2 diabetes: who do not reach their target HbA1c because of significant hypoglycaemia or who experience significant hypoglycaemia on NPH insulin irrespective of the level of.	Page 26of 44 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 1.6.36 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 1.6.37 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate..	
insulin regimen	0	0.1697	2	Page 26of 44 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 1.6.36 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 1.6.37 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate..	Page 26of 44 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 1.6.36 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 1.6.37 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate..	
page 26of	0	0.1697	2	Page 26of 44 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 1.6.36 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 1.6.37 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate..	Page 26of 44 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 1.6.36 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 1.6.37 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate..	
pre-mixed biphasic	0	0.1697	2	Page 26of 44 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 1.6.36 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 1.6.37 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate..	Page 26of 44 who need help from a carer or healthcare professional to administer insulin injections and for whom switching to one of the long-acting insulin analogues would reduce the number of daily injections. 1.6.36 Monitor adults with type 2 diabetes who are on a basal insulin regimen (NPH insulin, insulin detemir or insulin glargine ) for the need for short-acting insulin before meals (or a pre-mixed biphasic insulin preparation). 1.6.37 Monitor adults with type 2 diabetes who are on pre-mixed (biphasic) insulin for the need for a further injection of short-acting insulin before meals or for a change to a basal bolus regimen with NPH insulin or insulin detemir or insulin glargine , if blood glucose control remains inadequate..	
1.7.14 assess	0	0.0	2	Erectile dysfunction1.7.13 Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review. 1.7.14 Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options. 1.7.15 Consider a phosphodiesterase-5 inhibitor to treat problematic ere	Erectile dysfunction1.7.13 Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review. 1.7.14 Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options. 1.7.15 Consider a phosphodiesterase-5 inhibitor to treat problematic ere	
annual review	0	0.0	2	Erectile dysfunction1.7.13 Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review. 1.7.14 Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options. 1.7.15 Consider a phosphodiesterase-5 inhibitor to treat problematic ere	Erectile dysfunction1.7.13 Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review. 1.7.14 Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options. 1.7.15 Consider a phosphodiesterase-5 inhibitor to treat problematic ere	
contributory factors	0	0.0	2	Erectile dysfunction1.7.13 Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review. 1.7.14 Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options. 1.7.15 Consider a phosphodiesterase-5 inhibitor to treat problematic ere	Erectile dysfunction1.7.13 Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review. 1.7.14 Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options. 1.7.15 Consider a phosphodiesterase-5 inhibitor to treat problematic ere	
dysfunction1.7.13 offer	0	0.0	2	Erectile dysfunction1.7.13 Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review. 1.7.14 Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options. 1.7.15 Consider a phosphodiesterase-5 inhibitor to treat problematic ere	Erectile dysfunction1.7.13 Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review. 1.7.14 Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options. 1.7.15 Consider a phosphodiesterase-5 inhibitor to treat problematic ere	
erectile dysfunction	0	0.0	2	Erectile dysfunction1.7.13 Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review. 1.7.14 Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options. 1.7.15 Consider a phosphodiesterase-5 inhibitor to treat problematic ere	Erectile dysfunction1.7.13 Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review. 1.7.14 Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options. 1.7.15 Consider a phosphodiesterase-5 inhibitor to treat problematic ere	
erectile dysfunction1.7.13	0	0.0	2	Erectile dysfunction1.7.13 Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review. 1.7.14 Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options. 1.7.15 Consider a phosphodiesterase-5 inhibitor to treat problematic ere	Erectile dysfunction1.7.13 Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review. 1.7.14 Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options. 1.7.15 Consider a phosphodiesterase-5 inhibitor to treat problematic ere	
offer men	0	0.0	2	Erectile dysfunction1.7.13 Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review. 1.7.14 Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options. 1.7.15 Consider a phosphodiesterase-5 inhibitor to treat problematic ere	Erectile dysfunction1.7.13 Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review. 1.7.14 Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options. 1.7.15 Consider a phosphodiesterase-5 inhibitor to treat problematic ere	
problematic erectile	0	0.0	2	Erectile dysfunction1.7.13 Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review. 1.7.14 Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options. 1.7.15 Consider a phosphodiesterase-5 inhibitor to treat problematic ere	Erectile dysfunction1.7.13 Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review. 1.7.14 Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options. 1.7.15 Consider a phosphodiesterase-5 inhibitor to treat problematic ere	
treatment options	0	0.0	2	Erectile dysfunction1.7.13 Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review. 1.7.14 Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options. 1.7.15 Consider a phosphodiesterase-5 inhibitor to treat problematic ere	Erectile dysfunction1.7.13 Offer men with type 2 diabetes the opportunity to discuss erectile dysfunction as part of their annual review. 1.7.14 Assess, educate and support men with type 2 diabetes who have problematic erectile dysfunction, addressing contributory factors such as cardiovascular disease as well as possible treatment options. 1.7.15 Consider a phosphodiesterase-5 inhibitor to treat problematic ere	
